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 i 
Use of Cotrimoxazole Prophylactic Treatment in HIV exposed children and its impact 
on malaria 
Nyanyiwe Masingi Mbeye 
Introduction and methods 
The rapidly growing population of HIV exposed children entails widespread use of cotrimoxazole 
prophylactic treatment (CPT) to protect them from HIV opportunistic infections given their increased 
susceptibility compared to non-HIV exposed children. A number of studies have reported that CPT 
also provides protection against malaria but estimates of its effectiveness vary and there is little 
information on the impact of the prevalence of antifolate resistance mutations on its effect. Since daily 
CPT provides prophylaxis against malaria, it could modulate the development of malaria-specific 
immunity and increase the incidence of malaria after it is stopped (a rebound effect). Moreover, 
factors that influence CPT adherence in this group are not known. This thesis reviewed studies that 
examined the effect of CPT provided at the age of 6 weeks to 14 months on malaria incidence in 
children in Sub-Saharan Africa (systematic review) and investigated the incidence of malaria and 
other morbidities during and after CPT in the first two years of life in HIV exposed children in 
southern Malawi (cohort study). Lastly, CPT adherence was explored using narrative and grounded 
theory approaches (qualitative study). 
Results 
The systematic review included 3 Randomised Controlled Trials (RCTs) and four cohort studies 
fulfilling the eligibility criteria, with a total of 5,978 children (1,692 HIV exposed; 2,800 non-HIV 
exposed; 1,486 HIV-infected). Children on CPT were less likely to develop clinical malaria episodes 
than those without prophylaxis (combined Incidence Rate Ratio (IRR) = 0·37, 95% CI 0·21, 0·66) but 
there was substantial between-study heterogeneity (I-squared=94%, p<0·001). The protective efficacy 
of CPT was highest in an RCT from Mali, where the prevalence of antifolate resistant plasmodia was 
low. In meta-regression analyses there was some evidence that the efficacy of CPT declined with 
increasing levels of resistance. Mortality was reduced with CPT in an RCT from Zambia, but not in a 
cohort  study  from  Côte  d’Ivoire.    In  the  cohort study of 500 HIV exposed and 500 non-HIV exposed 
children matched on age and residence; the incidence of uncomplicated malaria was 65% lower in 
year 1 in the HIV exposed group (IRR = 0.35, 95% CI 0.25, 0.49, p<0.001). In year 2 after CPT was 
stopped, the incidence was similar to that in non-HIV exposed group (IRR = 0.94, 95% CI 0.53, 1.68, 
p=0.839) among the first 315 children that had completed the follow-up period at the time of the 
analysis. The same pattern was observed for all-cause morbidity and hospital admissions where a 
lower risk was observed during year 1 and similar estimates between the groups were obtained in year 
2.  In the qualitative study, Participation in the cohort study empowered HIV infected women to 
make  decisions  about  their  children’s  health  and  develop  useful  strategies  to  promote  uptake  of  CPT.  
The women themselves, their families, the communities in which they lived and the health care system 
related and influenced each other through social interaction which played a role in influencing actions 
either positively or negatively. Despite negative influences that might have arisen at any level, the 
determination of the individual to take a health related action and the realisation that the recommended 
action would prevent any negative outcomes motivated the mothers to believe that they could 
successfully do something to prevent any negative health outcomes on their children. 
Conclusions  
CPT significantly reduced the incidence of malaria in children in the systematic review and meta-
analysis as well as in HIV exposed children in the cohort study in year 1. Marked reductions in the 
incidence of severe malaria, all-cause morbidity and hospital admissions during the period in which it 
was given were observed in the cohort study. Although the cohort study was not able to show any 
benefits on all-cause mortality, CPT was associated with significant reductions in mortality in the 
systematic review. The follow up in year 2 is on going but preliminary results suggest that the 
incidence of malaria does not increase after cessation of CPT at 14 months of age. The improved 
health outcomes of HIV infected women motivate the women to continue administering CPT to their 
children despite any deterring factors that might arise.  
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CHAPTER 1 : GENERAL INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“Footprints  made  in  the  sands  of  history  are  not  made  by  the  ones  sitting  down” 
- Bob Moawad (modified) 
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1.1 Introduction 
The co-existence of HIV and malaria in sub-Saharan Africa poses serious public health 
challenges as they both affect children under the age of five and pregnant women more 
(Steketee, 2001). To date, there has been wide scale up of Prevention of Mother to Child 
Transmission (PMTCT) of human immunodeficiency virus (HIV) interventions in most 
settings in sub-Saharan Africa (UNAIDS, 2013c). Sustained progress of the uptake of 
PMTCT interventions has reduced the incidence of HIV infections in children (UNAIDS, 
2013c). Although not infected with HIV, the exposure to HIV in children born to HIV 
infected women increases their susceptibility to opportunistic infections due to their 
continued exposure to HIV during breastfeeding and a compromised maternal immune 
system caused by HIV in the mother, which may lead to reduced transplacental transfer of 
antibodies to the foetus in utero (Moraes-pinto, 1996). At birth, these children are 
challenged with increasing numbers of virulent congenital or maternally acquired neonatal 
infections resulting from increased shedding and higher pathogen levels related to 
immunosuppression in HIV infected mothers (Moraes-pinto, 1996). This likely interferes 
with the ability to adequately support development of infant’s immune capacity and viral 
exposure of the foetus in utero resulting in reduced capacity of the infant himself to fight 
common infections (Chougnet, 2000b, Clerici, 2000). These immunological deficiencies 
also interfere with the levels of immunoglobulin present in breast milk which are 
important in protecting infants against infections (Thomas, 2004). In the absence of any 
form of treatment, HIV infected children have a 2 year median survival (Dunn, 2003) with 
significantly higher mortality at all ages than their HIV exposed but not infected 
counterparts (Brahmbhatt, 2006) although when compared with non-HIV exposed 
children, HIV exposed children, have a 16% higher mortality (Brahmbhatt, 2006). Severe 
morbidity and early mortality in HIV infected and HIV exposed children more than 
doubles when maternal CD4 counts are low and HIV viral load (HIV RNA) is high 
(Brahmbhatt, 2006). Without any mitigating interventions these children experience high 
fatality rates of between 40-90% from PCP, a severe form and rapidly progressive 
pneumonia that generally occurs between 3 and 6 months of life, often as the first sign of 
HIV infection and before child is definitively determined to be HIV infected (Rabkin, 
2005). 
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As a preventive measure, HIV exposed children are currently being given daily 
cotrimoxazole prophylactic Treatment (CPT) from the age of four to six weeks or at their 
first encounter with the formal health services, until they stop breastfeeding and are no 
longer at risk of getting infected (WHO, 2009b). Cotrimoxazole has been shown to be 
effective in reducing bacterial infections even in areas where there is a high background in 
vitro resistance to it (Chintu, 2004). In addition, it potentially offers an effective and 
sustained malaria chemoprophylaxis, even in areas like Malawi, Uganda and others where 
resistance to sulphonamides may be high (van Oosterhout et al., 2005), and significantly 
lowers incidence of malaria episodes, both parasitaemic and presumptive among both HIV 
exposed and HIV infected children (Graham, 2010). This could potentially impair the 
acquisition of natural immunity to malaria in infants and therefore abrupt cessation of 
cotrimoxazole use at 12 months after stopping breastfeeding in children who remain HIV-
negative could be associated with an increased risk of malaria in terms of frequency and 
severity in the following year. There is a wide variation between studies on the effect of 
CPT on malaria hence the studies described in this thesis are designed to systematically 
review the effect of CPT on malaria incidence and investigate the risk and benefits 
associated with its use in HIV exposed infants during the period that they are taking it and 
in the year after they have stopped but also understand the household level impact related 
to administering daily CPT to HIV exposed children.  
 
Presently   in   Malawi,   there   is   an   ‘opt   out’   system   where   all   pregnant   women   are  
encouraged to test for HIV (Health, 2012). Therefore, all women are offered HIV testing 
and those found positive are offered anti-retroviral therapy (ART) which is usually a 
combination of Tenofovir (TDF), Lamivudine (3TC) and Efavirenz (EFV). This is a 
modification of the newly WHO recommended PMTCT regimen also known as Option 
B+ for all HIV infected as well as breastfeeding women. Breastfeeding infants born from 
these mothers are given Zidovudine (AZT) or Nevirapine (NVP) from birth until 4-6 
weeks (Health, 2012). Between the age of 4-6 weeks, guardians bring infants to the 
PMTCT clinic where a filter paper sample is taken for HIV PCR testing. If positive they 
start on ART immediately. However if the infant is negative and the mother would like to 
breastfeed, infants are put on daily CPT for the entire period they are breastfeeding. They 
are then requested to return to the PMTCT clinic every month for review. Using the 
present WHO guidelines on HIV and infant feeding (WHO, 2009a), mothers are 
recommended to breastfeed until the child is 12 months old and/or even more. Studies in 
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Malawi have generally reported low uptake of PMTCT interventions largely related to 
fear of negative community reactions, lack of spousal support and also failure to disclose 
one’s  HIV  status  (Chinkonde, 2009, O'Gorman, 2010) 
 1.2 Study Aims and Objectives 
1.2.1 Overall Objective:  
To investigate the risks and benefits of daily CPT in HIV exposed children on malaria and 
other co-morbidities, and explore the perceptions around the impact at household level of 
administering daily CPT.  
 1.2.2 Specific Objectives: 
 To systematically review the effect of CPT on the prevention of clinical malaria 
and all-cause mortality in HIV positive and HIV exposed children in different 
settings in sub-Saharan Africa by conducting a systematic review of the literature 
and a meta-analysis. 
 To compare the incidence of uncomplicated and severe malaria, all-cause sick 
visits, all-cause hospital admissions and all-cause mortality in HIV exposed 
children before and after stopping daily CPT to non-HIV exposed children in a 
cohort study in southern Malawi. 
 To explore the lived experiences of HIV positive mothers giving daily CPT to their 
children by conducting a social science study in southern Malawi. 
1.3 Thesis Structure  
This thesis is presented in six chapters. Chapter one presents the introduction/background 
information to the study area and introduces the overall aim and specific objectives for the 
thesis. Chapter two gives a detailed review of the literature highlighting relevant evidence 
on the subject matter. The systematic review and meta-analysis follow in chapter three 
presenting available evidence on the use of cotrimoxazole for preventing malaria in sub-
Saharan African children. Chapter four provides the introduction, methods, results and 
discussion for a large epidemiological cohort study comparing the effect of CPT in the 
period when HIV exposed children were taking daily CPT (year 1) and the period when 
they had stopped (year 2). The qualitative study on experiences of HIV infected mothers 
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administering daily CPT to their HIV exposed but uninfected children are presented in 
Chapter five.   
 
Most chapters are separate studies on their own and addressing a specific objective given 
in the introductory chapter of the main thesis. For example, chapter three addresses 
specific objective number one while chapter four and five address specific objectives two 
and three respectively. At the end in chapter six, a general discussion, recommendations 
and conclusions for all the three studies are presented. Figure 1.1 illustrates the structure 
of this thesis.  
1.4 Definition of Terms 
HIV Exposed children: Infants or children born to mothers living with HIV 
Non-HIV Exposed children: Infants or children born to mothers not living with HIV 
(HIV negative mothers) 
HIV Infected children: Infants or children infected with HIV 
Adherence to medication: The extent to which patients take medications as prescribed by 
their health care providers 
Rebound malaria: A hypothetical overshoot that could occur in populations that have 
lost their immunity 
Uncomplicated malaria: Symptomatic infection with malaria parasitaemia without signs 
of severity and/or evidence of vital organ dysfunction 
Severe Malaria: Acute malaria with major signs of organ dysfunction and/or high level of 
parasitaemia 
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Figure 1.1: An illustration of thesis structure 
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2.1 Introduction 
This chapter describes an up to date understanding of the epidemiology of malaria in children 
in the context of this study, available malaria control interventions and factors influencing 
uptake and impact of these interventions on households. 
2.2 The Malaria Parasite  
Severe malaria and deaths in endemic Africa are mostly attributable to malaria resulting from 
infection with Plasmodium falciparum parasites, which is the most virulent of the five species 
of Plasmodium known to infect man (P. falciparun, P. vivax, P. malariae, P. ovale and P. 
knowlesi).  Briefly, P. falciparum is more prevalent in Africa south of the Sahara (Mmbando 
et al., 2009). Its characteristic feature of destroying red blood cells and adherence to cells in 
certain tissues gives rise to problems such as severe malarial anaemia and cerebral malaria 
respectively resulting in death (Mmbando et al., 2009). P. vivax is another important malaria 
species that is recognized to have a more widespread distribution primarily occurring in areas 
outside Africa. Its ability to survive in cooler climates allows it to develop inside the 
mosquito vector at lower temperatures subsequently causing infections during winter periods 
when P. falciparum is less prevalent (WHO, 2013b). The most minor of the Plasmodium 
species are P. ovale and P. malariae whose infections are mild in nature and less prevalent in 
most endemic areas. The unusual characteristic feature of P. malariae is its chronic blood 
stage infection which may take years (Institute, 2013). Recently, P. knowlesi, a simian malaria 
parasite with similar clinicopathological syndrome to P. falciparum has been established as a 
fifth human Plasmodium species. This parasite is commonly found in forest areas of 
Southeast Asia in Malaysia, Singapore and other countries in the region initially affecting 
humans in close proximity with macaque monkeys but recent data indicates that P. knowlesi 
might exist in communities further from the forests (Drakeley, 2014). This knowledge has led 
to more studies being currently conducted by a consortium led by the London School of 
Hygiene and Tropical Medicine. The aim is to characterise the biological, environmental and 
social factors responsible for causing infections within human populations and determine the 
magnitude of public health threat caused by P. knowlesi (Drakeley, 2014). Its unique feature 
that distinguishes it from P. falciparum is that it does not sequester significantly in the 
microcirculation (White, 2008). Previously, P. knowlesi was misdiagnosed as P. malariae 
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because microscopy could not differentiate the two. However, following results from nested 
Polymerase Chain Reaction (PCR) speciation assays, Singh et al were able to confirm that P. 
knowlesi was responsible for causing malaria in humans (White, 2008, Singh, 2008).  
 
In most malaria endemic areas, infections caused by two or even more malaria parasites are 
more frequent. In tropical regions, P. falciparum and P. malariae tend to occur together while 
mixed infections of P. falciparum and P. vivax are common in sub-tropical areas. When this 
happens, the complications of P. falciparum which usually tend to be the dominant species 
are reduced (Warrell, 2002). Since parasite detection mainly targets P. falciparum in most 
settings where P. falciparum is dominant, P. vivax may be missed during diagnosis resulting 
in its reappearance after some time. This requires appropriate programming of control 
interventions. There have also been mixed infections of P. falciparum and P. ovale (Warrell, 
2002).  
2.3 The malaria burden in children in sub Saharan Africa (SSA) 
The survival of children early in life is adversely affected by exposure to malaria during 
pregnancy which in addition to contributing to spontaneous abortions and stillbirths, largely 
accounts for premature delivery, low birth weight and overall mortality (Murphy, 2001, 
Desai, 2007).  Murphy and Breman estimated that each year, each child aged <5 years 
experiences four to nine febrile episodes of which 30-60% is a result of malaria (Murphy, 
2001). These febrile illnesses are a major cause of hospital admissions in SSA (Murphy S.C., 
2001). An analysis of 200 articles on malaria in children, showed that the annual hospital 
admission rate for children <5 years presenting with malaria or malarial febrile episodes is 
31/1000 which translates to almost 3 million children with malaria who are admitted to clinics 
each year in endemic areas (Murphy S.C., 2001). Moreover, as much as 20% of all deaths in 
children under five years of age in Africa are attributable to malaria (WHO, 2001). WHO 
estimates show that in 2012, 80% of the more than 200 million P. falciparum malaria 
episodes worldwide and 90% of all deaths from malaria occurred in Africa (WHO, 2013b). Of 
these malaria deaths, 77% were among children under the age of five (WHO, 2013b). Apart 
from preterm delivery and low birth weight; complications of severe malaria such as cerebral 
malaria and severe malarial anaemia (SMA) are principle ways in which malaria contributes 
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to child mortality (Murphy S.C., 2001). African vectors have a long life span and a strong 
human-biting behaviour which may suggest why more than 90% of the global malaria deaths 
are occurring in Africa (WHO, 2003b).  
2.4 The health situation and malaria in under-five children in Malawi 
2.4.1 Health profile for under-five children in Malawi 
According  to  a  United  Nations  Children’s  Fund  (UNICEF)  report,  over  600  children  are  born  
every year in Malawi. The majority of these (94.5%) are initiated on breastfeeding 
immediately after birth and 86.4% are introduced on supplementary foods by the age of 
between six and eight months. The neonatal, infant and under-five mortality rates in Malawi 
in 2012 were estimated to be 24, 46 and 71 per 1,000 live births (Table 2.1).  The under-five 
mortality rate decreased markedly from 244/1000 live births in 1990 to 71/1,000 live births by 
2012. The most common causes of morbidity in the under-fives between 2008 and 2012 in 
these children were pneumonia (70.3%), followed by diarrhea (69%). During this period, 
32.5% of the children who had a febrile illness were treated with an antimalarial (UNICEF, 
2013). Although there has been great achievements in the scale up of PMTCT interventions 
and that these have led to the reduction of new HIV infections among children globally, 
180,000 children aged 0-14 years were still living with HIV in Malawi in 2012 (UNAIDS, 
2013c). 
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Table 2.1: Selected basic health indicators for children in Malawi  
Indicator 
Total population under-five children (million) in 20121 2.8 
Under-five mortality rate (per 1,000 live births) in 2012 71 
Infant mortality rate (per 1,000 live births) in 2012 46 
Neonatal mortality rate (per 1,000 live births) in 2012 24 
Annual number of births (per 1,000 total population), 2012 638.9 
Annual number of under-five deaths (thousands), 2012 43 
Prevalence of low birth weight (%), 2008-2012 13.5 
Early initiation of breastfeeding (%), 2008-2012 94.5 
Exclusive breastfeeding <6 months (%), 2008-2012 71.4 
Breastfeeding at age 2 years (%) 2008-2012 76.8 
Pneumonia (%) 2008-2012, care seeking for suspected pneumonia 70.3 
Diarrhoea (%), 2008-2012 treatment with ORS 69 
Malaria (%) 2008-2012, antimalarial treatment among febrile children 32.5 
Children aged 0-14 years living with HIV 2012 180,000 
Orphans due to AIDS 2012 770,000 
Women aged 15 and above living with HIV 2012 560,000 
HIV prevalence (%) among pregnant women 2012 10.6 
Source: http://www.unicef.org/infobycountry/malawi_statistics.html 
 
2.4.2 Provision of health Services in Malawi 
The Ministry of Health (MoH) is the main provider of health services in Malawi providing 
about 60% of all health services. The Christian Health Association of Malawi (CHAM) is the 
second largest provider contributing about 37% of health services. The remaining 4% is 
shared among the Ministry of Local Government, private sector and commercial companies 
(Health, 1999). These services are provided at three main levels: primary, secondary and 
tertiary. In Zomba district, free public health services are provided at Zomba Central hospital 
(ZCH) and 33 Health Centres run by the Zomba District Health Office (MLGRD, 2013). The 
mission hospital and private hospitals offer their services at a fee.  Zomba Central hospital is a 
tertiary hospital under the MoH serving as a referral hospital for all the other hospitals in the 
whole eastern part of the southern region. However, because there is no district hospital in the 
district, it also serves as a district hospital.                                                         
1 Projected under-five population by the National Statistics OfficeNSO. 2008. 2008 Population and Housing 
census. National Statistics Office, Zomba, Malawi.  
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2.4.3 The malaria disease burden in under-five children in Malawi 
Estimates by the Health Management Information System (HMIS) show a rise of 
approximately 40% in new cases of malaria in the general population from 3.6 million in 
2004 to 6.1 million in 2009 despite successful implementation of malaria control 
interventions outlined in the 2005-2010 national malaria strategic plan (MoH, 2005b). These 
infections account for more than 33% of all outpatient visits and remain the principle cause of 
morbidity and mortality in pregnant women and under-five children (MoH, 2012) and a 
leading cause of hospital admissions in these children (Buhendwa, 2008). Most of the 
hospitalisations from malaria and anaemia (often attributable to malaria) are also responsible 
for about 30% of all hospital deaths in under-five children (Buhendwa, 2008). Malawian 
children under the age of five, just like elsewhere in parts of endemic Africa, are at the 
greatest risk because during this time they have lost the immunity they acquired 
transplacentally from their mothers and have not yet acquired adequate protective immunity 
against severe malarial disease (Ndawala J., 2000). However, severe disease and death from 
malaria decline as the children grow (Snow, 1998) mainly because of acquisition of malaria 
specific immunity which is achieved by exposure to malaria infection (Doolan, 2009). 
2.4.4 Malaria transmission in Malawi 
Malaria occurs throughout the country all year round. Hospital based data by the HMIS 
indicates that there were 6.1 million malaria cases in 2009 (MoH, 2011b) representing nearly 
50% of the whole population. Half of these occurred in children under the age of five. 
However, these figures could likely increase if community based active malaria surveillance 
data were also used together with hospital data to estimate prevalence. For instance, a recent 
nationwide Malaria Indicator Survey (MIS) reported a malaria prevalence rate of 43% in 
children aged between 6 months and five years who did not show any malaria symptoms 
(MoH, 2012). The MIS is a nationally representative assessment of the coverage of malaria 
control strategies conducted every two years within six weeks of the end of the rainy season 
in malaria endemic countries mostly in sub Saharan Africa (MoH, 2012). 
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2.4.5 Common malaria vectors in Malawi 
In Malawi, malaria is endemic in 95% of the country with over 98% of malaria infections 
caused by Plasmodium falciparum (Buhendwa, 2008, Mzilahowa, 2012). The main malaria 
vectors prevalent in Malawi are Anopheles funestus, Anopheles gambiae and Anopheles 
arabiensis (Spiers, 2002, Mzilahowa, 2012). Some variation from high to low malaria 
transmission intensity has been observed within Malawi such that areas with higher 
temperatures along the lakeshore and lowlands of the lower Shire experience high malaria 
transmission resulting in average annual infection prevalence of more than 40% or more 
compared to upland areas which have relatively cool temperatures especially in most parts of 
the Northern region of Malawi with average annual infection prevalence of less than 5% 
(Gething, 2011, Services, 2007). High transmission has also been observed during the rainy 
season that begins in October and lasts in April in most parts of the country. Although a 
decrease in malaria-specific mortality by 2.2% was registered during the period 2004 to 2009, 
a steady increase in malaria incidence was observed among both under five children and those 
aged more than 5 years over the same period (MoH, 2010, MoH, 2012).  
 
2.4.6 Strategies for malaria control in Malawi 
In its efforts to curb malaria, the government of Malawi through the National Malaria Control 
Programme (NMCP) has ranked malaria as one of its priorities in the Essential Health 
Package that aims at directing scarce resources to public health and clinical services provided 
for free at both primary and secondary care levels (Njie H., 2007). This has been the most 
effective and efficient way of improving health services delivery in resource limited settings 
like Malawi. With assistance from its development partners, the government of Malawi 
embarked on scaling up different malaria control interventions as outlined in its 2011-2015 
National Malaria Control Strategic plan (MoH, 2011b) with a goal to achieve universal access 
of all malaria control interventions by 2015 through:  
 Increasing the proportion of those suffering from malaria who have access to and are 
able to use correct, affordable and appropriate treatment within 24 hours of onset of 
symptoms from 21.9% to 50% 
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 Increasing the proportion of pregnant women who have access to and receive two or 
more doses of Intermittent Preventive Treatment in pregnancy (IPTp) for malaria 
prevention from 60.3% to 80% 
 Increasing percentage of children under five years of age sleep under an Insecticide 
treated Net (ITN) from 55.4% to 80% 
 Increasing percentage of pregnant women sleep under an ITN from 49.4% to 80% 
 Increasing number of high burden districts implementing Indoor Residual Spraying 
(IRS) from 1 to 12 
 Increasing number of households owning at least one ITN from 58.1% to 90% 
 Increasing percentage of out-patient suspected malaria cases who are confirmed by 
microscopy to 50% 
 Increasing percentage of out-patient suspected malaria cases who are confirmed by 
malaria Rapid Diagnostic Test (mRDT) from 0% to 80% 
2.4.7 Uptake of malaria control interventions in Malawi 
One year into implementation of the 2011-2015 malaria strategic plan, progress in uptake of 
some malaria control measures is being registered as reported by the 2012 Malaria Indicator 
survey (MIS) report notably the increase from, 55.4% to 56% in the proportion of children 
under the age of five sleeping under an ITN in the previous night. During the same period, the 
proportion of children aged below five years with fever who had received an effective 
antimalarial treatment on the same day or next day increased by over 40% (MoH, 2012). 
Although vector control measures such as IRS are implemented at a small scale in specific 
districts, there has been an increase in scale of implementation from 2% of all households in 
2010 to 9% of all the households in 2012 (MoH, 2012, MoH, 2010). Despite the gains 
achieved with malaria control interventions, the disease still remains a serious public health 
problem and the need for strengthening uptake of these interventions and exploration of 
complimentary interventions cannot be overemphasized. Table 2.2Error! Reference source 
not found. is a summary of current uptake of malaria control interventions in children aged 
below five years. 
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Table 2.2: Malaria status and uptake of some control interventions in under-five 
children in Malawi in 2012 
Age in 
months 
Malaria 
prevalence by 
mRDT 
Prevalence of 
anaemia 
Hb<8g/dl 
Proportion with fever 
treated with an 
effective antimalarial 
within 24 hours 
Proportion slept under 
an ITN in the previous 
night 
6-8 35.9 13.0 68.1 62.7 
9-11 31.7 16.6 
12-17 31.6 12.9 64.0 58.3 
18-23 39.0 11.0 
24-35 46.1 9.4 68.8 55.1 
36-47 46.7 7.3 63.3 55.3 
48-59 50.0 4.1 57.6 48.9 
Source: Adapted from MIS report 2012 (MoH, 2012); Hb: Haemoglobin 
 
2.5 The vectors capable of transmitting malaria from man-to man  
The malaria parasite is transmitted from man-to-man exclusively through the bites of female 
anopheles mosquitoes (WHO, 2003b) which are capable of transmitting the parasite to 
hundreds of individuals in a space of  few months making it more infectious than HIV. There 
are about 400 different species of anopheles, but there are only about 60 that are vectors of 
malaria and of these, about 40 are important. The most important vectors in SSA are the An. 
gambiae complex, An. arabiensis, An. funestus, An. melas and An. merus (Service, 1996, 
Sinka E.S., 2010). The salt water tolerant coastal species of the An. gambiae complex like An. 
melas and An. merus despite not being as efficient at transmitting malaria as An. gambiae and 
An. Arabiensis, they are often found in high densities that they also achieve the Dominant 
Vector Status (DVS) (Bryan, 1983, Cuamba, 2009). 
  
It has been observed that distribution and abundance of the mosquito vector is determined by 
temperature and extent of water availability for larval breeding; seasonal fluctuation of 
mosquito populations; vectorial capacity (the number of new infective bites received daily by 
a single host) (Eldridge B.F., 2004) of the common vector species and duration of conditions 
suitable for mosquito survival (Shiff, 2006b). The best combination of adequate rainfall, 
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temperature and humidity have been associated with creating favourable conditions for 
breeding and survival of anophelines in the tropical areas of the world (CDC, 2010).   All of 
the important vector species bite at night and they breed in shallow collections of freshwater.  
More intense transmission is said to occur in places where the mosquito is relatively long-
lived (so that the parasite has time to complete its development inside the mosquito) and 
where it prefers to bite humans rather than animals (WHO, 2003b). This information suggests 
that understanding of malaria epidemiology is key to planning and targeting of effective 
control interventions. 
2.6 Malaria endemicity and disease pattern 
Several ways are used to measure the intensity of malaria transmission. The most direct 
measurement is the use of Entomological Inoculation Rate (EIR) which refers to the number 
of infectious bites per person per unit time usually measured or expressed per year. This 
method has been used to quantify the parasite-infected mosquito pool and its tendency to 
transmit parasites to human population (Shaukat A.M., 2010). In order to measure the 
prevalence of peripheral blood-stage  infections  in  the  community,  the  parasite  ‘rate’ (PR) (the 
proportion of the population or sample that is infected with asexual stage parasites) (Hay, 
2008, Gething, 2011) has been utilised. In younger children aged between zero and eleven 
months in areas with perennial intense transmission, the parasite rate constantly exceeds 75% 
(MAP, 2010). This happens because of increased susceptibility to malaria due to lack of 
malaria specific immunity in this age group. Moreover, similar estimates have been observed 
with the use of spleen rates to describe endemicity patterns of malaria in different regions 
(Warrell, 2002). These two measurements however, fall short of capturing the seasonality in 
transmission of malaria as compared to EIR. The strengths and weaknesses of these 
measurements as summarized in Table 2.3 may guide in the selection of a more appropriate 
method depending on the context.  
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Table 2.3: Indices of malaria transmission 
Index What is measured Advantages Disadvantages 
Entomological 
Inoculation 
Rate (EIR) 
Infectious bites per 
unit time (usually per 
year) 
Direct reflection of 
vector control and 
antigametocidal 
drugs 
 No standard protocols 
 Variability in 
methodologies 
 Few trained specialists 
Parasite Rate 
(PR) 
Proportion of the 
population found to 
carry asexual 
parasites in RBCs; 
can also assess 
gametocyte rates; by 
age group 
Direct reflection of 
inoculation, 
immunity and 
treatment 
effectiveness in 
humans 
 Microscopy 'gold standard' 
 Prone to technical efforts 
 Changes may occur 
following environmental 
and control factors 
Annual 
Parasite Index 
(API) 
Number of parasite 
infections in a well-
defined geographical 
area; usually per 
1,000 persons per 
year 
Direct reflection of 
all prevention and 
control effects on 
humans 
 Depends on active case 
detection system, which is 
often poor 
Spleen rate 
(SR) 
Proportion of 
children 2-9 years of 
age with a palpable 
spleen 
Non-invasive, 
indirect way of 
measuring impact of 
malaria on spleen 
 Variability in examiners; 
 Many causes of 
splenomegaly; 
 Point prevalence 
measurements can 
vary/change rapidly 
Source: Shaukat, A.M., et al., Malaria journal, 2010; 9:122 (Shaukat A.M., 2010); RBC: Red Blood Cells 
 
Malaria transmission tends to vary across regions. On one end of the transmission spectrum is 
stable transmission which is characterised by intense transmission either throughout the year 
or during the rainy season. On the other end is unstable transmission with seasonal 
transmission under normal rainfall conditions and a decline in transmission in times of 
drought. However, P. falciparum malaria transmission is endemic in most parts of Africa, 
Southeast Asia and South America (Figure 2.1) (Gething, 2011). 
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Figure 2.1:The spatial distribution of Plasmodium falciparum malaria endemicity in 
2010 
 
 
 
Source: Gething et al, Malaria Journal 2011. http://www.malariajournal.com/content/10/1/378 
Key: Dark   grey   areas   =   Stable   malaria   (PfAPI   ≥0.1   per   1,000   pa;;  Medium   grey   areas   =   Unstable   malaria  
(PfAPI<0.1 per 1,000 pa); Light grey areas = No risk (PfAPI = 0 per 1,000 pa) (Gething, 2011) 
 
This geographical variability in malaria transmission intensity, explains why population 
groups at risk of malaria also differ as well as their control measures. It is estimated that the 
majority of deaths in tropical Africa occur in areas of stable transmission of falciparum 
malaria. In these areas, the two groups at highest risk are very young children, mainly because 
they have not yet acquired clinical immunity and pregnant women, whose immunity to 
malaria is temporarily impaired (WHO, 2003b, Chuma J., 2010). Evidence of more adult 
malaria has been observed in areas of unstable transmission often with low transmission 
intensity especially during the rainy season. Unlike in stable malaria transmission areas, in 
unstable areas, children aged between 4 and 6 easily succumb to cerebral malaria. 
Nevertheless, seasonal morbidity is seen in all population groups (Shiff, 2006b).  
2.7 Determinants of malaria transmission 
Historically, malaria transmission has been associated with both climatic and non-climatic 
factors in addition to social and human host factors.  
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2.7.1 Climatic factors  
Climate refers to “the average pattern of variation in temperature, humidity, atmospheric 
pressure, wind, precipitation, atmospheric particle count and other meteorological variables in 
a given region over long periods of time” (NASA, 2005, NAMC, 2014, Skybrary, 2014). At 
global level, climatic factors significantly influence the pattern and level of malaria 
transmission. Among the factors outlined in the definition; temperature, rainfall and humidity 
have been described to directly influence malaria transmission.  
2.7.1.1 Temperature 
Temperature highly influences development of both the vector and parasite. Increases of 
about 30-100% in mosquito abundance have been associated with an increase of just 0.5 
degrees Celsius in temperature and more recent modelling suggests that even at relatively 
lower temperatures such as 26 degrees Celsius, malaria transmission can occur (Mordecai, 
2013) compared to previously reported temperature ranges of 32-33 degrees Celsius for 
endemic transmission and optimum rate of spread in disease-free regions (Craig, 1999, 
parham, 2010). Optimal temperatures are believed to increase the number of blood meals and 
reproduction resulting in the abundance of mosquitoes (Clements, 1992) and allow for 
successful development of the parasite to reach the infective stage within the mosquito 
furthermore  facilitating the process of sporogony. In contrast, very low temperatures have 
been shown to delay this process while higher temperatures on one hand are associated with 
more rapid development of vectors and increased frequency of feeding by female anopheles 
mosquitoes. However, when the temperatures are very high, they lead to the development of 
smaller and less fertile adult mosquitoes. High levels of malaria transmission have been 
reported to occur in low-lying areas and most tropical areas because these areas have 
favourable conditions for malaria transmission like warmth and constant temperatures than 
highlands (Atieli, 2011, Minakawa, 2006).   
2.7.1.2 Rainfall 
Another important determinant of malaria transmission is rainfall. This explains high malaria 
transmission after the rainy season in most areas of unstable transmission (Shiff, 2006a). In 
the Africa Sahel where malaria is predominantly seasonal, malaria incidence increases by 
more than 2-fold during the rainy season compared to the dry season affecting younger 
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children aged 2-4 years more than older children. This is largely attributed to the high EIR of 
0.78 infective bites/person/per night resulting from fluctuation of mosquito abundance as 
Anopheles gambiae s/l. are seen to breed more prolifically in temporary and turbid water 
bodies such as ones formed by the rains (le sueur, 1988). Very excessive rains however, have 
been associated with washing away of slowly moving waters where mosquito larvae breed 
resulting in disruption of breeding sites as mosquito larvae and pupae get stranded along the 
banks of streams and some are washed away (Warrell, 2002) although in some highland areas 
in Uganda excessive rainfall has been associated with increased malaria (Kilian, 1999). A 
study in western Kenya observed that with a monthly 10 millilitre increase in rainfall, malaria 
cases increased from 1.4% to 10.7% in the highlands with a 2-3 month lag time (Hashizume, 
2009). However, the situation might be different in low-lying areas. Figure 2.2 demonstrates 
the association between rainfall and vector density. High vector density was observed during 
the rainy season compared to the dry season when a series of entomological surveys based on 
human landing catches in Benin (Cottrell, 2012) were conducted. In these surveys, 
mosquitoes were collected between 10 pm and 6 am every six weeks for two years and 
rainfall was recorded twice daily. High parasite density was present during the rainy season 
compared to the dry season. This demonstrates the significant contribution of rainfall on 
malaria transmission, as highland areas are usually associated with low transmission. 
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Figure 2.2: Number of Anopheles gambiae s.l. collected per man per day as a function of 
rain 
 
Source: Cottrel, G., Kouwaye, B., et al., PloS One 7(1); 2012 (Cottrell, 2012) 
2.7.1.3 Humidity 
There is lack of studies that have demonstrated the direct relationship of humidity on its own 
to malaria transmission. The distribution of the mosquito vector has mainly been related to 
relative humidity which refers to the amount of moisture in the air at a specific temperature, 
expressed as a percentage (Yang, 2010). Temperature thus plays a major role in determining 
the extent of malaria transmission (Yang, 2010). Areas with relative humidity of more than 
60%, have been associated with the increase in the longevity of adult vectors (Warrell, 2002) 
which even doubles when relative humidity reaches 80% (Ye, 2008). With high relative 
humidity, mosquitoes have shown to have better survival and their activity increases. This 
may explain why they prefer to feed during the night as the relative humidity is higher at 
night (Haque, 2010).  
2.7.2  Non-climatic factors 
2.7.2.1 Malaria vectors 
The variability in the transmission ability of different species of mosquitoes depends on the 
biology and behaviour of the mosquitoes themselves. The Anopheles gambiae group are 
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known as the most efficient malaria vectors in the world (Sinka, 2010). Their preference to 
bite human beings than feeding on animals and their ability to occupy and breed in a wide 
range of sites (Takken, 2003) partly explains the higher malaria incidence in Africa where the 
An. gambiae is predominant compared to the other parts of the world.  
2.7.2.2  Social Factors 
The local and regional differences in levels of socio economic development may explain the 
variability in malaria burden (Breman et al., 2004).  Factors observed to determine this 
variability include access to health care and health education, quality of housing, general 
poverty as well as the existence of active malaria control programmes that provide access to 
malaria prevention and treatment measures (WHO, 2005b). This explains high burden of 
malaria in poorest nations in Figure 2.1 (CDC, 2010, Gething, 2011) where poverty is often 
wide spread and access to health services is often poor (Wang, 2005). These countries 
generally have the least resources for adequate control efforts (WHO, 2003b) while in 
developed countries, industrialization and improved housing conditions were instrumental in 
the elimination of malaria (Budiansky, 2002).   The process of urbanization in these areas 
eliminated open spaces for mosquito breeding, increased pollution of the remaining breeding 
sites thereby limiting the dispersion opportunities for adult mosquitoes (Lindsay, 1990) and 
lowering of the vector densities resulting in decreased malaria exposure per capita (Trape, 
1987, Smith, 2004). Although most African settings are currently undergoing urbanization, 
the process is often marked with poor drainage systems, sanitation and housing and wide 
economic imbalance that have facilitated malaria transmission (Wang, 2005). The problem of 
urban malaria has been recognized by many authors and following this, a meeting convened 
by the Knowledge Program at the Liverpool School of Tropical Medicine and the 
International Water Management Initiative/System-wide initiative on malaria, issued the 
Pretoria Statement on Urban Malaria that emphasized the need to protect vulnerable people 
from effects of urban malaria in order to preserve their livelihoods and build conditions for 
economic growth and to avoid diversion of scarce resources away from rural areas 
(Donnelley, 2005). Unless appropriately addressed, urban malaria in SSA will remain a major 
public health problem. 
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2.7.2.3  Human host factors 
Host susceptibility to malaria plays a major role in malaria disease pattern. Epidemiologic 
studies conducted in areas of high malaria transmission in Africa and Southeast Asia; indicate 
an age-dependent development of protective immunity against malaria (Sharma K.S., 2004). 
The acquisition of clinical immunity to malaria is said to be dependent upon the frequency of 
parasite exposure from birth (Doolan, 2009). Consequently, the age at which disease 
presentation heightens, the clinical span of disease and the life-time risks of disease, appear to 
be influenced by the intensity of transmission in a given community (Snow, 1998). As a result 
of this, malaria mortality is highest during the first few years of life in areas with high 
transmission rates. However in the absence of any sustained malaria prevention strategies, by 
the age of five, most children develop a considerable degree of immunity which reduces the 
risk of P. falciparum malaria specific mortality, provides protection against severe disease 
and reduces the frequency of clinical malaria episodes (Sharma K.S., 2004) (Marsh, 1992). 
For this reason, young children in Africa are more likely to die from malaria as they are yet to 
develop their immunity, whereas in areas with less transmission and low immunity, all age 
groups are at risk (WHO, 2000b). In HIV infected and HIV exposed children, the process of 
acquiring malaria specific immunity in the presence of an inadequate transplacental transfer 
of immunoglobulins from the HIV infected mother (Moraes-pinto, 1998) and effective 
malaria prevention strategies (Chougnet, 2000a) is complex. 
2.8 Malaria Diagnosis 
Several methods for diagnosing malaria are in use in many parts of the world. Malaria can be 
diagnosed by using laboratory methods as well as clinical methods (Wilson, 2013). Table 2.4 
summarizes the most commonly used methods, their advantages and disadvantages. For 
laboratory diagnosis, WHO recommends use of both microscopy and malaria Rapid 
Diagnostic Tests (mRDTs) for detection of malaria parasites in places where both are 
available (WHO, 2011).  In such circumstances, microscopy helps in confirming whether 
mRDTs are able to detect malaria when determination of parasite density is required. In terms 
of clinical diagnosis, medical personnel can diagnose the disease using the medical 
knowledge and other signs and symptoms presented by the patient. However, self-diagnosis is 
also a common method in many African settings where patients diagnose themselves as 
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having malaria. For example, in Sierra Leone, more than 75% of individuals reported to have 
diagnosed themselves after experiencing symptoms suggestive of malaria (Ansumana, 2013).  
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Table 2.4: Description of available malaria diagnostic methods 
Method Sensitivity/Specificity Advantages Disadvantages 
Rapid diagnostic test: based on 
pLDH: 
(Optimal-Flow Inc) 
Sens: 93.2% 
Spec: 98.5% 
       Differentiates P.falciparum from non-
falciparum infections 
       Speed and ease of use; minimal training 
requirements to achieve reliable result 
       Reportedly does not remain positive 
after clearance of parasites 
       No electricity, no special equipment 
needed; could be used in community 
outreach programmes 
       Cannot differentiate between non-
falciparum species 
       Will not quantify parasitaemia 
Rapid diagnostic stick test 
based on PfHRP-II: (ParaSight-
F- Becton-Dickinson; Malaria 
PfTest-ICT diagnosis) 
Sens: 84%-97% 
Spec: 81%-100% 
Lower values probably due 
to low parasite densities 
       Speed and ease of use; minimal training 
requirements to achieve reliable results 
       No electricity, no special equipment 
needed; could be used at health post or 
community outreach 
       Card format easier to use for individual 
tests; dipstick test easier to use for batched 
testing. 
       Will not diagnose non-falciparum 
malaria although subsequent generation 
tests will be able to do this 
       Will not quantify parasitaemia 
       Can remain positive after clearance 
of parasites 
Light Microscopy Optimal conditions: 
Sens: >90% 
Spec: 100% 
Typical field conditions: 
Sens: 25%-100% 
Spec: 56%-100% 
       Species-specific diagnosis 
       Quantification of parasitaemia aids 
treatment follow-up 
       Requires relatively high degree of 
training and supervision for reliable 
results 
       Sensitivity and specificity dependent 
on training and supervision 
       Special equipment and supplies 
needed 
       Electricity desirable 
       Time-consuming 
Fluorescent Microscopy: 
Acridine Orange (AO) stained 
thick blood smears 
AO: Sens: 42%-93% 
Spec: 52%-93% 
       Results attainable more quickly than 
normal microscopy 
       Special equipment and supplies 
needed 
       Sensitivity of AO poor with low 
parasite densities 
 
Table continued 
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Table 2.3 continued 
Method Sensitivity/Specificity Advantages Disadvantages 
Quantitative Buff Coat (QBC) 
– (Becton-Dickinson) 
QBC: 
Sens: 89% 
Spec; >95% 
 Speed and ease of use (takes 15 minutes 
to detect parasites) 
 Can easily detect low levels of 
parasitaemia as more blood is used per 
sample 
 No loss of parasites during the 
procedure 
       Electricity required 
       Unreliable species diagnosis; non-
specific staining of debris and non-
parasitic cells 
       QBC will not quantify parasitaemia 
       Acridine orange is a hazardous 
material 
Clinical, especially based on 
formal algorithm such as 
integrated Management of 
Childhood Illnesses (IMCI) or 
similar algorithm 
Variable depending on level 
of clinical competency, 
training and malaria risk 
(endemicity): with IMCI 
Low Risk: 
Sens: 87% 
Spec: 8% 
High Risk: 
 
Sens: 100% 
Spec: 0% 
       Speed and ease of use 
       No electricity, no special equipment   
needed beyond normal clinical equipment 
(thermometer, stethoscope, otoscope, timer) 
       Can result in high degree of 
misdiagnosis and over-treatment of 
malaria 
       Requires close supervision and 
retraining to maximize reliability 
Source: Wilson, M.L., et al., 2013; Bloland, P.B. WHO 2001 (Bloland, 2001, Wilson, 2013) 
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2.9 Major complications of malaria in under-five children 
In children, severe malaria is mainly manifested by three clinical syndromes. These include 
severe anaemia, cerebral malaria and increased rate of and depth of breathing commonly 
known as Acute Respiratory Distress Syndrome (Newton, 1998). Although severe malaria is 
mostly attributed to P. falciparum (WHO, 2000a), P. vivax and P. knowlesi can also cause 
severe disease (WHO, 2012b). More than 90% of deaths from severe malaria result from 
infections with P. falciparum (WHO, 2012b, WHO, 2000a). The delay in seeking treatment 
for uncomplicated malaria is a significant risk factor for severe malaria in children (WHO, 
2012b). 
2.9.1  Severe Malarial Anaemia (SMA) 
Initially as early as 1989, WHO defined malarial anaemia as a haemoglobin concentration of 
<50g l-1 or a haematocrit (Hct) <0.15 in the presence of a plasmodium falciparum 
parasitaemia >10,000 parasites  l-1 with a normocytic blood film (warrell, 1989). A decade 
later, this definition was challenged by some researchers because of its use of a predetermined 
cut off point for parasitaemia which remain widely variable dependent on age and level of 
endemicity (Menendez, 2000b, Menendez et al., 1997). Moreover, this definition requires 
proper and adequate red blood cell morphology examination that may not be performed at 
every health facility in endemic areas due to scarce expertise. Menendez and colleagues 
concluded that such a definition would limit its use for the epidemiological study of malarial 
anaemia and the clinical management of the patients (Menendez, 2000b). This led to a more 
widely applied definition that states that malarial anaemia is a reduction in haemoglobin 
concentration  or  heamatocrit  below  the  ‘normal’   for   the  age,  sex  and  state  of  pregnancy,   in  
the presence of malarial parasitaemia of any density in endemic areas (Menendez, 2000b). It 
is estimated that malaria and anaemia are responsible for about 40% of all under five 
hospitalizations and 30% of all under-five hospital deaths in Malawi (USAID, 2009). Under 
normal circumstances, factors significantly associated with paediatric anaemia include 
bacteraemia, nutritional and micronutrient deficiencies in Vitamin A and B12, 
hemoglobinopathies, hookworm, genetic disorders and HIV (Abdalla, 2004, Calis, 2008). 
Furthermore, in the presence of malaria infection, haemoglobin concentrations may reduce by 
between 15 and 20g l-1 for both sexes and all age groups in a community (Menendez, 2000a). 
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About 60% of anaemia episodes (Hct <0.25) is believed to arise from malaria in highly 
endemic areas (Menendez, 1997). The main causes of anaemia during an acute uncomplicated 
falciparum malaria is the destruction of red blood cells or decreased production of red blood 
cells occurring 48 hours after the onset of fever (Menendez, 2000a). These mechanisms lead 
to shock, impaired consciousness and respiratory distress in young children (Table 2.5Error! 
Reference source not found.) (Mackintosh, 2004). 
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Table 2.5: Clinical features of malaria and possible mechanisms of disease 
Syndromes Clinical features Disease Mechanism 
Severe anaemia Shock 
Impaired consciousness 
Respiratory distress 
Reduced Red Blood Cell production (reduced 
erythropoietin activity, proinflammatory 
cytokines); increased RBC destruction 
(parasite-mediated, erythrophagocytosis 
antibody and complement-mediated lysis) 
Cerebral complications 
(Cerebral Malaria) 
Impaired consciousness 
convulsions long-term 
neurological deficits 
Microvascular obstruction (parasites, platelets, 
rosettes, microparticles); proinflammatory 
cytokines; parasite toxins 
Metabolic acidosis Respiratory distress, hypoxia, 
tachypnea; acidaemia; reduced 
Central Venous pressure 
Reduced tissue perfusion (hypovolaemia, 
reduced cardiac output, anaemia); parasite 
products, proinflammatory cytokines; 
pulmonary pathology (airway obstruction, 
reduced diffusion) 
Other Hypoglycaemia, disseminated 
intravascular coagulation 
Parasite products and/or toxins, 
proinflammatory cytokines; cytoadherence 
Source: Adapted from Mackintosh, C.L., et. al. Trends in Parasitology 2004 (Mackintosh, 2004) 
 
SMA is more prevalent in HIV-1 infected and HIV-1 exposed children. A large cohort study 
to determine if HIV-1 exposure and/or infection increased prevalence of SMA with acute 
malaria in Kenya showed that HIV-1 exposed children were twice likely to have SMA (Hb 
<6g/dl) than HIV-1 negative children and the risk increased by three-fold in HIV-1 infected 
as compared to HIV-1 negative children (Otieno, 2006). There is lack of data to confirm 
whether these adverse outcomes may be exacerbated by some treatments used in HIV 
exposed and HIV infected children such as the use of cotrimoxazole prophylaxis which is said 
to be associated with some haematological adverse reactions including aplastic anaemia, 
megaloblastic anaemia, and haemolytic anaemia (Goldberg, 1993). An understanding of such 
may form a basis for appropriate interventions to prevent adverse complications from malaria 
because even if treated in hospital, children with severe anaemia remain at a higher risk of 
anaemia after discharge with a 15 fold incidence of mortality compared to children who did 
not have severe anaemia (Phiri, 2008).  
2.9.2  Cerebral Malaria 
Worldwide, 19% of over half a million children under the age of five affected by cerebral 
malaria, die (Murphy S.C., 2001). An estimated 2% of childhood survivors of cerebral 
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malaria in Africa experience neurological complications including learning impairments and 
disabilities due to brain damage lasting more than 6 months. Cerebral malaria is defined as an 
unarousable  coma  not  attributable  to  any  other  cause,  with  a  Blantyre  coma  scale  of  ≤2  lasting  
for more than one hour with no other evident cause of coma (e.g. meningitis, post-ictal state 
and hypoglycaemia); with presence of P. falciparum malaria by blood film (Robert, 1996).  
The diagnosis of cerebral malaria is supported with the presence of malarial retinopathy on 
ophthalmoscopy (Beare, 2006). However, post-mortem examination of the brain either by 
autopsy or supra-orbital sampling remains a definitive diagnosis of cerebral malaria (Milner, 
2005). Children with cerebral malaria suffer serious consequences that result from complex 
pathophysiological changes leading to microvascular obstruction, proinflammatory cytokines 
and parasite toxins. These lead to impaired consciousness, convulsions and long-term 
neurological challenges (Ngoungou, 2008).  
2.9.3 Acute Respiratory Distress Syndrome 
Signs and symptoms of respiratory distress have been observed in many African children 
(Murphy, 2001). Acute Respiratory Distress Syndrome (ARDS) is one of the complications of 
severe malaria occurring in 40% of children with severe falciparum malaria (Walter, 2012) 
but some have argued that it occurs more frequently in adults than in children (Mohan, 2008). 
Although it has been known to be caused by conditions such as sepsis, bacterial, viral diseases 
and aspiration pneumonia, evidence suggests that it also on its own present as a severe 
complication of severe malaria. Severe forms of P. vivax malaria have been associated with 
ARDS because P. vivax has the ability to immobilise chondroitin sulphate A and hyaluronic 
acid to a much lesser degree than P. falciparum. However, sequestration of parasitized 
erythrocytes and lung inflammatory changes in P. falciparum malaria are thought to result in 
ARDS (Walter, 2012) as well. Irrespective of effective treatment, ARDS has been associated 
with  poor  prognosis  accompanied  with  a  sharp  deterioration  in  one’s  condition.  This  has  been  
described to result from compensation of metabolic acidosis, noncardiogenic pulmonary 
oedema, concomitant pneumonia and severe anaemia (Walter, 2012). 
2.10  Measures for malaria control in children 
The  Roll  Back  Malaria   Partnership   defines  malaria   control   as   “reducing  malaria  morbidity  
and mortality to a locally acceptable level through deliberate efforts using the preventive and 
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curative   tools   available   today”   (Partnership, 2008). There are many ways to achieve this. 
Prevention and control with the use of ITNs, IRS and case management remain the effective 
malaria control strategies in both adults and children (Partnership, 2008).  The use of 
chemoprevention for malaria is presently recommended in both pregnant women as 
Intermittent Preventive Treatment in pregnancy (IPTp), in infants as Intermittent preventive 
Treatment in infants (IPTi) and Seasonal Malaria Chemoprevention (SMC) formerly known 
as Intermittent Preventive Treatment in children (IPTc) in resource limited settings 
(Kayentao, 2013, WHO, 2013b).  
2.10.1 Use of chemoprevention to control malaria in children 
Intermittent Preventive treatment in infants and Seasonal Malaria chemoprevention are the 
two main strategies for malaria chemoprevention in children.  
2.10.1.1 Intermittent Preventive Treatment in infants  
IPTi is recommended for all infants at risk of Plasmodium falciparum infection in sub-
Saharan African countries with moderate-to-high malaria transmission and low levels of 
parasite resistance to SP (WHO, 2010e). The implementation follows the already existing 
immunisation services in the Expanded Programme for Immunisation (EPI) in that it is 
administered at defined intervals corresponding to immunisation schedules DPT2, DPT3 and 
Measles vaccine. However, despite the ease of implementation and cost-effectiveness of this 
intervention, the 2013 World Malaria report indicates that only Burkina Faso has adopted this 
as a national policy following WHO recommendation in 2009 (WHO, 2013b). It is not clear 
yet whether this lack of wide-scale implementation of this intervention is resulting in 
concerns about the impact of resistance to SP. For example, a large double-blinded placebo 
controlled trial in Tanzania, compared three different drugs used as IPTi in children. These 
drugs were Mefloquine, SP and a combination of chlorproguanil and Dapsone. A 38% 
protective efficacy against malaria in infants was demonstrated with mefloquine, a long acting 
efficacious drug while SP and Chlorproguanil-Dapsone were not efficacious (Gosling, 2009). 
The protective efficacy of Mefloquine was high immediately following administration of the 
treatment and rapidly waned off. A secondary analysis of trials on ITPi in Tanzania 
established that the protective efficacy of Mefloquine was not sustainable beyond 2 months 
after the third dose (Cairns, 2010). More sustained and high efficacy chemoprevention 
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options therefore need to be explored. However, in a pooled analysis of six IPTi-SP trials use 
of SP for IPT in infants showed a protective efficacy of 30.3% against clinical malaria and 
38.1% against hospital admissions associated with malaria parasitaemia during the period that 
the children received the treatment (Aponte, 2009). 
2.10.1.2 Seasonal Malaria Chemoprevention  
Seasonal Malaria chemoprevention (SMC) refers to “administration  of  full  treatment  courses  
of an effective antimalarial medicine during the malaria season to prevent malaria illness in 
children aged 2-59 months (WHO, 2012c).   This   intervention   is   most   effective   in   Africa’s  
Sahel sub-region where amodiaquine plus SP are effective. SMC in this region has a more 
than 65% protective efficacy against malaria in young children under the age of five (Error! 
Reference source not found.). It is not known yet whether there is a correlation between the 
high efficacy levels and prevalence of antifolate resistance as there is limited data to 
corroborate these findings with country specific prevalence of antifolate resistance in this 
region. A meta-analysis of reported dhfr and dhps mutant genotype frequencies in African 
Plasmodium parasite populations reported a 3% prevalence of the dhps double mutant 
genotype in this region compared to 44.3% in East Africa (Sridaran, 2010). Pearce et al have 
recently shown significant increase in dhfr but not dhps mutations in areas where IPTi was 
implemented in Tanzania (Pearce, 2013). Nonetheless, more countries in this region are 
currently in the process of finalizing the adoption of SMC as policy (WHO, 2012c).  
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Table 2.6: A summary of studies on Seasonal Malaria Chemoprevention in Africa 
Author 
(year) 
Country Malaria 
transmission 
SMC Age of 
children 
Protective Efficacy (95% 
CI) 
References 
Cisse, B 
(2006) 
Senegal Seasonal AS and SP (given at 3 
occasions during malaria 
transmission season for a 
duration of 3 months) 
2-59 months 86% (80%-90%) (Cisse, 2006) 
Dicko et al 
(2008) 
Mali Highly seasonal SP administered at two 
occasions at monthly 
intervals 
<5years and >5 
years 
<5years old: 42.5% (28.6%-
53.8%) 
>5years old: 35.9% 
(11.8%-53.4%) 
(Dicko, 2008) 
Kweku 
(2008) 
Ghana Intense with two 
seasonal 
peaks 
Arm 1: SP bimonthly 
Arm 2: AS+AQ monthly 
Arm 3: AS+AQ bimonthly 
3-59 months AS+AQ Monthly group: 
69% (63%-74%) 
SP group: 24% (14%-33%) 
AS+AQ group: (6%-27%) 
(Kweku, 
2008) 
Dicko (2011) Mali Highly seasonal SP and AQ (given at 3 
occasions, monthly intervals) 
3-59 months 82% (78%-85%) (Dicko, 2011) 
Konate 
(2011 
Burkina 
Faso 
High transmission 
but seasonal 
SP +AQ 
Placebo 
(monthly intervals during peak 
malaria transmission) 
3-59 months IRR clinical malaria: 
0.29 (0.26%-0. 32%) 
(Konate, 
2011) 
Bojang 
(2011 
The 
Gambia 
Highly seasonal SP Single dose 
AQ Single dose 
6 years and under RD 1.6 (0.24-3.5) (Bojang, 
2011) 
AS: Artesunate, SP: sulfadoxine pyrimethamin, AQ: Amodiaquine, IRR: Incidence rate Ratio, RD: Risk Difference 
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2.10.2 Use of Insecticide Treated bed-nets 
The use and effectiveness of ITNs in reducing the malaria burden has been demonstrated in 
many settings of diverse malaria transmission patterns. There are two forms of ITNs: 
Conventional ITNs which require re-treatment with insecticides at determined intervals and 
Long Lasting Insecticide Nets (LLINs) which are treated with insecticides at source by the 
manufacturers. These do not require re-treatment with insecticides until they outlive their 
lifespan (WHO, 2013b). Although ITNs had been previously thought of mainly providing 
personal protection, there is increasing evidence that high coverage of ITNs within a 
community produces mass effect and therefore its effect in reducing transmission is 
community-wide than individual (Hawley, 2003). Since most of the important vectors for 
malaria transmission in humans in Africa bite at night and in early hours of the morning 
(WHO, 2013a), with few biting earlier, they are  susceptible to ITNs but huge impact in 
reducing malaria prevalence of more than three fold is achieved where Plasmodium ovale and 
Plasmodium malariae are common compared to  P. falciprum (ter Kuile, 2003). A pooled 
analysis of five trials by Lengeler et al examined the effect of ITNs on all cause child 
mortality from all areas of stable malaria transmission in SSA and showed a protective 
efficacy of 18% and a 50% reduction in the incidence of clinical episodes for both P. 
falciparum and P. vivax respectively (Lengeler, 2004) demonstrating the high efficaciousness 
against P.vivax.  
2.10.2.1 ITNs and IRS used in combination for the control of malaria 
Eisele, T et al, applied the LiST model which is used to estimate the number of child malaria 
deaths that can be prevented from scale-up of malaria prevention interventions in P. 
falciparum settings (Eisele, 2010). With their model, they were able to show that a 
combination of ITNs and IRS reduce malaria attributable mortality in children aged 1-59 
months by 55%. The LiST model assumes that increases in the coverage of an intervention 
result in a reduction of one or more cause-specific deaths or in reduction of a risk factor 
(Eisele, 2010). The synergistic effect of the joint use of ITNs and IRS has also been shown in 
many studies in sub-Saharan Africa (Fullman, 2013, Hamel, 2011, Pinder, 2011, 
Kleinschmidt I., 2009) although there is strong argument to the contrary suggesting that it is 
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difficult to isolate the effect of ITNs and IRS on malaria control in situations where other 
interventions such as use of artemisinin combination therapy, larviciding, environmental 
management and heath education are also in use (Bhattarai, 2007, Over, 2004, Okumu, 2011). 
Researchers in Eritrea have argued that there is no added advantage of using the two 
interventions in combination because their nature of indoor use targets the same malaria 
vectors that tend to rest inside the house before or after taking a blood meal (Nyarango, 2006).  
On the other hand, IRS appears to be most effective when it is used alone in medium to low 
transmission areas compared to when it is used in high transmission areas (Fullman, 2013). 
Other than all-cause child mortality and malaria-specific mortality, ITNs are highly 
efficacious against clinical malaria, anaemia and any parasitaemia from the age of 6 months 
(ter Kuile, 2003) as Figure 2.3 below for an area with intense perennial transmission in 
western Kenya illustrates. 
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Figure 2.3: Protective efficacy of insecticide-treated bed nets by age 
 
 
Source: ter kuile, F.O., et al., Am. J. Trop. Med. Hyg., 2003 (ter Kuile et al., 2003) 
2.10.3 Other Vector control strategies 
2.10.3.1 Larviciding 
In 2012, WHO issued an interim position statement on use of larviciding for malaria control. 
Larviciding which WHO defines as the “regular application of chemical or biological agents 
to kill the mosquito larvae or create a situation which is unfavourable for mosquito breeding”  
(WHO, 2012a),  was  first  used  in  the  1930’s  and  1940’s  in  Brazil,  Egypt  and  the  copper  mines  
in Zambia (WHO, 2012a, Killeen, 2002). In Zambia, water management with larvicides and 
drainage reduced malaria mortality, morbidity and incidence by 70-95% within few years and 
the protective efficacy of this intervention was sustained for two decades (Killeen, 2002). In 
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Brazil, rigorous measures of larval control were employed when part of the country was 
infested with An. gambiae which claimed the lives of hundreds of people. During this time, a 
well-organized rigorous campaign was launched where all small water bodies preferred by 
An. gambiae were searched and larvicides applied. This was complemented by other methods 
that targeted the adult mosquito. Within two years, the An. gambiae was eradicated in this 
area (Killeen, 2002). The same methods effectively eradicated the An gambiae in Egypt in the 
early 1940s (Killeen, 2002). However, despite these historical pieces of evidence, WHO does 
not give a straightforward recommendation on the use of larviciding for malaria control in 
sub-Saharan Africa largely because of its inability to effectively target all the larval breeding 
sites which are so numerous and changing from one time to the other (WHO, 2012a). Killeen 
et al however argue that bed nets and clinical management alone are not enough to effectively 
control malaria as they face a lot of challenges in terms of distribution and utilization but also 
the ever changing behaviour of human biting mosquitoes (Killeen, 2002). As such other 
malaria control strategies would complement the current ones for better results.  
2.10.3.2 Environmental Management 
An internationally recognized definition of Environmental Management (EM) by WHO puts 
in  to  context  the  use  of  this  strategy  for  malaria  control.  WHO  defines  EM  as  “the  planning,  
organization, carrying out and monitoring of activities for the modification and/or 
manipulation of environmental factors or their interaction with man with a view to preventing 
or minimizing vector propagation and reducing man-vector-pathogen” (WHO, 1982). In a 
systematic review of studies covering two centuries, all but one study reported protective 
efficacies on clinical malaria parameters that ranged from malaria hospital admission, malaria 
related deaths, malaria morbidity, spleen rate and malaria incidence of 79.5%-88.0% (Keiser, 
2005). In these studies, the mostly used EM strategies were environmental modification 
which created sustained effect on land, water or vegetation to reduce malaria control; 
environmental manipulation which was temporary in nature whereby unfavourable conditions 
for the vector were created and human habitation was modified (Keiser, 2005). It has been 
argued that the study that did not show any protection from EM, used improper methods in 
the implementation of the programme (Keiser, 2005). Although most of these studies were 
done a long time ago and difficult to verify the methods used and whether simultaneous use 
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of other malaria control interventions like ITNs and chemoprevention could likely have 
affected the results, EM is a promising complimentary strategy for sustained malaria control 
in malaria endemic regions. 
2.10.4 Malaria Case Management in children 
Adequate case management of malaria patients is an integral part of malaria control. Delays 
in accessing prompt and effective treatment result in fatal consequences in vulnerable 
populations like the under-five children (Velema, 1991). Management of malaria mostly in 
under-five children starts at home with a caregiver either giving an anti-malarial or an 
antipyretic (Velema, 1991) before seeking care at the hospital. Currently ACTs are considered 
the recommended treatment for uncomplicated malaria in both adults and children replacing 
choloroquine and sulfadoxine pyrimethamine which were rendered ineffective as a result of 
increased resistance which contributed to significant mortality (Frosch, 2011). A clinical 
diagnosis of malaria in under-five children is sufficient for an ACT prescription in high 
transmission areas whereas for older children and adults, a definitive parasite based diagnosis 
is a prerequisite (WHO, 2006c, WHO, 2005a). 
2.11 Uptake of malaria control interventions in children 
In most malaria endemic areas, the uptake of malaria control interventions has remained low 
despite available evidence showing that they are effective (Hanson, 2004). There is paucity of 
data on factors directly linked to uptake of these interventions in children. However, in 
pregnant women, personal attributes such as educational level, marital status, knowledge 
about the interventions, gravidity, and health facility factors like distance to the health facility, 
unavailability of services and poor quality of services at the health facility are highly 
associated with uptake of malaria control interventions (Mutulei, 2013). In a report by the 
Medicines for Malaria Venture (MMV) the author cites the continual use of non-
recommended antimalarials to treat children including monotherapies as barriers to uptake of 
paediatric medicines (MMV, 2013). Since children are under direct care of their parents and 
caregivers, adult-related factors such as above could be used as proxy measures for 
determining factors that influence the uptake of malaria control interventions in these 
children.  
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In Malawi, the uptake of various malaria interventions has been generally poor. According to 
the 2012 Malaria Indicator Survey (MIS) report (Programme, 2012), only 32% of households 
owned one or more insecticide treated nets and 56% of children under-five slept under a net in 
the previous night. Coverage of IPTp is relatively high for the region with 77% of pregnant 
women receiving one dose of SP (Programme, 2012). However, only 54% of pregnant 
women received the recommended two doses in Malawi. As a result, malaria still remains an 
important cause of morbidity and mortality in this country (MoH, 2005a).  
2.12 Sulfadoxine – Pyrimethamine and Cotrimoxazole cross-resistance 
SP and cotrimoxazole also known as sulfamethoxazole-trimethoprim share a similar chemical 
structure. Since they both provide their antimicrobial action through inhibition of the same 
enzymes in the folic acid biosynthetic pathway (pyrimethamine and trimethoprim inhibit 
dihydrofolate reductase, whereas sulfadoxine and sulfamethoxazole inhibit dihydropteroate 
synthetase), cross-resistance could develop, and a decrease in the antimalarial efficacy of 
cotrimoxazole may occur in parallel with SP resistance development (Iyer et al., 2001, Feikin 
et al., 2000). A study in Malawi that investigated the efficacy of cotrimoxazole in treating 
malaria found similar cure rates with SP (adequate clinical and parasitological responses of 
87.2% and 80% respectively) (Hamel et al., 2005). Laufer et al (Laufer et al., 2006) have also 
shown the potential of return of efficacy of the antimalarial chloroquine after a few years of it 
not being used. It is not known if the removal of the use of SP for the first line treatment of 
malaria in the general population could have reduced the degree of resistance of P. falciparum 
to cotrimoxazole.  
2.13 Malaria rebound 
Malaria rebound could be referred to as a hypothetical overshot that could occur in 
populations that have lost their immunity (Coleman, 1999).  
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2.13.1 The risk of malaria rebound with the use of malaria control measures such as 
ITNs 
The use of malaria control interventions such as insecticide treated bed nets only provide 
partial reduction in exposure to malaria such that those people sleeping under ITNs would 
still experience mosquito bites but less frequently compared to those not using ITNs 
(Coleman, 1999).  Since acquisition of natural immunity in young children is dependent on 
the number of subsequent infective mosquito bites (Doolan, 2009), the protective nature of 
ITNs is suggested to reduce the rate at which effective immunity to malaria is attained in ITN 
users (Coleman, 1999, Kariuki et al., 2003). There have been suggestions that marked 
transmission reductions areas with high malaria transmission may result in a delay in the 
acquisition of protective immunity and a consequent shift in the epidemiological profile of 
malaria with an increase in the average age at which children develop severe forms of malaria 
and also the prominence of cerebral malaria (Coleman, 1999, Snow and Marsh, 2002).  
2.13.2 Malaria rebound after stopping malaria chemoprophylaxis 
Similarly, there is concern that children who receive sustained malaria protection are at a 
higher risk of malaria morbidity and mortality once the protection is stopped. In one study, 
Gambian children who had received variable malaria chemoprophylaxis over most of their 
first 5 years of life were followed up for 5 years (Greenwood et al., 1995). The risk of clinical 
malaria during the first year after stopping pyrimethamine–dapsone was significantly higher 
in children who had received chemoprophylaxis. A rebound effect was also observed in a 
study in Tanzania where infants between 2 and 12 months of age were given weekly 
pyrimethamine-dapsone. After the end of the intervention period, infants who received 
chemoprophylaxis had almost doubled rates of severe anaemia and malaria during the 
following year than those who received a placebo (Menendez et al., 1997). A summary of 
studies showing malaria rebound effects after termination of a malaria chemoprophylaxis is 
presented in Table 2.7Table 2.7 below.  
 
Some beneficial effects after termination of malaria chemoprophylaxis were observed in some 
parts  of  Africa   in   the  1950’s  where   regular  drug  administration   for  up   to  2   years   in   school  
children did not interfere with pre-existing immunity and termination did not create additional 
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risk (Menard, 2003). This might have resulted from the acquired immunity to malaria in older 
children compared to infants who are immune naïve. Furthermore, the use of IPTi-SP in 
different settings in Africa was also not associated with rebound effects after treatment was 
stopped (Aponte, 2009). It is likely that this resulted from the incomplete and interim nature 
of the protection provided by IPTi because of the interim nature of the intervention which 
leaves children unprotected in between rounds, including for a 4 to 6 months of exposure 
prior to the last course of IPTi at 9 months of age. 
 
Daily CPT however may provide more complete protection from malaria. This is because 
cotrimoxazole has been found to offer antimalarial effects in several studies (Sandison, 2011, 
Kamya et al., 2007, Gasasira et al., Thera et al., 2005). Without adequate exposure to malaria 
during the first year of life, infants do not have a chance to develop a significant degree of 
naturally acquired immunity. Therefore, children receiving daily CPT from birth to 14 
months may have a higher risk of malaria after it is stopped. 
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Table 2.7: Studies showing malaria rebound effect after termination of drug treatment 
 
 
1P-D: pyrimethamine-dapsone;  2SP: sulfadoxine-pyrimethamine; 3MDA: mass drug administration 
Source: O’Meara,  W.P.,  et  al.,  2005,  Malaria  Journal 
2.14 Malaria and HIV Co-infection 
Both HIV and malaria have greatly affected sub-Saharan Africa. These diseases have a wide 
overlap in geographical distribution resulting in co-infection in that those with HIV have 
frequent episodes of malaria and malaria increases HIV plasma viral load (Kublin, 2005a). 
There is evidence that during a febrile malaria attack, there is a one-log increase in viral load 
in HIV infected patients in their chronic stage (Table 2.8) (Kublin, 2005b) and on the other 
hand, HIV infection significantly increases susceptibility to malaria infection (Patnaik, 2005). 
Further, an 8% increase in the peak of the HIV epidemic and a 13% increase in the peak of 
malaria is seen in the presence of interaction between the two diseases (Abu-Raddad, 2006). 
In HIV infected pregnant women, both placental and peripheral malaria parasitaemia are 
significantly associated with higher placental viral load (Mwapasa, 2004). This increased viral 
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load is suggested to be an important factor in the transmission of HIV from mother-to-child, 
with more transmission occurring when the viral load is high. It is estimated that more than 
50% of women with high viral load of greater than 50,000 RNA copies/ml, transmit the virus 
(Thea, 1997, Fang, 1995) at a 6-fold transmission rate compared to those with undetectable 
viral load (Thea, 1997).  
 
A study of HIV-infected but treatment naïve children aged between 25-59 months admitted 
with malaria in Kenya showed that HIV infection significantly modified the age-dependent 
acquisition of malaria-specific immunity and reduced the extent of IgG response to merozoite 
antigens (Muema, 2011). There is also evidence that malaria parasitaemia in HIV infected 
individuals, is associated with increased activation of CD4+ cells and up regulation of 
proinflammatory cytokines (Alemu, 2013). This process increases the number of susceptible 
cells that are targeted by HIV-1 infection such that an increase in the number of target cells 
will also increase the viral load (Alemu, 2013).  On the other hand, these CD4+ cells play a 
pivotal role in the immune response to malaria. Their availability is essential to help B cells 
produce the antibody that is important for parasite clearance (Langhorne, 2006). They also 
produce cytokines that rapidly increase the phagocytic and parasitological response of the 
innate immune system, and diminish this response later on to minimize immunopathology 
(Langhorne, 2006). The consequences of HIV and malaria co-infection can be summarized by 
a vicious cycle of successive pathophysiological processes presented in Figure 2.4. In the 
absence of any interventions, these events may constantly repeat themselves resulting in more 
infections and deaths. 
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Figure 2.4: A diagrammatic presentation of the vicious cycle of HIV and malaria co-
infection 
 
The lowering of CD4+ cell levels increases parasitaemia in children and deteriorates their 
clinical status. In more advanced HIV disease where immunosuppression is more pronounced, 
the frequency of malaria episodes and malaria parasite densities increases 
(Chaisavaneeyakorn, 2002). This results from minimal malaria-specific antibodies which 
diminish in numbers as the HIV disease advances (van Geertruyden, 2009). Low levels of 
CD4+ cells and high amount of HIV viral load in mothers of HIV infected and HIV exposed 
children leads to doubling of severe morbidity and early mortality in the children (Dunne, 
2003). HIV-1 alone has been found to be an important risk factor for the increase in parasite 
density in HIV infected children less than five years old with cerebral malaria (Imani, 2011a). 
An additional 3 million cases of malaria and 65 thousand malaria related deaths annually are 
estimated to be as a result of the impact of HIV (WHO, 2008, UNAIDS, 2007b). The 
resultant rates of HIV and malaria co-infection and interactions between the two diseases pose 
major public health problems. Generally, people living with HIV experience a higher 
incidence of malaria and increased parasitaemia than those not infected mainly resulting from 
Malaria parasitaemia in HIV infected individuals Increased CD4+ activation& upregulation of proinflammatory cytokines 
Increased HIV replication leading to increase in viral load 
Increased HIV transmission 
Reduced CD4+ cells, immunosuppression & poor malaria response 
Increased susceptibility to malaria infection 
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the HIV immunosuppression that is believed to speed up the rate of parasite maturation in the 
liver and causes alteration of the course of the disease leading to a severe form of disease in 
those with malaria (Imani, 2011b). Clinical malaria treatment failure in these patients has 
been attributed to decreased ability to clear drug resistant parasites as a result of HIV 
(UNAIDS, 2007a). Greater understanding of interactions between HIV and malaria 
interventions is key to unlocking their potential in preventing morbidity and mortality. In 
recent studies, Protease Inhibitors like Lopinavir-ritonavir have shown to dramatically lower 
the incidence of malaria after treatment with artemether lumefantrine (Achan, 2012). 
Lopinavir-ritonavir, leads to the inhibition of lumefantrine which would extend the post-
treatment prophylactic effect or antimalarial synergy between lumefantrine and lopinavir 
(Achan, 2012). Studies by the ACT Consortium are on going to elucidate the drug-drug 
interactions between the two diseases (Consortium., 2013). Table 2.8 is a summary of 
assumptions related to the interaction of HIV and malaria co-infection. A log increase of 0.82 
in HIV viral load level is seen with malaria infection in the chronic stage of HIV compare to a 
log increase of 0.08 in the absence of clinical malaria (Abu-Raddad, 2006). Furthermore, 
susceptibility to malaria infection in HIV-1 infected people is enhanced by 103% during the 
advanced stage compared to 0.4% in the chronic stage (Abu-Raddad, 2006).  
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Table 2.8: The core assumptions of HIV/Malaria interaction model 
 
Assumption Parameter Value 
Logarithm increase in HIV viral load level during malaria infection:   
Acute stage  0 
Chronic stage with clinical malaria  0.82 
Chronic stage with non-clinical malaria  0.08 
Advanced stage  0.2 
Susceptibility enhancement to malaria infection in HIV-1 Infected    
people:   
Acute Stage  0.00% 
Chronic Stage  0.44% 
Advanced Stage  103% 
Duration of heightened viral load during malaria episodes   42 days 
Fractional reduction in sexual activity during malarial malaria infection:   
Clinical  10% 
Non-clinical  3% 
Fraction of malaria infected patients developing clinical malaria   
HIV negative  16% 
HIV positive  31% 
Enhanced HIV mortality in dually infected patients   
Areas of stable transmission  0.00% 
Areas of non-stable transmission  25% 
Source: Abu-Raddad et.al. 2006 (Abu-Raddad, 2006) 
 
2.15 The burden of HIV in sub Saharan African children 
HIV continues to pose enormous public health challenges worldwide. According to the 
UNAIDS report on the update of HIV epidemic, seventy per cent (70%) of the 35.3 million 
people living with HIV, are in sub Saharan Africa (UNAIDS, 2013b). Malawi is at the 
epicentre of the epidemic that is responsible for eight deaths every hour (Bello, 2006). Out of 
a population of nearly 15 million, almost 1.1 million people in Malawi were living with HIV 
at the end of 2012 (UNAIDS, 2013c). The majority of HIV infections occur through 
heterosexual sex and women are more affected by HIV than men (Bello, 2006). Several 
explanations have been suggested on why women are the most vulnerable. Although a study 
in Uganda in the early 21st century did not find any differences in the per act transmission of 
HIV from man or woman to the uninfected partner (Gray, 1994), many studies in both the 
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developed and undeveloped world have reported an efficient transmission of HIV from a man 
to a woman compared to the other way round (Royce, 1997). Use of normal contraceptives 
more especially injectables has been linked to increase in the acquisition of HIV among HIV 
negative women. Women on injectable contraceptives also tend to have higher genital HIV-1 
RNA concentrations compared to women on other contraceptives or not on contraceptives 
(Heffron, 2012, Lavreys, 2004). Other factors such as anal sex, vaginosis, use of intrauterine 
devices and low CD4 counts of a male sexual partner have been suggested to increase 
women’s  susceptibility  to  HIV  (Lazzarin, 1991, Taha, 1998, Nicolas, 1994).  
2.16 The Epidemiology of Mother to child transmission of HIV 
Most of the HIV incidence (i.e. newly acquired infections) occur among young people, 
particularly those between the ages of 13 and 24 years when they become sexually active 
(Bello, 2006). HIV may be transmitted in utero, during labour and through breast-feeding to 
infants (WHO/UNAIDS/UNICEF/UNFPA, 2003). Recently, 260,000 children in low and 
middle-income countries became newly infected with HIV through mother-to-child 
transmission, down by 35% from 2009 (UNAIDS, 2013b). The 2003 Joint WHO and UN 
report shows that without any intervention, 27-30% of children born to HIV infected mothers 
will acquire the virus (WHO/UNAIDS/UNICEF/UNFPA, 2003) with a transmission rate of 5-
10% during pregnancy, 10-20% during labour or 5-20% during breastfeeding (Cock, 2000, 
Raisler, 2005). Most transmission takes place in late pregnancy and during delivery compared 
to early pregnancy (Newell, 2001). However, post-natal transmission as a result of 
breastfeeding substantially contributes to the overall risk of mother to child transmission of 
HIV (Newell, 2001). Maternal HIV disease progression is highly associated with vertical 
transmission of HIV from mother to child more especially HIV infected pregnant and 
breastfeeding women with high HIV viral load and low CD4+ counts are more likely to 
transmit the virus to their children compared to those with low viral load and high CD4+ 
count (Ruiz, 1998). Duration of membrane rupture has been shown through a meta-analysis of 
fifteen cohort studies to increase the risk of HIV transmission and is more prevalent among 
premature infants (Group, 2001). Irrespective of CD4 count, viral load and whether the 
woman is on antiretroviral drugs; delivery by elective caesarean section has been significantly 
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associated with a 50% reduction in the risk of HIV transmission from mother to child (Study, 
1999, Ioannidis, 2001).  
2.17 The natural history of the HIV disease in children 
In the absence of any intervention, children with HIV infection acquired through MTCT 
experience a rapid evolution of the disease compared to adults with a mean survival range of 
6 to 8 months with only 70% of children reaching the age of six (Ruiz, 1998). It is postulated 
that children (15-20%) who acquire the virus early during pregnancy develop severe 
immunodeficiency with opportunistic infections and encephalopathy in the first year of life 
and die within the first three years (Ruiz, 1998). However, those (80-85%) who acquire the 
virus late in pregnancy experience a slow disease progression and live for several years (Ruiz, 
1998).  The evolution of HIV in children is said to be strongly influenced by both maternal 
and infant factors such as severity of maternal disease and development of opportunist 
infections in the child which are believed to influence the acquisition of opportunist infections 
or death in the early years of life and overall progression of the disease respectively (Ruiz, 
1998). All children born to HIV infected mothers (HIV exposed children) are recommended 
to have HIV virological testing at 4-6 weeks of age or at earliest encounter with health care 
professionals (WHO, 2010a) as serological tests may not accurately diagnose HIV due to 
circulating maternal antibodies. At the age of 9 months, a repeat HIV test is performed mostly 
tailored with the immunizations at 9 months (WHO, 2010a). . 
 
A recent WHO recommendation promotes initiation of ART irrespective of immunological 
status or WHO clinical staging for all infants diagnosed with HIV in the first year of life and 
for all HIV infected children between the age of 12 and 24 months (WHO, 2010a). Although 
WHO recommends that CD4 should be measured at the time of HIV infection and every six 
months thereafter or prior to initiating ART (WHO, 2010a), this has been a challenge in 
resource poor settings due to limited capacity (Peter, 2008). However, monitoring of 
haemoglobin level is required at the initiation of ART and at 8 weeks after initiation of 
Zidovudine (AZT) (WHO, 2010a). 
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2.18 The impact of maternal CD4 and viral load in HIV exposed infants 
Despite successful gains achieved from effective PMTCT interventions in reducing new HIV 
infections in children, concern arises regarding the health of HIV exposed infants. There have 
been reports from the Caribbean, South Africa, South East Asia and Europe concerning an 
increase in the morbidity and mortality resulting from infectious diseases among HIV 
exposed children (Marinda E, 2006, Shapiro RL, 2007, Mussi-Pinhata MM, 2007, Fulforf T-
A, 2012, horne C, 1997). Compared to the general population and non-HIV exposed children, 
an increase in new neonatal infections, neonatal sepsis, acute gastroenteritis, hospitalization, 
post-operative complications and neonatal sepsis has been reported in HIV exposed children 
(Singh HK, 2011, Taha TE, 2000, Epalza C, 2010, McNally LM, 2007, Slogrove A, 2012). 
This is partly explained by chronic maternal infections during pregnancy which can 
significantly interfere with infants immune response to future infections irrespective of the 
vertical transmission of pathogens. Infants born to mothers with HIV viral load as high as 
more than 1,000 copies per ml have been observed to have decreased relative as well as 
absolute CD4+ T counts at 2 and 6 months of age compared to their counterparts born to 
mothers with undetectable HIV viral load of less than 50 copies/ml (Kuhn, 2002, Faye, 2007). 
A study in Malawi found reduced CD4 percentage at one month of age in HIV exposed 
children compared to non-HIV infected counterparts (Moraleda, 2014). Available evidence 
suggests a greatly increased placental production of inflammatory cytokines; tumor necrosis 
factor alpha and interleukin 8 among HIV infected women treated with ART than in HIV 
uninfected women (Economides, 1998). However, HIV infected mothers with high HIV viral 
load have been observed to generate higher levels of the pro-inflammatory cytokines 
Interferon gamma and Tumor necrosis factor alpha which is thought to remain high in women 
with high viral load thereby potentially driving the differences in CD4 counts in newborns 
(Economides, 1998) consequently increasing their risk of HIV opportunistic infections. 
2.19 Transfer of maternal immunity and its implication on the HIV disease in the 
child 
The scaling up of anti-retroviral distribution and other interventions around childbirth, has 
been associated with a reduced incidence of paediatric HIV infection and disease (UNAIDS, 
2013a). When given to the mother during pregnancy, anti-retroviral drugs induce a direct drug 
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effect on maternal viral replication resulting in decreased HIV RNA in maternal circulation as 
well as genital secretions and significantly improves the CD4+ cell counts (McGowan, 2000). 
The increase in uptake of ART among HIV infected women in 2012, contributed to a 
reduction of 35% in new HIV infections among children in the same year (UNAIDS, 2013a). 
This   leads   to   increased   numbers   of   HIV   ‘exposed’   children,   because   as   the   adult   HIV  
population remain healthier and lives longer (Bello, 2006), they reconsider childbearing 
(Myer, 2010).  At  a  minimum,  maternal  HIV  antibody  is  present   in   the  child’s  blood  for   the  
first six months of life (de Moraes-Pinto, 1996). Sometimes after six months, levels of 
maternal antibodies fade and most children who are not infected test negative for the HIV 
antibody test by 12 months of life (de Moraes-Pinto, 1996). Occasionally, it takes HIV 
uninfected children as long as 18 months to lose maternal antibodies (Rabkin, 2005).  These 
children, despite not being infected with HIV, have an increased susceptibility to HIV 
opportunistic infections resulting from a compromised maternal immune system caused by 
HIV in the mother, which may lead to reduced transplacental transfer of antibodies to the 
foetus in utero (Moraes-pinto, 1996). At birth, HIV exposed children are challenged with 
increasing numbers of virulent congenital or maternally acquired neonatal infections because 
of increased shedding and higher pathogen levels related to immunosuppression in HIV 
infected mothers (Moraes-pinto, 1996). This likely interferes with the ability to adequately 
support development of infant immune capacity and viral exposure of the foetus in utero 
resulting in reduced capacity of the infant himself to fight common infections (Chougnet, 
2000b, Clerici, 2000). These immunological deficiencies also interfere with the levels of 
immunoglobulins present in breast milk which are important in protecting infants against 
infections (Thomas, 2004). In the absence of any form of treatment, HIV infected children 
have a 2 year median survival (Dunn, 2003) with significantly higher mortality at all ages 
than their HIV exposed but not infected counterparts (Brahmbhatt, 2006) although when 
compared with non-HIV exposed children, HIV exposed, but uninfected children have a 16% 
higher mortality (Brahmbhatt, 2006). Severe morbidity and early mortality in HIV infected 
and HIV exposed children more than doubles when maternal CD4+ cell counts are low and 
HIV RNA is high (Brahmbhatt, 2006). Without any mitigating interventions these children 
experience high fatality rate of between 40-90% from PCP, a severe form and rapidly 
progressive pneumonia (Rabkin, 2005) that generally occurs between 3 and 6 months of life, 
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often as the first sign of HIV infection and before child is definitively determined to be HIV 
infected (Rabkin, 2005).  
2.20 Prevention of Mother-to-Child Transmission of HIV in Malawi 
In Malawi, all children under 24 months are actively screened for HIV exposure most 
especially those who present with sickness to under five clinics, the Out-Patient Department 
(OPD), nutritional rehabilitation unit and paediatric ward (MoH, 2014). Children born and/or 
breastfeeding from HIV infected mothers are immediately enrolled in the HIV Care clinics 
and tested for HIV using DNA-PCR from the age of six weeks in order to detect perinatal 
HIV infection and allow early initiation of ART (MoH, 2014). After the first HIV test at six 
weeks, HIV exposed children are seen on a monthly basis until the age of 6 months. 
Thereafter, they are seen every 3 months until they are 24 months of age. However, the 
scheduling of visits is determined by the health of the child (MoH, 2014). A negative HIV 
rapid test obtained at 6 weeks after stopping breastfeeding is a determinant for stopping 
routine follow-ups for these children. At twelve and 18 months, a repeat HIV test using an 
antibody test is done to rule out HIV infection since most children breastfeed up to 24 months 
(MoH, 2011a). During the period the children are being monitored, they receive daily CPT for 
prevention of HIV opportunistic infections. 
 
Malawi introduced Prevention of Mother-to-Child Transmission (PMTCT) of HIV 
interventions as a primary preventive intervention for transmission from mother to child in 
2003 using single-dose Nevirapine (NVP) as the primary ARV prophylaxis regimen used to 
prevent paediatric HIV infections (MoH, 2008). Although uptake of PMTCT interventions 
was low by women who needed it, 64% of the 544 health facilities were providing PMTCT 
services by 2007 (MoH, 2008). Lack of partner involvement and fear of stigma and 
discrimination were some of the reasons observed as deterrents to uptake of these 
interventions by HIV infected pregnant women (Chinkonde, 2009, MoH, 2008). In line with 
2006 WHO PMTCT recommendations, the government of Malawi in 2007 introduced 
combination ARV prophylaxis regimen to further reduce the risk of MTCT of HIV (MoH, 
2008). In its guidelines released in 2008, all HIV pregnant women who met the criteria for 
starting ART as per WHO Clinical staging and CD4+ count (WHO Clinical stage 3 & 4 or 
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WHO Clinical stage 1 & 2 with a CD4 count of <250) were started on combination ART of 
AZT/3TC/NVP.  Infants born to women on ART were given a four weeks course of AZT 
twice a day (MoH, 2008). For those HIV infected women not on routine ART, single dose 
NVP was provided at 16 weeks gestation irrespective of their clinical stage and CD4 count. 
This was accompanied with instructions to take at the onset of labour. In addition, the women 
were started on a twice-daily dose of AZT from 28 weeks gestation until delivery. Since ART 
was only given to women who met the WHO clinical staging and those with a low CD4+ 
count, all HIV infected pregnant women not eligible for ART were given maternal AZT from 
28 weeks of pregnancy or as soon as possible thereafter; single-dose NVP plus a 7 day tail of 
AZT and 3TC. Infants born to these women were given a one-week course of AZT (MoH, 
2008). 
 
Following new guidance from WHO on PMTCT of HIV and infant feeding in the context of 
HIV released in 2010, the government of Malawi, revised its PMTCT guidelines to align with 
the new WHO recommendations. However, considering the evidence that Malawi had 
gathered through implementation of previous PMTCT regimens and the high fertility rate of 6 
children   per   woman’s   life   time   and   mean   breastfeeding   period   of   23   months (Schouten, 
2013); Malawi opted to start lifelong ART for all HIV infected pregnant women and 
breastfeeding women regardless of CD4+ count or clinical stage also known as the option B+. 
This was thought to greatly improve the prevention of mother to child transmission of HIV 
and was believed to offer minimal  differences  in  duration  of  ART  over  a  woman’s  life  time  
between option B and option B+ considering the high number of children women have in 
countries like Malawi (Schouten, 2013, MoH, 2011a). Option B+ was therefore a 
modification of the WHO recommendation which promoted lifelong ART for HIV infected 
women who needed it and short term ARV prophylaxis for prevention of MTCT of HIV 
during pregnancy, labour and delivery and breastfeeding for HIV infected women (WHO, 
2010c) . In the current clinical management of HIV in children and adults guidelines, mothers 
already on ART continue the same ART regimen as pregnancy and breastfeeding is not 
regarded as a contraindication while HIV infected mothers not yet on ART or who stopped or 
interrupted, start lifelong TDF/3TC/EFV as soon as possible during labour or after delivery 
(MoH, 2014). 
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2.21 HIV/AIDS interventions in children 
The population of HIV exposed children is constantly increasing following scale up of 
PMTCT interventions (UNAIDS, 2013a).  Optimizing the survival of these children requires 
a careful assessment of the risks and benefits associated with interventions available for them. 
The World Health Organization promotes four components for effective prevention of mother 
to child transmission of HIV (WHO, 2010b). These include: 
a) Primary prevention of HIV infection among women of child bearing age 
b) Preventing unintended pregnancies among women living with HIV 
c) Preventing HIV transmission from a woman living with HIV to her infant 
d) Providing appropriate treatment, care and support to mothers living with HIV and 
their children and families 
 
Prevention and management of HIV opportunistic infections remain critical components of 
care in HIV exposed children. ART significantly reduces severity of HIV disease (Patel, 
2012) with significant rise in CD4+ cell percentage manifesting after 6 to 12 months of 
starting ART for all WHO clinical stages of HIV infection (Patel, 2012). Eighty-six per cent 
of new HIV infections in children in SSA have been prevented with the use of ART in 
pregnant women since 2005 (UNAIDS, 2013b). Before ART was widely available in resource 
limited settings, use of CPT in HIV infected children led to significant reductions in HIV 
opportunistic infections such as Pneumocystis jiroveci (formerly known as Pneumocystis 
carinni pneumonia (PCP) (WHO, 2006b). The ability of cotrimoxazole to reduce hospital 
admission rates as well as mortality in HIV infected children (Chintu, 2004), culminated in 
the recommendation by the World Health Organization that all HIV exposed infants born to 
mothers living with HIV should receive CPT starting at 4-6 weeks of age (or at first encounter 
with health care system) and continued until breastfeeding is stopped and HIV infection can 
be excluded (WHO, 2006b). However, this prophylaxis requires careful assessment of its 
benefits versus the detriments when given to HIV exposed children.  Cotrimoxazole has been 
shown to be effective in reducing bacterial infections even in areas where there is a high 
background in vitro resistance to it (Chintu et al., 2004a). In addition, it potentially offers an 
effective and sustained malaria chemoprophylaxis, even in areas like Malawi, Uganda and 
others where resistance to sulphonamides may be high (van Oosterhout et al., 2005), and 
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significantly lowers incidence of malaria episodes, both parasitaemic and presumptive among 
both HIV exposed and HIV infected children (Graham, 2010). This could potentially impair 
the acquisition of natural immunity to malaria in infants and therefore abrupt cessation of 
cotrimoxazole use at 12 months after stopping breastfeeding in children who remain HIV 
negative could be associated with an increased risk of malaria in terms of frequency and 
severity in the following year.  
 
For these children, adherence to CPT is a major factor in ensuring optimal responses and is a 
significant predictor of survival. In HIV disease, ART adherence rates of 100% are required 
for optimal viral suppression. Surprisingly, adherence to ART in most African settings is 
believed to be lower than the 50% reported for developed countries (WHO, 2003a). A paucity 
of data on adherence in young children especially on CPT exists as most research has focused 
on adherence in adults. In these adults both personal and hospital related factors have 
demonstrated to play an important role in enhancing adherence to treatment. At its meeting in 
June 2001, the WHO adherence group recognized that adherence is a reflection of a certain 
type of behaviour towards taking an appropriate action and came up with a consensus 
definition of adherence   as   “the   extent   to   which   a   person’s   behavior   such   as   taking  
medications, following a diet, and/or executing lifestyle changes, corresponds with agreed 
recommendations   from   a   health   care   provider” (WHO, 2003a). Thus understanding factors 
that influence this adherence in HIV exposed children is key to identification of specific 
behaviour modifying interventions.  
2.22 The complexity of long term treatments in young children 
Little information is available about the extent of factors associated with long-term treatment 
in HIV disease in children. In terms of adherence to these treatments, a study of adults taking 
ART and cotrimoxazole for pneumocystis carinni pneumonia (PCP), showed that the majority 
of patients (79%) taking cotrimoxazole had detectable urinary cotrimoxazole (Eldred et al., 
1998) which  was  used  as  an  indicator  of  adherence.  In  most  of  these  (≥80%),  adherence  was  
associated  with  presence  of   family  and  patients’  beliefs  of   their  ability   to  adhere to therapy 
(Eldred, 1998). In Africa where the majority of HIV infected and exposed children live, 
determinants of paediatric adherence to daily drug regimens have not been widely assessed 
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nor are the effects of the PMTCT programmes on family/household dynamics and how 
parents of HIV infected or exposed children cope with the situation. From a culturally 
grounded ecological theory perspective, Vreeman and others in Kenya described paediatric 
ART adherence to consist of relationships that exist between the child, parents, the care giver, 
household, community and the health care system that are connected by sharing of 
information as well as social interaction Figure 2.5. They explain that these interactions and 
any disintegration in the connections that exist between different entities may influence 
pediatric ART adherence (Vreeman, 2009). However, it is not known whether these theories 
could likewise explain paediatric CPT adherence as well as how the long term interventions 
for HIV exposed children would impact on the lives of guardians. 
 
Figure 2.5: Culturally grounded ecological model of paediatric ART adherence 
 
Source: Vreeman R.C. et al., Qualitative health research 19 (12) 1716-1729. 
 
The culturally grounded ecological model is thought to close the gaps that exist with using the 
Health belief Model (HBM). Developed in the 1950s, the HBM was initially more concerned 
with the subjective state of the individual than with past experience (McCormick-Brown, 
1999). Apart from the four main constructs which include: perceived seriousness, perceived 
susceptibility, perceived benefits and perceived barriers; the relationship between the health 
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professionals and the patient and availability of social support are believed to be important 
catalysts of behavior change (McCormick-Brown, 1999). The two theories (the culturally 
grounded ecological model and the HBM) therefore compliment each other to adequately 
explain  people’s  behavior  towards  compliance  to  treatments.   
In chronic non-HIV treatments in the United States, the process of adherence in children was 
more associated with family structure as well as relationship with healthcare providers. In 
addition religious beliefs and child related factors such as developmental stage and 
temperament were also some of the contextual issues to influence adherence (Landier, 2011). 
In order to determine the concepts that explain adherence to CPT in young children in our 
context, and unveil how the lives of mothers giving CPT to their young HIV exposed children 
evolve, there is need to understand the influence of interrelatedness of existing systems and 
how the women respond to them. A few studies in Malawi in HIV infected mothers, have 
mainly focused on the poor attendance to PMTCT clinics (Bwirire et al., 2008, Chinkonde et 
al., 2009). There has been no study that has properly described the lived experiences of 
mothers with HIV exposed children on CPT. There is need to understand cultural, social and 
personal environments that would determine how mothers of young children receiving daily 
CPT cope with the situation of caring for their children. Several authors have highlighted the 
lack of adequate information from health professionals as the reason for unpreparedness to 
provide care to sick relatives amongst most caregivers (Bucher, 2001). This puts the family 
members in an unfamiliar position with the type of care they must provide but also the 
amount of care that needs to be provided (Scherbring, 2002). There is evidence that caregivers 
receive very little information related to managing their tasks but also to emotional demands 
of caregiving (Scherbring, 2002). This is believed to originate from the inability of family 
caregivers to interact effectively with health professionals in the hospital setting making 
transition to home care a difficulty for many (Scherbring, 2002). In order to develop cost-
effective plans of care and achieve positive client outcomes, health care providers need to 
communicate effectively with clients and caregivers. The evidence on household dynamics 
related to administering long term treatment to children in the communities in rural setting is 
scarce but would be helpful in formulating a theoretical perspective that may enhance 
understanding of factors that influence adherence and women’s   experience   in   general   and  
form a basis for identifying appropriate interventions for complying to uptake of the services.  
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2.23 Factors associated with long-term medication adherence  
Long-term medication adherence is influenced by self, family, community and forms of 
support available from them; healthcare system factors that take into consideration 
availability of resources and policies for accessing, making available and accepting medical 
services. There are also factors that are related to the intervention itself and patient 
characteristics (Murray, 2004). The suppositions that influence adherence to treatments in 
adults are suggested to be multi-faceted (Table 2.9) consisting of patient factors, healthcare 
factors as well as the type of treatment one is taking. It is not clear whether paediatric CPT 
adherence in HIV exposed children in influenced by the same factors.  
 
Table 2.9: Factors associated with medication non-adherence 
 
 Patient factors  Type of Treatment  Healthcare factors  Social factors 
 Actual or perceived side 
effects  
 Rejection of the diagnosis 
 Limited Understanding of 
the diagnosis 
 Loss of faith in 
medications 
 Poor memory 
 Lack of self-efficacy 
 Language or literacy 
barriers 
 Knowledge and 
understanding about the 
rationale of treatment 
 Beliefs 
 Complex treatment 
regimen 
 Long duration of 
treatment 
 Previous treatment 
failure 
 Frequent changes in 
treatment 
 Lack of immediacy 
of beneficial effects 
 Side effects 
 Reduced access to 
medicines and/or 
medical support 
 Health professionals 
lack of time 
 Lack of health 
professionals 
 Lack of continuity 
of care: changing 
providers 
 Lack of 
collaboration 
between health 
professionals 
 Lack of on-going 
communication 
 Poor medication 
distribution and 
costs 
 Costs of 
transportation to 
the health facility 
 Low levels of 
patient education 
 Language 
barriers 
 Lack of effective 
social support 
  
  
  
  
  
  
Source: Adapted from the national heart foundation of Australia (Aslan, 2011) 
 
From a theoretical perspective, the Health Belief model, protection motivation theory, 
theories of reasoned action, self-efficacy, social cognitive and ecological theories of 
perception strongly contribute to the explanation of adherence to treatment (Biddle, 2000) 
(Table 2.10). The use of theories in explaining behaviour helps to describe the associations 
that occur between various factors and result in more effective behavior change interventions. 
Stepnowsky and others attributed the importance of using theories to guide research to the 
following reasons (Stepnowsky, 2013, Ritterband, 2009):  
 59 
 help to describe (and explain) how behaviours change and symptoms improve 
through the use of behavioural change programs;  
 guide program development and facilitate testing of the intervention;  
 help to firmly link an intervention to a theoretical foundation; 
 grounding adherence interventions in theory are important to help the literature build 
a foundation and grow over time 
Table 2.10Table 2.10 is a summary of different theories related to adherence. Despite the 
wide existence of theoretical backgrounds to adherence to treatment presented, paucity of 
theories to explain adherence in young children exists. 
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Table 2.10: An Overview of behavioural theories related to adherence 
 
Theory Description 
Social Cognitive 
theory 
(SCT) 
 
The SCT is centered on four factors that influence  an   individual’s  behavior.   In   the   first  place   the   individual  must  be  able   to  
involve himself in a certain behavior and have self-belief that this involvement will result in a certain outcome i.e. adherence. 
Availability of social support from family, friends and medical staff are catalysts to behavior change that is enhanced because 
of accurate knowledge of the intervention (Bandura, 2004).  
Cognitive behavioral 
therapy (CBT): 
 
The CBT was formulated for post trauma patients whereby they use their traumatic experiences to adapt or influence the way 
they react to similar traumatic events in life. In CBT, an individual uses meanings, judgements, appraisals and assumptions he 
has encountered in life experience to influence his feelings and actions to respond to a particular life event such as adherence 
which thus deters or enhances the process of adaptation (Antonio). However if an individual encounters a new experience, he 
either assimilates it into the existing experience or adjusts the existing experience to fit the new experience. CBT has been 
shown to be effective for a wide range of situations including adherence to treatment (Resick, 1992). 
Trans theoretical 
model (TTM):  
 
The Trans theoretical Model (TTM) draws upon several other theories of behavior change. In this model, change is not instant 
but it occurs over time allowing the individual to progress through several stages (Lenio, 2014). Unlike other theories, in the 
TTM, the person relies on himself to make a decision to change behavior while in other theories influences of social support 
and biological factors play a major role (Lenio, 2014). The individual carries an appraisal of the situation in which he weighs 
the risks and benefits of the new behavior and decides whether to change behavior or maintain the present behavior depending 
on the outcome of the appraisal. In circumstances where the benefits outweigh the risks, behavior change takes place (Velicer, 
1998, Scholl, 2002). 
Health belief model 
(HBM):  
 
The   Health   Belief   Model   (HBM)   focuses   on   individual   factors   that   may   influence   one’s   perceptions   of   either   changing   a  
behavior or not. In this model, for an individual to take a recommended action like adherence to treatment, he weighs benefits 
versus the barriers of taking a particular action. These may include physical, psychological or financial factors. For instance, a 
patient may realize the benefit of taking his treatment and adhering to it but may not be able to access it due to stock outs or 
other reasons or may not have adequate information about the medication instructions. In such a scenario, the patient may be 
motivated but since the medication is not available or there are no instructions on how to take the medications, the barriers 
outweigh the benefits and this may result in non-adherence to treatment. Moreover, with this model, individuals evaluate if they 
are susceptible to a particular threat and whether the threat is severe. In 1974, Rosenstock noted that motivation for an action 
results from a combination of perceived susceptibility and severity while the pathway for action is achieved by the comparison 
of perceived benefits to perceived barriers. Thus the likelihood that a positive action like adherence to treatment would be 
considered with increase in the strength of the perceptions of severity, susceptibility and benefits (which are mostly affected by 
demographics and previous experiences) and the weakness in perceptions of barriers (Rosenstock, 1974). 
Table continued 
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Table 2.10 continued 
 
 
 
 
. 
Theory Description 
Health action process 
approach (HAPA):  
 
According to Health action process approach (HAPA), for an individual to achieve a successful behavior change, goes through 
two phases: the pre-intentional motivational phase and the post-intentional volitional phase (Gaston, 2012). The first phase is 
primarily for forming an intention while the second phase is where the intention is translated into action. In a meta-analysis of 94 
studies, Gollwitzer and his colleagues, individuals who are likely to follow through on their intentions are the ones who identify 
the context (how, when, where, with whom and for how long) in which they would perform the target behavior. Moreover, 
individuals are able to act on their intentions even in the presence of barriers if they pre-decide how to best avoid unwanted 
influences on behavior. The effects of action planning on behavior change are believed to be enhanced formulation of coping 
strategies for the anticipated barriers (Gollwitzer, 2006). 
The ecological theory 
of perception 
This is a general theory of perception and control of behavior that stresses the relation between the organism and its environment 
as well as the relation between perception and action such as adherence to medications. It focuses on the perception and control 
of behaviours that occur naturally and on aspects of the animal and the environment that determine the success or failure (CEHD, 
2014). It largely aspires to describe, explain and predict perception and action by all animals and all situations at all ages (CEHD, 
2014). This theory originates from the work of Eleanor Gibson, who emphasized direct perception via detection of higher-order 
stimulus variables, as opposed to reductionist, constructivist-representational account of perception (Braund, 2008).  
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CHAPTER 3 : THE ROLE OF COTRIMOXAZOLE PROPHYLAXIS IN THE 
PREVENTION OF MALARIA IN SUB-SAHARAN AFRICAN CHILDREN: A 
SYSTEMATIC REVIEW AND META-ANALYSIS  
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3.1 Introduction  
Globally, WHO estimates that there were about 207 million cases of malaria in 2012 and an 
estimated 627 000 deaths, with the great majority of malaria deaths occurring in sub-Saharan 
Africa in children under five years of age (WHO, 2013b). When these children are co-infected 
with HIV, they tend to have a higher malaria parasite density than HIV uninfected ones and 
HIV-1 infection is associated with severe and fatal malaria (Berkley, 2009). Independent of 
parasite density, both exposure to HIV-1 in children born to HIV-infected mothers and HIV 
infection are associated with severe malarial anemia during acute P. falciparum infection 
(Otieno, 2006). In HIV infected children, WHO recommends daily CPT until immune 
recovery is observed on antiretroviral therapy (ART) (WHO, 2006a). For HIV exposed 
children CPT is recommended from the age of four to six weeks until they stop breastfeeding 
and HIV infection is ruled out (WHO, 2006a). 
 
Cotrimoxazole is an antimicrobial drug containing a fixed dose combination of 
sulfamethoxazole and trimethoprim. The combination of these drugs causes a synergistic 
bactericidal effect against a variety of bacterial infections and has also shown to be effective 
against protozoal infections (Wormser et al., 1982). Randomized clinical trials (RCTs), 
observational studies and economic analyses have shown that CPT is cost-effective in 
preventing PCP which accounts for a large proportion of AIDS diagnoses and deaths in 
infants with HIV infection and reduces morbidity and mortality among infants and children 
living with or exposed to HIV (Chintu et al., 2004b). Estimates of the effectiveness of CPT 
for preventing malaria, however, vary widely. For example, a clinical trial (Thera et al., 2005) 
showed that in Mali CPT had a 99.5% protective efficacy against episodes of clinical malaria 
and another RCT showed that in Uganda the reduction in the incidence of malaria was only 
39% (Sandison et al., 2011). Nonetheless, the uptake of CPT by national programs has been 
slow meaning that CPT is being underutilized (Date et al., 2010, Hutchinson et al., 2011). A 
major concern with CPT is that its widespread use in high malaria transmission areas may 
favour cross-resistance to sulphadoxine-pyrimethamine (SP), a drug used for intermittent 
preventive therapy (IPT) for malaria in pregnant women (Sridaran et al., 2010). However, it 
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remains to be determined if the presence of antifolate resistant mutations affect the protective 
efficacy of CPT against malaria. 
 
This systematic review of the literature and a meta-analysis explored the effect of CPT on 
malaria incidence and mortality in HIV positive, HIV exposed and non-HIV exposed children 
in different settings in sub-Saharan Africa. This chapter has recently been published in the 
Tropical Medicine and International Health journal (Mbeye, 2014).  
 
3.2 Objectives 
1. To assess the effectiveness of cotrimoxazole prophylaxis on prevention of malaria in 
children 
2. To determine the effect of cotrimoxazole prophylaxis on all-cause mortality in 
children 
3. To explore whether the effect of CPT on malaria prevention is affected by the 
prevalence of SP resistance.  
3.3 Methods 
3.3.1 Study design 
A systematic review of relevant literature was conducted to assess the effect of cotrimoxazole 
on prevention of malaria and all-cause mortality in children but also whether the malaria 
preventive effect of CPT is affected by presence of SP resistance. The results of different 
studies were combined using meta-analysis in order to summarize and ascertain the effect of 
cotrimoxazole on the prevention of malaria in children in sub-Saharan Africa. Furthermore, a 
meta-regression analysis was used to explore the association between SP resistance and 
cotrimoxazole malaria preventive efficacy. As defined by the Cochrane collaboration, a 
systematic review attempts to collate all empirical evidence that fits pre-specified eligibility 
criteria to answer a specific research question. It uses explicit, systematic methods that are 
selected to minimize bias, thus providing reliable findings from which conclusions can be 
done and decisions made (Liberati, 2009). The same authors define meta-analysis as the “use 
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of statistical methods to summarize and combine the results of independent studies” (Liberati, 
2009).  
The methods for conducting the review and meta-analysis were specified apriori in a 
comprehensive protocol which was registered with the international prospective register of 
systematic reviews (PROSPERO) (Booth, 2013). The reporting of the review followed the 
Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines 
that consist of a 27-item checklist (Appendix 1) and a four-phase flow diagram essential for 
transparent reporting of a systematic review (Liberati et al., 2009).  
3.3.2 Search strategy 
In order to identify relevant articles for the subject, databases like PubMed and EMBASE 
were searched on May 29, 2013 looking for both RCTs and prospective cohort studies 
assessing the effect of CPT on the incidence of malaria and mortality in children aged 0-15 
years in sub-Saharan Africa. Free text words and medical subject headings (Mesh) describing 
the age group, the intervention and the outcome were combined in PubMed. The detailed 
PubMed search, which was developed in collaboration with an expert librarian, is given in 
Figure 3.1. The PubMed search was adapted for EMBASE. Additionally, data on SP 
resistance was identified by contacting authors at the World Wide Antimalarial Resistance 
Network (WWMRN) in the USA. In terms of malaria transmission intensity, data was 
obtained from the published Malaria Atlas Project estimates for 2007 and 2010 of the P. 
falciparum parasite prevalence in children aged 2–10 years (PfPR2–10) (Hay et al., 2009, 
Gething et al., 2011) by matching by latitude and longitude, to the observational studies or 
trials that were included in the review. The PfPR2–10 data from 2007 were used for studies 
conducted between 2000 and 2008, and the 2010 estimates were used for the more recent 
studies. 
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Figure 3.1: The search strategy for PubMed 
((((child OR children OR childhood OR infant* OR newborn* OR neonate* OR adolescen*)) AND 
(cotrimoxazole OR co-trimoxazole OR co trimoxazole OR trimethoprim-sulphamethoxazole OR 
trimethoprim sulphamethoxazole OR tmp-smx OR tmp smx OR bactrim)) AND (((malaria OR 
plasmodium OR plasmodium infection* OR paludis* OR malarial fever OR marsh fever)) AND 
((((((therapy OR therapeut* OR treatment* OR pharmacotherap*)) OR (diagnosis OR diagnosed)) OR 
(epidemiol* OR preval* OR inciden*)) OR (mortalit* OR death* OR surviv* OR case fatalit*)) OR 
(prevention OR preventative OR preventive OR protect* OR prophyla* OR control OR controlled))))  
OR 
 ((("Malaria/diagnosis"[Mesh] OR "Malaria/drug therapy"[Mesh] OR "Malaria/epidemiology"[Mesh] 
OR "Malaria/mortality"[Mesh] OR "Malaria/prevention and control"[Mesh])) OR 
("Mortality"[Mesh]))) AND ((((("Child"[Mesh]) OR "Child, Preschool"[Mesh]) OR "Infant"[Mesh]) 
OR "Infant, Newborn"[Mesh]) OR "Adolescent"[Mesh])) AND ("Trimethoprim-Sulfamethoxazole 
Combination"[Mesh]) 
 
3.3.3 Study Selection 
All RCTs and cohort studies published between January 1990 and May 2013 that compared 
the incidence of malaria and/or all-cause mortality in children receiving and not receiving 
CPT were included. The exposure of interest for this review was Cotrimoxazole prophylaxis 
which was also the exposure investigated in the cohort study. However, in terms of HIV 
exposure, the review included HIV infected children in addition to HIV exposed but not 
infected children while only the latter were included in the cohort study in order to investigate 
rebound after stopping CPT. The inclusion of HIV infected and non HIV infected children 
helped to understand the effect of CPT across all children in SSA. No language restrictions 
were applied.  Studies in adult populations aged 15 years and above and studies from regions 
other than sub-Saharan Africa were excluded. Two reviewers independently selected studies 
first based on titles and abstracts, and, in a second step, based on the full text of potentially 
eligible articles.  
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3.3.4 Data Extraction 
A detailed data extraction form was developed (Appendix 2) and tested on four studies (2 
RCTs and 2 Observational studies) and was refined accordingly before using it to extract data 
for this study. Two independent reviewers extracted data on the study design and setting, the 
characteristics of study populations, malaria incidence and mortality in children receiving 
CPT and control groups. In addition, data on the prevalence of sulfadoxine-pyrimethamine 
resistance–conferring point mutations in the dihydrofolate reductase (dhfr) and 
dihydropteroate synthase (dhps) genes was extracted. After extraction, the data between the 
two reviewers was compared. Disagreements were resolved by discussion between the two 
reviewers and a third reviewer.  
3.3.5 Assessment of the risk of bias 
For both RCTs and cohort studies, two reviewers independently examined each included 
study for risk of bias using a standard form. The form for RCTs included information on the 
sequence generation, allocation concealment, blinding (participants, personnel and outcome 
assessor), incomplete outcome data, selective outcome reporting and other sources of bias. 
The methodological components of the trials were assessed and classified as high, low or 
unclear risk of bias as recommended by the Cochrane collaboration (Higgins et al., 2011). 
Where differences arose, these were resolved by discussions with the third reviewer. For 
cohort studies, a checklist reproduced in Table 3.1 covered the selection of comparison 
groups, confounding, the assessment of exposures and outcomes, the completeness of follow-
up and the reporting of outcomes was used to assess the risk of bias.  
 68 
Table 3.1: Checklist for the assessment of the risk of bias in cohort studies 
Domain Description Reviewer's 
assessment 
Selection bias Were groups selected from the same underlying 
source population? 
Yes No Unclear 
 Were the data collected for the purpose of this 
study? 
Yes No Unclear 
 Were the calendar periods of follow up the same in 
the two groups? 
Yes No Unclear 
 Was the comparability of groups assessed? Yes No Unclear 
 If yes describe the variables compared:  
 Potential confounders? Yes No Unclear 
 Outcome variables before intervention? Yes No Unclear 
Confounding Did the researchers describe how they decided 
which potential confounding domains should be 
considered? 
Yes No Unclear 
 If yes describe the method used:  
 Did the authors control for confounding at the 
design stage? 
Yes No Unclear 
 If yes list on which domains participants were 
matched: 
 
 Did the researchers adjust for confounding at the 
analysis stage? 
Yes No Unclear 
 If yes, which method was used:  
 Stratification Yes No Unclear 
 Multivariable regression Yes No Unclear 
 Propensity scores (matching) Yes No Unclear 
 Propensity scores (multivariable regression) Yes No Unclear 
 Causal modelling (IPTW, g estimation) Yes No Unclear 
 What potential confounders were considered?  
 Please provide list below:  
Information bias Were the defintions / approaches to assess 
exposures and outcomes the same in the 
comparison groups? 
Yes No Unclear 
Loss to follow up Was follow-up near complete  (>90%)? Yes No Unclear 
Outcome reporting 
bias 
Did the study have a protocol pre-specifying the 
outcome? 
 
 Malaria Yes No Unclear 
 Mortality Yes No Unclear 
 Was investigation of the effect of the intervention on 
the outcome a pre-specified objective of the primary 
study? 
 
 Malaria Yes No Unclear 
 Mortality Yes No Unclear 
Overall assessment What is the risk of bias in this study? High Low  
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3.3.6 Statistical Analysis 
The primary outcome of interest was incidence of malaria and the secondary outcome was all-
cause mortality. Inverse-variance random-effects meta-analysis was used to combine incidence 
rate ratios (IRR) for malaria and hazard ratios (HR) for mortality. Calculation of exact confidence 
intervals for the IRR and an estimate of the standard error of the IRR was obtained by dividing the 
difference of the log rate ratio and the upper confidence interval by 1.96. For cohort studies, 
results from analyses that maximally adjusted for potential confounders were used. Random 
effects meta-regression was used to assess the association between antifolate resistance and the 
effectiveness of CPT on malaria incidence. The markers used for resistance were the dhps A437G 
and the dhps K540E mutations. As dhps mutations have started to occur more recently and show a 
more geographically heterogeneous distribution than the major dhfr mutations (S108N, N51I and 
C59R), they were expected to have a stronger spatio-temporal correlation with SP efficacy. The 
dhps A437G mutation was used because the analysis included a study from West Africa, where 
the dhps K540E mutation is largely absent. For the two studies that did not report any resistance 
data, modeled data provided by the World Wide Antimalarial Resistance Network was used. The 
details of the data used in the model can be found on WWARN's Molecular Surveyor 
(http://www.wwarn.org/surveyor/) and http://www.drugresistancemaps.org (Flegg et al., 2013, 
Naidoo and Roper, 2013). Meta-regression was also used to examine whether the effectiveness of 
CPT depended on the study design (RCT or cohort study), the duration of the study, whether the 
children on CPT group were HIV-infected, or on the annualized parasite prevalence. All statistical 
analyses were performed using Stata version 12.1 (College Station, TX) and Comprehensive 
Meta-Analysis software. 
3.4 Results 
3.4.1 Study and participant characteristics 
The searches of PubMed and EMBASE identified 500 publications. Screening of titles and 
abstracts resulted in 15 potentially eligible studies. Nine studies, including three RCTs and six 
observational studies met the inclusion criteria (Figure 3.2) (Sandison et al., 2011, Thera et al., 
2005, Chintu et al., 2004b, Gasasira et al., 2010, Dow et al., 2012, Ezeamama et al., 2012, 
Desmonde et al., 2011, Kamya et al., 2007, Arinaitwe et al., 2012). Two reports (Kamya et al., 
2007, Arinaitwe et al., 2012) were excluded because they were based on study populations 
already included in the analysis (Gasasira et al., 2010, Sandison et al., 2011). In total 1,692 HIV-
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exposed, 2,800 HIV-uninfected and 1,486 HIV-infected children aged between six weeks (Dow et 
al.(Dow et al., 2012)) and 15 years (Thera et al.(Thera et al., 2005)) were included in the meta-
analyses. The studies originated from six countries in sub-Saharan Africa: Uganda, Mali, Malawi, 
Tanzania,  Zambia  and  Côte  d’Ivoire.  The  number  of  children   in  each  study  ranged  from  170   to  
2,298 and the duration of follow-up ranged from 3 to 28 months. Transmission intensity at the 
time of the study was highest in the rural study site in Mali (Pfpr: 0·49)  and  in  urban  Côte  d’Ivoire  
(0·68) and lowest in the urban sites in Tanzania and Zambia (0·07) (Table 3.2 and Table 3.3). 
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Figure 3.2: Flow Chart for identification of eligible studies 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Records identified through database 
searching: 
PubMed: n= 147 
EMBASE: n= 353 
Other sources (n=0) 
 
Review of titles and 
abstracts: n= 448 
(n =  330 ) 
Excluded: 
Inclusion criteria not met: n= 6 
Duplicates: n=2  
Full text articles assessed 
for eligibility: n= 15 
 
Studies included in 
analyses: n= 7 
Excluded: 
Duplicates: n= 52 
Excluded: 
Inclusion criteria not met: n= 433 
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Table 3.2: Characteristics of studies and children included in the systematic review and meta-analysis of CPT and malaria 
incidence  
Author 
(year) 
Country 
(Setting) 
Pfpr Months 
of fup 
Desig
n 
CPT regimen Children in CPT group 
 
 Children in control group 
      No. Age (years) HIV 
status 
 No. Age (years) HIV status 
Malaria incidence 
Thera 
(2005) 
Mali 
(rural) 
0.49 3 RCT TMP 150 mg/m2           
SMX 750 mg/m2 
Thrice-weekly 
160 10 (2.9) Healthy 
children 
 80 10 (2.8) Healthy 
children 
Gasasira 
(2010) 
Uganda 
(urban) 
0.20 28 Cohort Once-daily 292 6.0 (2.6) HIV- 
infected  
 517 7.4 (2.7) Healthy 
children 
Sandison 
(2011) 
Uganda 
(rural) 
0.38 24 RCT TMP 40-80 mg/kg 
SMX 200-400 
mg/kg               
Once-daily 
90 9.6 (8.3-
12.4) 
HIVex   80  10.0 (8.9-13.5) HIVex  
Dow 
(2012) 
Malawi 
(urban) 
0.34 6 Cohort TMP 40mg/kg   
SMX 200mg/kg 
1239 NR HIV-
exposed 
 283 NR HIV-
exposed 
Ezeamama1 
(2012) 
Tanzania 
(urban) 
0.07 27 Cohort NR 255 NR HIV-
infected 
& HIVex 
 2043 NR HIV-
uninfected 
 
Abbreviations: NR: not reported; RCT: Randomized Controlled Trial, Pfpr: annualized parasite prevalence in children 2-10 years of age in X-survey 
1The study by Ezeamama et al included 255 HIV infected and 2043 HIV exposed uninfected children. Cotrimoxazole prophylaxis was analysed as time-varying covariate, based on 
whether or not the mother reported giving cotrimoxazole to her child over the past month. 
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Table 3.3: Characteristics of studies and children included in the systematic review and meta-analysis of CPT and mortality  
 
Author 
(year) 
Country 
(Setting) 
Pfpr Months 
of fup 
Desig
n 
CPT regimen Children in CPT group Children in control group 
      No. Age (years) HIV 
status 
 No. Age (years) HIV status 
Chintu 
(2004) 
Zambia 
(urban) 
0.07 18.9 RCT TMP 40-80 mg  
SMX 200-400 mg 
Once-daily 
265 4.2 (2.8-8.3) HIV- 
Infected 
 269 4.5 (2.1-8.2) HIV-
Infected 
Desmonde 
(2011) 
Cote  d’Ivoire  
(urban) 
0.68 12 Cohort NR 271 NR HIV- 
Infected 
 134  NR HIV-
Infected 
Abbreviations: NR: not reported; RCT: Randomized Controlled Trial, Pfpr: annualized parasite prevalence in children 2-10 years of age in X-survey 
Cotrimoxazole prophylaxis was analysed as time-varying covariate, based on whether or not the mother reported giving cotrimoxazole to her child over the past 
month. 
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3.4.2 Risk of bias 
Overall, the studies included in this review were of high quality. All three RCTs reported 
adequate generation of random allocation sequences, whereas only Chintu et al. and 
Sandison et al. reported allocation concealment (Chintu et al., 2004b, Sandison et al., 
2011). Chintu et al. used double blinding whereas the two others were open-label studies. 
The three trials adequately addressed incomplete outcome data: proportions of dropouts 
were low and outcome data was missing for less than 3% of children. There was no 
evidence of selective reporting in any of the studies. In each of the four observational 
studies included in this review, the CPT and non-CPT groups were selected from the same 
population and followed up for the same calendar period. The only exception was the 
study by Dow et al. in which the incidence of malaria was compared between HIV-
exposed children before and after 2006, the year CPT guidelines were introduced in 
Malawi. All studies adjusted for potential confounders at the analysis stage; however, the 
variables included in the multivariable models differed across studies (Table 3.4). Finally, 
patient retention was over 80% in all the four cohort studies. 
 
Table 3.4: Variables included in adjusted analyses from individual cohort studies 
Study Country Variables adjusted for 
Gasasira et al. Uganda Age 
Stratification by time periods 
Dow et al. Malawi Age, rainy season, ART status, first pregnancy 
Ezeamama et al. Tanzania Season 
Mother:  
Age, CD4, education, marital status, Socio-economic 
status, Bed-net use, history of neonatal mortality  
Child:  
CD4, sex, low birth-weight, CTX compliance, 
breastfeeding, intervention status 
Desmonde et al. Ivory Coast Age, sex, CD4, PMTCT, mother dead, follow-up center 
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3.4.3 Malaria incidence 
Five studies including 2,036 children on CPT and 3,003 not on CPT evaluated the 
association between CPT use and malaria incidence. Children on CPT were less likely to 
develop malaria episodes than those without prophylaxis (IRR 0·37, 95% CI 0·21, 0·66) 
but there was substantial between-study heterogeneity (I-squared=94%, p<0·001) (Figure 3.3). The RCT by Thera et al received little weight in the meta-analysis (8%). When it 
was excluded from analysis the efficacy of CPT decreased by 50% (IRR 0·50; 95% CI 
0·30, 0·84) but between study heterogeneity remained similar (I-squared=94%, p<0·001). 
The four remaining studies included in this analysis all received weights between 23% and 
24% Figure 3.3. 
 
Figure 3.3: Meta-analysis of RCTs and cohort studies of the effect of CPT on the 
incidence of malaria in children 
 
3.4.4 Prevalence of resistance mutations 
Three studies analyzing the association between CPT and malaria incidence also reported 
on the prevalence of antifolate resistance mutations (Table 3.5) (Thera et al., 2005, 
Sandison et al., 2011, Gasasira et al., 2010). Gasasira et al. and Sandison et al. compared 
the presence of resistance mutations in children receiving and those not receiving CPT in 
moderate and high transmission areas in Uganda (Sandison et al., 2011, Gasasira et al., 
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2010). The prevalence of the dhfr/dhps quintuple mutants, composed of the dhfr 51I, 59R, 
and 108N and dhps A437G and K540E mutations, was between 86% and 95% and there 
was no significant difference between comparison groups. Thera et al. reported on 
antifolate drug resistance in a moderate transmission rural area in Mali. In their study, 
14% of the children had the triple dhfr mutants at baseline and the prevalence of this 
resistance pattern did not change during CPT. Double dhps mutants were not found (Thera 
et al., 2005).  
 
Table 3.5: Prevalence of antifolate resistance mutations in studies of the effect of CPT on 
malaria incidence 
Study  Thera             
et al. 
Gasasira         
et al. 
Sandison     
et al. 
Dow            
et al.1 
Ezeama
ma et 
al.1 
Country  Mali Uganda Uganda Malawi Tanzani
a 
Study period  2000 2005-06 2007-08 2004-09 2004-08 
DHPS gene 
mutations 
      
Gly-437 (437G)  38% 96% 100% 96% 77% 
Glu-540 (540E)  0% 97% 100% 98% 71% 
1 Estimates for Dow et al. and Ezeamama et al. were obtained from modeled data provided by the World 
Wide Antimalarial Resistance Network. For details of the data used in the model see WWARN's Molecular 
Surveyor (http://www.wwarn.org/surveyor/) and http://www.drugresistancemaps.org. 
DHPS: dihydropteroate synthase 
 
There was some evidence that the effectiveness of CPT decreased with increasing 
prevalence of the dhps A437G and dhps K540E resistance mutations as shown in Figure 3.4 and in Figure 3.4 respectively but this did not reach conventional levels of statistical 
significance (p=0·11 and p=0·09, respectively). There was little evidence that the 
reduction in malaria incidence was related to the study design (p=0·42), the duration of 
the study (p=0·42), whether the children on CPT were HIV-infected (p=0·75), or on the 
annualized parasite prevalence (p=0·35). 
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Figure 3.4: Results from meta-regression of the efficacy of CPT on malaria incidence 
in the presence of antifolate resistance mutations dhps A437G  
 
Key: Dashed bubbles: Cohort studies; Solid bubbles: RCTs; red line: the regression line; The size of the 
circle is proportional to the inverse of the incidence rate ratio. 
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Figure 3.5: Results from meta-regression of the efficacy of CPT on malaria incidence 
in the presence of antifolate resistance mutations dhps K540E 
 
Key: Dashed bubbles: Cohort studies; Solid bubbles: RCTs; red line: the regression line; The size of the 
circle is proportional to the inverse of the incidence rate ratio. 
 
3.4.5 Mortality 
One RCT from Zambia (Chintu et al) and   one   observational   study   from   Cote   d’Ivoire  
(Desmonde et al) reported on the association between CPT and all-cause mortality. 536 
participants on CPT and 403 not on CPT were followed for 12-19 months.  CPT reduced 
mortality by 43% (HR 0·57, 95% CI 0·43, 0·77) in the RCT. The crude estimate from the 
observational study was similar (HR 0·53, 95% CI 0·23, 1·25), however the protective 
effect of CPT disappeared after adjustment for age, sex and immunodeficiency status (HR 
1·13, 95% CI 0·37, 3·43). 
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3.5 Discussion 
This systematic review and meta-analysis of the effect of CPT on the incidence of malaria 
in children from four countries in sub-Saharan Africa has shown that CPT reduced malaria 
incidence by 63%. However, the number of studies included was small and the 
heterogeneity across them substantial. The protective efficacy of CPT seemed to depend 
on the population prevalence of resistance mutations in the parasite genes Pfdhfr and 
Pfdhps but remained important in areas with very high levels of antifolate resistance. The 
evidence on the role of CPT in reducing mortality among children was even poorer as 
only two studies could be included: an RCT from Zambia showing a statistically 
significant reduction of mortality by 43% with CPT and an observational study from Côte 
d’Ivoire   reporting   no   difference   between   children   receiving   and   not   receiving   CPT 
(Chintu, 2004, Desmonde, 2011).  
 
Although the studies included in the meta-analysis of CPT and malaria were different in 
their design, study population and geographical settings, all showed a protective effect of 
CPT on the incidence of malaria. The reduction in malaria incidence was less (50% 
reduction) when the outlier (Thera et al.(Thera et al., 2005)) was excluded from the 
analysis, but the association between CPT and malaria incidence remained statistically 
significant. The study by Thera et al. (Thera et al., 2005) was the only one done in HIV-
negative children, in whom the protective efficacy of CPT might be different than in HIV-
infected children. Two cohort studies compared HIV-infected children on CPT with HIV-
exposed or healthy children not on CPT (Gasasira et al., 2010, Ezeamama et al., 2012). 
HIV infection increases the risk of malaria and the protective effect of CPT might 
therefore have been underestimated in these studies. Interestingly, the impact of CPT on 
malaria incidence seemed to depend on the geographical area where the study was 
performed, possibly in relation with the prevalence of resistance mutations in Pfdhfr and 
Pfdhps genes. The meta-regression showed that there was a trend towards a higher 
protective efficacy of CPT on malaria in regions where the prevalence of the resistance 
mutation dhps A437G was lowest, but this was essentially driven by one study (Thera et 
al., 2005). Other factors including geographical differences in transmission intensity may 
also have played a role in generating this association. These results underline the paucity 
of data from regions other than East Africa and the lack of large studies in HIV-uninfected 
children. Of note, a study from Uganda showed that CPT was not associated with a higher 
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prevalence of resistance mutations in HIV-infected children and adults with P. 
falciparum parasitemia (Malamba et al., 2010).  
 
This review confirms the substantial effect of CPT on malaria incidence and mortality in 
African children. Despite the limited evidence available, WHO has recommended CPT for 
all HIV-infected children for many years (WHO, 2006b). However, despite the low price 
and relative safety of the drug (Mermin et al., 2004), this preventive strategy has not been 
widely used for HIV-uninfected children. In a sub-study of the ARROW trial, in which 
children older than 3 years and on ART for longer than 96 weeks were randomized to 
continue or stop CPT, those who discontinued the drug were more likely to be 
hospitalized, including for malaria (Bwakura-Dangarembizi and al., 2013). The fact that 
the protective effect of CPT was most important in patients with high CD4+ cell counts 
supports the view that this might be a valid approach for malaria prevention in immune-
competent children. However, there have been concerns that the widespread use of CPT 
would lead to an increase in antifolate resistance in sub-Saharan Africa (Lynen et al., 
2007). These resistance mutations have shown to have an impact on the efficacy of 
sulfadoxine-pyrimethamine (Naidoo and Roper, 2013), which is currently the only drug 
recommended for intermittent preventive treatment (IPT) for malaria in pregnant women 
(Garner and Gulmezoglu, 2006, Menendez et al., 2007, Kayentao et al., 2013, ter Kuile et 
al., 2007). Only one study included in this meta-analysis assessed the prevalence of 
antifolate resistance mutations before and after the use of CPT and did not show an 
increase in the prevalence of these mutations over time (Thera et al., 2005), consistent 
with other CPT studies in HIV infected adults (Malamba et al., 2010, Malamba et al., 
2006). 
 
Although several publications have reviewed the evidence on the protective efficacy of 
CPT on malaria (Kamya et al., 2012, Manyando et al., 2013), this is the first report to 
include a meta-analysis and a thorough assessment of the risk of bias of both RCTs and 
observational studies. The most important limitation of this report is the low number of 
studies which could be included in the analyses. Only five studies were eligible for the 
meta-analysis assessing the effect of CPT on malaria incidence. As a consequence, it was 
not possible to conduct sub-group analyses to effectively assess sources of heterogeneity. 
Furthermore, as the publications originated from only four countries in Africa and also 
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that Asia was excluded, the results are not representative of the overall situation in sub-
Saharan Africa and cannot be applied to other regions such as Asia. Moreover, Asia would 
not have added much to the review as pooling the findings would have been difficult 
considering the differences in malaria transmission epidemiology and co-existence of 
vivax with the hypnozoite stage (Price, 2009). The association between CPT and mortality 
was only evaluated in one RCT and one observational study. A meta-analysis was 
therefore not performed for this outcome. Finally, only one study evaluated the protective 
efficacy of CPT on malaria in HIV-uninfected children (Thera et al., 2005).  
The omission of Septrin (an international brand name for cotrimoxazole) might only have 
had impact higher up in the flow chart but did not impact on the final number of studies 
included as all studies also mentioned the word cotrimoxazole. The many advantages of 
CPT prophylaxis in HIV-infected as well as those exposed to HIV but not infected (HIV 
exposed) justify its recommendation in routine clinical care. However, CPT is not widely 
prescribed to children who are HIV-negative, partly due to the lack of evidence and 
because, in contrast to HIV-infected children who are in regular medical care, the delivery 
of this treatment would not be straightforward in this population. 
3.5.1 Summary of discussion 
This study has described studies evaluating the effect of CPT on the incidence of malaria 
in children and has also provided a pooled estimate of its effect. Furthermore, it has shown 
how this effect is affected in the presence of antifolate resistance. In brief the study has 
shown that CPT reduces malaria incidence and mortality in children in sub-Saharan Africa 
but study designs, settings and results were heterogeneous. CPT appears to be beneficial 
to HIV-infected, HIV exposed as well as HIV uninfected children. 
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CHAPTER 4 : MALARIA REBOUND IN HIV EXPOSED CHILDREN AFTER 
STOPPING COTRIMOXAZOLE PROPHYLAXIS  
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4.1 Introduction 
The population of HIV exposed children is constantly increasing following scale up of 
PMTCT interventions (UNAIDS, 2013a).  Optimizing the survival of these children 
requires a careful assessment of the risks and benefits associated with interventions 
available for them. The use of CPT for the prevention of OIs (WHO, 2006b) has 
previously been associated with significant gains in reducing malaria and other 
morbidities in children in different African settings (Sandison, 2011, Mbeye, 2014, 
Kamya et al., 2007). However, it is not known whether the abrupt cessation of CPT at 12 
months in HIV exposed children who remain negative may be associated with increase in 
the risk of malaria, all-cause morbidity, admissions and mortality. While a number of 
studies on the use of malaria chemoprophylaxis have reported an increase in the episodes 
of malaria and other morbidities in the year following termination of chemoprophylaxis 
(Greenwood et al., 1995, Menendez et al., 1997, O'Meara et al.), a pooled analysis of six 
trials using SP for IPTi was not able to show rebound effects (Aponte, 2009). This study 
aimed at comparing the incidence of uncomplicated and severe malaria; all-cause sick 
visits, all-cause hospital admissions and all-cause mortality between HIV exposed and 
non-HIV exposed children during CPT and after it was stopped. 
4.2 Methods  
The overall aim of this study was to investigate malaria rebound after stopping 
cotrimoxazole prophylaxis in HIV exposed children. This chapter therefore, presents an 
overview of the methods that were used and furthermore, it describes the study location, 
detailed study procedures, data management, statistical methods used and ethical 
processes. Thereafter, the study findings are presented followed by a discussion of the 
findings.  
4.2.1 Study location 
This study was carried out in Zomba district in the Southern region of Malawi (Figure 4.2). With a population of approximately 15 million (Group, 2013), Malawi, a landlocked 
country stretches over 118,484 square kilometres sharing borders with Tanzania, 
Mozambique and Zambia. For administrative purposes, the country is divided into 28 
administrative districts headed by a District Commissioner (DC) (MLGRD, 2013). Within 
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the districts there are Traditional Authorities (TAs) comprising of specific village groups 
(MLGRD, 2013). The TAs play important roles in maintaining public peace, assisting in 
general administration and reinforcing any lawful directions of the DC (Cammack, 2009). 
The Malawi economy is agro-based with Agriculture accounting for 30.2% of the Gross 
Domestic Product (GDP) per capita of 360 USD in 2012 (Bank, 2013). 
 
With a mean annual rainfall varying between 635mm and 3,050mm for a rainy season 
lasting from November to April, Malawi experiences a sub-tropical climate which is more 
prominent in the lowland areas of the southern region with temperatures reaching as high 
as 39 degrees Celsius. Most of the northern region is relatively cooler with temperatures 
averaging between 20 and 27 degrees Celsius due to the highland areas common in this 
region (Services., 2007). 
4.2.1.1 Zomba District Profile 
Zomba district has a population of 670,533 and has a mixture of a peri-urban and rural 
population (Council., 2010). Its topography varies from hilly areas of Zomba plateau with 
an altitude of 2,085 metres above sea level to broad, flat plains of Lake Chilwa lying at an 
altitude of 627 metres below sea level (MLGRD, 2013). The district extends into the 
Phalombe plains where the prevalence of HIV among antenatal attendees was estimated to 
be 27% in 2007 (NAC, 2008). It also extends to Domasi area where HIV prevalence in 
2007 was 34% among antenatal attendees, second highest after Thyolo district located in 
the same region. Between 2012 and 2013 the district registered a monthly average of 155 
HIV infected pregnant women and 198 new HIV exposed newborns (MoH, 2013a). 
Health care services are provided by the Ministry of Health (MoH), private organizations 
and non-governmental organizations (UN-HABITAT, 2011). There is an active PMTCT 
program at the hospital, run in conjunction with Dignitas International, a medical 
humanitarian organization dedicated to improving access to treatment and quality of care 
for people with HIV/AIDS and related diseases (Dignitas., 2013). Malaria in this region is 
endemic with high rates of severe malaria observed in hospital. Most of these admissions 
are in younger children aged between 1 and 4 years (Kazembe et al., 2006). The risk of 
dying in hospital for these younger children is higher compared to older children aged 
between ten and fourteen years (Kazembe, 2006). Spatial modelling of hospital paediatric 
data showed that malaria-specific mortality was higher in areas further from the district 
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hospital and higher during the wet season (Kazembe, 2006). In terms of malaria control 
interventions, ITN coverage rose from 5.9% in 2000 to 30.3% in 2010 among people of all 
ages (NSO, 2011) largely due to free ITN distribution campaigns by the MoH (Okiro, 
2013).  More recent raw data by the HMIS at district level indicates a monthly average of 
7,655 malaria cases among under-five children in the district (MoH, 2013b) with more 
cases attended to in the month of January (Figure 4.1).  
 
Figure 4.1: Under-five malaria cases in Zomba district 2012-2013 
 
 
This site was chosen because of the malaria and HIV disease epidemiology, the already 
set-up infrastructure and the proximity to College of Medicine, Blantyre where storage of 
study samples and all procurement of study supplies was done. The study catchment area 
covered the whole district comprising of 9 TAs, 4 sub TAs and 1,561 villages (Figure 4.2). Some parts in TA Mlumbe were deliberately excluded because of high terrain during 
the rainy season. Since study follow-ups were home-based, it would have been impossible 
to reach participants by a motorbike during the rainy season. 
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Figure 4.2: Map of Zomba district showing TAs and villages 
 
 
 
 
 
Map of Malawi 
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4.2.2 Study Design 
A prospective cohort study was used to follow up two groups of children. One group was 
HIV exposed and received daily CPT from 6 weeks until the age of 14 months, while the 
other group was non-HIV exposed not on CPT. Since the groups were not assigned to 
specific forms of treatment or exposures by the study, as would have been the case in 
experimental  studies  (i.e.  trials),  a  cohort  design  was  used  where  ‘exposure’  (i.e.  CPT  use)  
was based on routine care and the HIV status of the mother rather than by the study 
(Bookwala, 2011). Experimental studies have previously been used to investigate the 
effect of CPT on malaria. For example, in one randomized clinical trial in Uganda, HIV 
exposed children who remained HIV negative after stopping CPT, were randomized to 
either continue on CPT or on placebo for 2 years (Sandison, 2011). This could have been 
the only way to achieve a nearly ideal comparison group, as randomizing them at the 
beginning would have had ethical implications. However, with such a design it would 
have meant extending the period of CPT in half of the children, which has practical and 
ethical limitations because of the unclear risk/benefit of the additional year of CPT. 
Another trial in Lilongwe used the same group of HIV exposed children, by taking their 
time before starting CPT as the unexposed period and time after they started CPT as 
exposed period. In studies like these where comparisons of outcomes for the two different 
periods are made for the same population (Dow, 2012); the difference in the time of 
outcome assessments makes it impossible to separate temporal changes in disease 
occurrence due to changes that may arise like the availability of malaria control 
interventions such as ITNs, IRS and other forms of prevention at specific time points. In 
the same pursuant of trying to achieve an ideal comparison group, some studies have 
randomized children of unknown HIV status into CPT and placebo (Gasasira et al.). As 
much as the groups are similar in some baseline characteristics with this type of 
randomization, unequal distribution of HIV infection between the groups would modify 
the effect of CPT, plus the ethics of withholding an intervention that is national strategy in 
some of the children can be debated.  
4.2.2.1 Description of exposure  
The exposure under investigation in the present study is CPT that was administered 
according to body weight once every day (Figure 4.3) in HIV exposed children from the 
age of six weeks until the age of 14 months when they were stopped from breastfeeding 
and tested HIV negative with both antibody and HIV PCR tests as part of PMTCT 
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interventions (WHO, 2010f). The exposure was not assigned to study participants by the 
investigator, but as part of normal PMTCT interventions, HIV exposed children receive 
this prophylaxis to prevent bacterial infections (WHO, 2006b). Naturally, this created an 
exposed group. Under normal circumstances, the ideal comparison group would have been 
HIV exposed children who are not on CPT. However, this was not possible due to ethical 
implications since it is a WHO recommendation to put all children in this category on 
CPT (WHO, 2006b). The only available comparison group therefore, was non-HIV 
exposed children born from HIV negative women. The selection of an age and residence 
matched comparison group in this study took into consideration environmental as well as 
personal attributes that may influence malaria in these children. 
 
Figure 4.3: The dosing schedule for Cotrimoxazole prophylaxis in children 
 
Source: UNICEF and WHO, 2009 (UNICEF, 2009) 
4.2.2.2 Study Procedures 
Baseline assessment of PMTCT services in selected districts 
Before the study protocol was written, a formative research was carried out in selected 
hospitals located closer to the College of Medicine in Blantyre to determine the status of 
PMTCT services and understand the target problem (Power, 2004, Ulin, 2005).  This 
assessment included questions on breastfeeding practices of HIV infected women with 
HIV exposed but not infected children, uptake of PMTCT interventions, availability of 
Early Infant Diagnosis (EID) services and availability and nature of follow up 
mechanisms. In addition to interviews, hospital records and registers were checked to 
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determine the magnitude of the situation. The hospitals that were assessed were the Queen 
Elizabeth Central Hospital (QECH) in Blantyre, Thyolo District Hospital, Chiradzulu 
District Hospital and Zomba Central Hospital. The findings of this assessment are not part 
of this report but were used to understand the context as well as guide in the study design 
and selection of the study site. 
Study preparatory procedures 
After the study team was assembled, a five-day study specific training for all study staff 
was conducted. The staff included a Study Coordinator who was a Clinical Officer 
responsible for coordinating clinic activities and examining study participants when they 
reported for scheduled and unscheduled clinic visits; two research nurses who worked 
closely with the PhD student in data collection as well as collection of blood samples; 
Laboratory Technicians who assisted with reading of malaria slides and three Research 
Assistants/field workers who assisted the PhD student in conducting home visits and 
dispensing of cotrimoxazole at home. During the training, the review of the study protocol 
with emphasis on methods for data collection and orientation on Standard Operating 
Procedures (SOPs) were covered. Two days were dedicated to practical experience of 
using Personal Digital Assistants (PDAs) during dry runs. This was repeated several times 
until everyone had mastered the processes. PDAs are electronic devices that were used for 
capturing data for the study as described in section 4.2.2.3. The dry runs presented 
opportunities to clarify the intent of the study and its procedures. Some areas that required 
revision were identified and revisions were made before conducting the  ‘wet   run’  a   few  
days before starting the study at the study site. The  ‘wet  run’  involved  taking  a  child  with  
characteristics similar to study participants through all study procedures in order to 
validate the study tools as well as procedures. 
 
The management team of ZCH provided a clinic space with a reception area, a laboratory, 
a counselling room where informed consenting process took place, an examination room 
which was dedicated for performing physical examinations and collection of blood 
specimens, and a data room where the touch screen computers and the server were housed 
(Figure 4.4). 
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Figure 4.4: Study clinic at Zomba Central Hospital 
 
 
District Sensitization meetings 
Several steps were taken in order to seek permission to conduct the study in the district 
and create awareness about the study among the community members. Immediately after 
permission to carry out the study at the site was granted by the Director of ZCH, 
successive awareness meetings with all government departments including the police, city 
assembly, district assembly, district health office and non-governmental organizations 
took place. District-wide meetings with Traditional Authorities and Group Village 
Headmen (GVH) followed. Separate meetings to brief all hospital departments at the 
study site about the study and how each department was going to be involved preceded the 
start of the study. Health Surveillance Assistants (HSAs) and Community Advisory Board 
(CAB) members with assistance from field project staff supplemented GVH sensitizations 
to reach out to everyone in the study catchment area. The CAB comprised of lay people in 
the  community  who  were  trained  on  the  study  protocol  using  layman’s  language for them 
to understand study aims and procedures. With this information, CAB members were able 
to create awareness about the study but also alert study staff on any arising 
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misconceptions about the study from the communities. In addition, they helped to dispel 
rumours and clarify any misunderstandings related to the study in the community.  
Participant Screening 
Pre-screening procedures 
Every morning, the study team carried out health education talks at the under-five and 
antenatal clinics to sensitize the women about the study. Other talks were done in support 
groups of HIV infected women and PMTCT clinics. The study also targeted the labour 
and post-natal wards with messages about the study. All women interested to join were 
asked to present to the study clinic for detailed explanation about the study and undergo 
screening procedures. 
 Screening procedures 
A checklist to assess the eligibility of study participants was administered to all guardians 
of the children that presented to the study clinic. For the HIV exposed group, between 0-2 
months old HIV PCR negative children that were breastfeeding but also receiving CPT 
were eligible for the study. Study staff ascertained that their guardians were willing to 
comply to study protocols and planning to reside in the study catchment area for the 
duration of the study before the informed consent was obtained. Children with serious 
illnesses or severe malnutrition were treated during the screening process and allowed to 
take part in the study once they recovered. For the non-HIV exposed children, the same 
eligibility criteria were applied except that they were not supposed to be on CPT. The 
study staff verified that the mother was HIV negative by checking her health passport 
book records. Records for all participants who were screened were recorded in the 
screening log. The log also indicated whether the participant was enrolled in to the study 
or not with reasons for non-enrolment clearly specified. 
Recruitment of study participants 
HIV exposed children were recruited from the hospital (labour ward, post-natal ward, 
PMTCT or under-five clinic) and were escorted to their homes by the study staff where an 
age and residence-matched, non-HIV exposed child was identified. This offered the 
opportunity to take a detailed location map for further follow ups which were mostly 
home-based but also allowed ease of follow up for participants who missed their 
scheduled clinic follow up visits. In the community, the non-HIV exposed child was 
randomly selected by spinning a Coke bottle and following the direction it pointed for at 
least 100 metres, the first child who resided along this path meeting the inclusion and 
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exclusion criteria was selected. If there were no children after 100 metres, the bottle was 
spun again until a child was found. The aim of the careful selection of non-HIV exposed 
children was to provide a non-biased comparison sample of the population from which the 
HIV exposed children came from (Rothman, 2012). No information was divulged on the 
sero-status of mothers participating in the study during selection of study participants. In 
addition, the   study  was   generally   called   “the  malaria   study”   in   the   community   to   avoid  
suspicions that some of study participants were HIV infected. These meticulous 
procedures were aimed at ensuring that the non-HIV exposed children also had the 
background prevailing risk factors for diseases especially malaria and patient attributes. 
By selecting non-HIV exposed children from same residency as HIV exposed children 
they had comparable environmental malaria attributes. Information on both child and 
household characteristics was collected (Appendix 3). Details for participants enrolled in 
to the study were recorded in the enrollment log. 
Follow up of study Participants 
After recruitment, each participant was followed until the age of 14 months in the first part 
(year 1) of the study. During this time, home-based, two-monthly study visits were 
conducted. Participants were told to report to the study clinic when they were sick and at 
visit 6 which occurred when the children reached 12 months of age. Additionally, since 
HIV exposed children received CPT during this time, they were requested to come to the 
study clinic again at visit 7 for HIV PCR results and stopping of CPT (Appendix 5). For 
non-HIV exposed children, visit 7 was done at home. The same 2-monthly visit schedules 
were done for the second part (year 2) of the study until children reached 24 months of 
age. 
Follow up procedures during cotrimoxazole prophylaxis 
Between recruitment and the time the children stopped CPT at visit 7 which occurred 
when children were 14 months of age, both groups were primarily followed in their homes 
every two months by study staff except when they were sick and when they had specific 
clinic visit schedules. This was done in order to avoid introducing bias in their health 
seeking behaviour (Rothman, 2012). For both clinic and community-based study visits, 
the study staff noted whether the child was alive or dead or suffered any illness since the 
last visit which was unreported; collected information on malaria control measures and 
checked anthropometric measurements including height, weight and Mid-Upper-Arm 
Circumference (MUAC). Vital signs like temperature, respiratory rate and pulse rate were 
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only checked during scheduled clinic visits (Appendices 4,5,6) as well as unscheduled 
clinic sick visits (Appendix 7). All participants were advised to come to the study clinic 
for any sickness. CPT and adherence counselling were provided to HIV exposed children 
accordingly during these visits. 
Clinic based follow up visits 
During the follow up period, there were scheduled and unscheduled clinic visits for both 
groups of children. Apart from the study enrollment visit, both groups of children were 
requested to come to the study clinic at visit 12 which was the last study visit as explained 
later. However, HIV exposed children were requested to come at visit 6 when they were 
12 months old for HIV testing and stopping of breastfeeding but also at visit 7 when they 
were 14 months old for HIV PCR results and stopping of CPT. Information collected at 
these visits was similar to that collected during community follow-up visits. During the 
unscheduled sick child visits to the study clinic, a detailed past history of illness since the 
child was last seen by study staff was collected including any information on hospital 
admissions and laboratory investigations (Appendix 8). All the information given was 
crosschecked with the information recorded in their health passport books. In addition, 
study participants underwent a full physical examination. During all sick visits a dry blood 
sample was collected on a filter paper for genotyping for recrudescent malaria infections 
in addition to a blood sample for Haemoglobin (Hb) and malaria smear. Children with 
parasitaemia were managed according to standard MoH guidelines. For a diagnosis of 
uncomplicated malaria, children were prescribed artemether lumefantrine (AL). Severe 
cases   were   given   parenteral   quinine   and   admitted   to   the   hospitals   children’s   ward   for  
observation and further medical care. For other diagnoses, treatment was also given 
according to guidelines.  HIV exposed children continued to take CPT unless medically 
contraindicated. Although rarely, any identified period during which CPT was not taken 
was duly recorded on the CPT adherence questionnaire.  
Home-based follow up visits 
During home visits, study participants who were not found in their homes were visited 
again within the following three days. Compliance to treatment including cotrimoxazole is 
generally difficult to measure. Random spot checks and unannounced pill counts were 
done in a subset of the study population to monitor adherence. Additionally, scheduled 
face-to-face CPT adherence interviews to identify any missing doses of cotrimoxazole and 
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reasons for missing the drug were conducted every four months with all guardians of HIV 
exposed participants.  
 
Although this was not a clinical trial, drug safety was assessed. CPT may be associated 
commonly with rash, fever, anaemia and more rarely with severe hepatitis and Stevens 
Johnson syndrome in children (Hamel et al., 2008).  
Follow up procedures after stopping cotrimoxazole prophylaxis 
This section describes methods of follow up of both HIV exposed and non HIV exposed 
children in their second year of follow up when the HIV exposed group stopped taking 
daily CPT. 
 
For HIV exposed children, present WHO guidelines on HIV and infant feeding strongly 
recommend that breastfeeding should be stopped when the child is 12 months old (WHO, 
2009b). Previous guidelines recommended that women stop breastfeeding when children 
were 6 months old, however many studies have shown that this is associated with an 
increased child mortality versus the potential benefit of reducing the risk of HIV 
transmission through breast milk (Taha, 2011). Therefore, in this study, when HIV 
exposed children reached 12 months of age, they were advised to stop breastfeeding. 
Cabergoline, a drug that stops lactation within a day on average was given (Melis, 1988, 
Rains, 1995) as a directly observed single dose of 2 mgs to  facilitate cessation of 
lactation. This drug is presently being used in PMTCT programs and is found to be highly 
acceptable and effective (Buhendwa, 2008). At this point, the child was reviewed in the 
study clinic and a filter sample of blood was taken as per PMTCT guidelines for HIV PCR 
testing. Since it takes around 6 weeks to have results for HIV PCR available, HIV exposed 
children were asked to report back to the study clinic for results and termination of CPT 
upon the nature of results. During this visit if the child remained HIV negative, CPT was 
stopped after HIV PCR results 8 weeks later (at the age of 14 months). This was properly 
documented. However, if the child sero-converted, CPT continued and was referred to the 
HIV clinic to start taking antiretroviral therapy and was informed to continue to report to 
the study clinic when sick for medical review and the study staff continued to follow up 
the child every two months until they were 24 months old. 
 
The HIV exposed children who remained HIV PCR negative after stopping cotrimoxazole 
prophylaxis and the non-HIV exposed children were followed up until they were 24 
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months old. They were visited in their homes every 2-months according to the same 
follow-up schedule in the first year except that CPT adherence interviews were not 
conducted. Both HIV exposed and non-HIV exposed children were requested to come to 
the clinic whenever they were sick. During these sick-child visits, these children 
underwent a full physical examination. A blood sample for Hb and malaria assessment 
plus a filter paper blood sample for genotyping for recrudescent malaria infections were 
collected. For every illness including malaria, children were managed according to 
standard MoH guidelines. Figure 4.5 is a presentation of study participant flow. A follow-
up period of around 10 months post-intervention was selected to observe for rebound 
malaria effect as most previous studies investigating this effect followed participants for a 
similar duration of time (Greenwood et al., 1995, Menendez et al., 1997). However, the 
data available for analysis has a wide variation between study participants on the period 
observed after CPT as the study is still on going. There are some participants who 
completed the 10 months of follow up while others did not. At visit 12, the last visit in the 
study, all participants were asked to come to the study clinic for final evaluation. During 
this visit, information on their past and current medical history was collected; the study 
clinician performed a full physical examination on all participants and blood samples for 
malaria parasites, anaemia and Dry Blood Sample were collected (Appendix 9).  
Study termination procedures 
At 24 months of age, all children were terminated from the study. In order to avoid 
separation anxiety, discussions on upcoming end of the study were initiated at visit 9 
when children were 18 months of age and continued until termination date. Study 
termination procedures included one-on-one discussion to review the purpose of the study 
and the reasons for coming to an end. In addition, guardians of HIV exposed children 
were counselled on prevention of any infections among the children. 
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Figure 4.5: Participant flow during study follow-up
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Laboratory procedures 
In the study, blood specimens were collected at first study visit (enrollment visit), visit 12 
(last study visit) and each sick child visit to the study clinic (Appendix 8). The blood 
specimen was collected to check for presence of malaria parasites, haemoglobin levels and 
future studies for genotyping and malaria recrudescence analysis. Passive surveillance was 
the main method of assessing malaria and anaemia to minimize discomfort, added 
suffering and risk associated with drawing of blood samples for research use, hence blood 
drawing was only limited to sick children and few scheduled visits so that it was in 
concert with procedures for medical care (Howie, 2011). Blood samples at the first visit in 
the study (enrollment visit) were collected to serve as baseline indicators. All Laboratory 
technicians working on the samples were unaware of the group the study participants 
belonged to in order to minimize chances of misclassifying the outcomes. 
 Assessment of malaria 
For a malaria diagnosis to be made, an assessment algorithm and definitions in Table 4.3 
was followed. The history of fever within 24 hours, temperature of ≥37.5 degrees Celsius 
and positive malaria smear by either microscopy or malaria rapid testing constituted a 
malaria diagnosis. Both thick and thin smears were collected from each participant at 
enrolment; every sick visit and at the last study visit. 
  
Malaria microscopy: This study used malaria microscopy as the main method for malaria 
diagnosis. Thick blood smears were collected and examined for P. falciparum asexual 
parasites. A thick smear was collected by finger prick and placed on a clean microscopy 
slide. It was then allowed to dry in the open air for up to 20 minutes. The slides were 
stained using Field stain and read under light microscopy by a first reader who was an 
experienced Laboratory Technician (Lab Tech). Another Lab Tech independently read 
these slides again in order to achieve precision. A third reader read all slides with 
discrepant results, defined as malaria slide positive for first reader and malaria slide 
negative for the second reader for the same study participant. Independent readers 
performed quality control checks by reading randomly selected slides. A thick smear was 
considered negative if 100 high-power microscopic fields revealed no parasites. For 
positive smears, malaria parasites were counted against 200 leucocytes.  
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Malaria Rapid Diagnostic Tests (mRDT): The Ministry of Health introduced use of 
mRDTs for malaria diagnosis in 2012. This method was adopted by all health facilities in 
Malawi including the present study. Paracheck Pf Rapid Test was used in this study as a 
supplementary test to malaria microscopy from 2013. This test detects P. falciparum 
histidine rich protein II in whole blood and is accurate in isolating P. falciparum infection. 
As  per   the  manufacturer’s   specifications,   a   drop   of   blood   collected  by   finger   prick  was  
placed in a square shaped hole. This was followed by putting two drops of buffer solution 
in another hole that was round shaped. A positive result for P. falciparum was confirmed 
when both the control and the test line were present. However, if only the control line was 
present, the test was negative. In circumstances where the control line did not appear, the 
results were considered invalid and the test was done again. The results were read between 
15 and 20 minutes from the time the buffer was added. 
Anaemia assessment 
Haemoglobin was checked on every study participant at enrolment, visit 12 (last study 
visit) and each sick visit. The test was done using a Hemocue® analyser (HemoCue AB, 
Ängelholm, Sweden). The child was pricked and after wiping the first drop of blood, the 
next capillary blood was collected using the microcuvettes which were then cleaned on the 
sides to wipe off any blood overflows before inserting them into the HemoCue machine. 
Each day, the machines were validated for control using the manufacturer supplied quality 
control kits. All quality control readings were recorded in a logbook.  
 Dry Blood Sample:  
A DBS sample was collected at visit 1 (enrollment); every sick visit and visit 12 (when 
children were 24 months old) on a filter paper for genotyping for malaria recrudescence 
analysis in future. 
HIV testing 
HIV testing in this study was done by Zomba Central Hospital as part of PMTCT services 
at the hospital. Children were tested using HIV PCR at 6 weeks of age to determine their 
HIV status. These tests were repeated when the children reached 12 months of age using 
both HIV PCR and rapid testing with Unigold. The HIV PCR was performed at the Queen 
Elizabeth Central Hospital in Blantyre. This delayed the turn-around-time for the results 
which were a determinant for either stopping or continuing with CPT. As such HIV 
exposed children reported back to the study clinic eight weeks later for a decision on CPT 
to be made. Study participants who sero-converted at this visit were referred to the HIV 
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clinic to start antiretroviral therapy but continued to be attended to in the study clinic 
when they got sick until the end of the study.  
Other blood tests 
During a sick child visit, extra tests as needed for medical management of the patient were 
performed. These included a full blood count and differentials, peripheral blood smear for 
red cell morphology and others. No tests were performed during community follow-up 
visits. DBS and already read malaria slides were transferred to the College of Medicine 
laboratory in Blantyre for storage. 
4.2.2.3 Data Management  
Data Collection 
A team comprising of four Research Assistants (RAs) or field staff followed up study 
participants in their homes on their scheduled visit dates. Data was collected electronically 
using PDAs (Figure 4.6). These PDAs were pre-programmed and uploaded with 
electronic Case Report Forms (eCRFs) using Visual CE programming software. The 
eCRFs had crosschecks for verification, validation rules and complied with Good Clinical 
Practice (GCP). After returning from the field, the PDAs were connected to the desktop 
allowing data to be directly uploaded into the database. The desktop was installed with 
MS SQL server that automatically backed up the data. In addition to administering visit-
specific eCRFs (Appendix 4), RAs also checked weight, height and Mid-Upper arm 
circumference.  
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Figure 4.6: Electronic data management flow 
 
 
 
For both scheduled and unscheduled clinic based study visits, data was collected using 
source documents in form of hard copies as well as visit-specific eCRFs uploaded on the 
clinic-based touch screen computers. The source documents were used to record a 
narrative   of   participants’   aim  of   the   visit,   vital   signs   and  physical   examination   findings  
and the action that was taken. The touch screens were directly linked with the database 
allowing instant synchronization of the data in the main database. The same mechanisms 
were utilized in the Laboratory (Lab) where the data for test results were directly entered 
into the lab database on the desktop computer installed in the Lab and this was instantly 
synchronized with the main database. At every point validation rules acted as check points 
for any errors.  
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Data Cleaning 
Each participant record was checked for any missing values, typing errors, correct coding 
and variable naming. Missing values were corrected by verifying with source documents. 
Appropriate corrections were made following GCP rules. Team meetings were done every 
Friday to discuss study implementation issues and ways of improvement. In addition, both 
planned and impromptu meetings were done with the PhD supervisor on any matters 
requiring urgent attention. 
4.2.2.4 Statistical Methods and Data analysis 
Sample size  
The sample size calculations were performed using the PASS 2008® software, version 
08.0.7 (Hintze, 2008). For the primary objective of rebound malaria effect during the post-
intervention period, the expected incidence of malaria in the non-HIV exposed children 
was assumed to be 0.8 per child per year.  It was also assumed that during the entire two-
year period of study 10% of children were going to die, 10% lost to follow-up and among 
the HIV exposed children 15% would become HIV PCR positive and continue on CPT. 
Thus if 500 children were recruited in each group 400 non-HIV exposed children and 340 
HIV-exposed children who would not seroconvert were expected to complete the study 
(i.e. 740 children).  It was anticipated that there was going to be over-dispersion, i.e. that 
the variability in the number of episodes of malaria for each child would exceed the mean.  
There were no data available on which to base an estimate for this. It was therefore 
anticipated that the parameter lied between 1 and 3.  The study incidence rate ratio (IRR) 
detectable with 80% and 90% power for sample of 740 children and various values of the 
dispersion parameter is indicated in Table 4.1 Table 4.1 below.  
 
Table 4.1: Values of dispersion parameter for the Incidence Rate Ratio 
 
Power 
IRR detectable for dispersion of: 
1.0 2.0 3.0 
80% 1.26 1.38 1.47 
90% 1.30 1.44 1.56 
 
It was anticipated that the incidence rate ratio for HIV exposed children post CPT 
compared with non-HIV exposed children would be at least 1.8, however the minimum 
IRR of interest was considered 1.5. The study thus had at least 80% power to detect an 
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IRR of 1.5 provided the dispersion parameter did not exceed 3. For the secondary 
objective of comparing the incidence of uncomplicated and severe malaria in HIV 
exposed children while taking CPT with non-HIV exposed children it was anticipated that 
the incidence in the non-HIV exposed children would be at least 1.0 per child per year and 
that the IRR would be reduced to 0.2 or less.  If the dispersion parameter was 3 and 400 
children in each group completed this phase of the study there was 90% power to detect an 
IRR of 0.63, and more than 99% power to detect an IRR of 0.2. 
Methods for data analysis 
Descriptive statistics were used to calculate frequencies and summaries of covariables. 
Chi-square test was used to detect any differences in categorical baseline characteristics 
between HIV exposed (HIVex) ‡  group and non-HIV Exposed (HIVun) §  group. The 
Fischer’s  exact  test  was  used  for  contingency  tables  where  the  expected  values  in  any  of  
the   cells  were   ≤5.   In   order   to   detect   the   differences   in   normally   distributed   continuous  
baseline characteristics, a two-sample t-test was used. Time at risk was calculated by 
subtracting the date of starting CPT from the date of exit from the study when children 
either completed study follow-ups at 24 months of age or when they withdrew from 
participation because of relocation or withdrawal of consent and when they died or sero-
converted. In cases where the exit date due to loss to follow up was not known, the last 
date of contact was considered as the exit date. The association between baseline 
characteristics and incidence of uncomplicated malaria was explored using multiple 
negative binomial regression analysis that also accounted for over-dispersed incidents. 
Other regression methods were also explored for the multivariate modelling, including 
Poisson regression, zero inflated negative binomial and Poisson regression models, and 
use of either cluster robust standard errors or random effect models. The random effect 
was included in the models to capture the correlation between malaria incidence 
measurements in year 1 and year 2 in each participant. The negative binomial regression 
models showed the best fit based on the Akaike Information Criterion (AIC) and the 
Bayesian Information Criterion (BIC) (Table 4.2). The general form of the models that 
were fitted to the data was Log () = Constant + 1group +2 year + 3 group*year. The 
natural logarithm of follow up time was used as an offset because study participants had 
different follow up time.  
                                                        
‡ HIVex is short form for HIV exposed children/group used in the this section, the results and discussion sections 
§ HIVun is a short form for non-HIV exposed children/group used in theis section, results and discussion sections 
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Multiple regression models were constructed to adjust for covariates that were associated 
with the outcome of interest. Covariables with clinical and statistical significance of 
p≤0.20 associated with the primary outcome were selected and tested for collinearity using 
the spearmans correlation test before inclusion into the initial full model. If collinearity 
was detected, defined as a correlation of 0.6 and above, one of the two variables was 
selected for inclusion in the full model to prevent the model from becoming unstable. The 
adjusted and unadjusted incidence rate ratios (IRRs) and corresponding 95% confidence 
intervals for the effect of group (HIVex vs. HIVun) and year (year 1 vs. year 2) on the 
incidence of uncomplicated malaria, all-cause sick visits, all-cause and malaria specific 
hospital admissions (severe malaria) and all-cause mortality were calculated by 
performing separate multiple regression analyses using models specified in Table 4.2Table 4.2. As CPT was typically discontinued at the age of 14 months, the variable 
year   was   defined   as   year1:   aged   ≤14   months   and   year2:   >14   months. The effect of 
confounding was explored using the impact of removing each covariable on the main 
effect estimate and the corresponding precision of the estimate (i.e. the width of the 
confidence intervals). If removal from the model of one covariable changed the effect 
estimate by >5% or negatively affected its precision, it was regarded as a potential 
confounder and kept in the final model. This process was repeated with each covariable 
until the final model remained with all the potential confounders. Kappa statistic was used 
to calculate agreement of malaria microscopy results between the two malaria slide 
readers. All analyses were performed using STATA version 13 statistical software. 
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Table 4.2: Model selection for multivariate analysis  
Outcome Model 
 Negative binomial with cluster 
robust standard errors 
Random effects negative binomial 
(beta random effects) 
AIC BIC AIC BIC 
Uncomplicated 
malaria 
2371.549 2396.537 2386.412 2416. 397 
All-cause morbidity 3845. 106 3976.932 3717.229 3872.596 
Severe malaria 1041.726 1167.353 1037.828 1163. 455 
All cause hospital 
admissions 
1042.543 1174.369 1014. 181 1141.3 
All-cause mortality Log-binomial regression 
Abbreviations: AIC: Akaike Information Criterion; BIC: Bayesian Information Criterion 
4.2.3 Ethical Considerations 
4.2.3.1 Ethical Approvals 
The study protocol was jointly reviewed and approved by the College of Medicine 
Research and Ethics Committee (COMREC) (Appendix 10) and the Ethics Committee at 
the Liverpool School of Tropical Medicine in Liverpool, United Kingdom (Appendix 11). 
Permission to carry out the study at the study site was sought from the Hospital Director 
of Zomba Central Hospital. Any amendments to the initial protocol were submitted to the 
two ethical committees for approval. Every year, annual progress reports on the study 
were submitted to both committees. 
4.2.3.2 Informed Consent 
The Informed Consenting process took place in a private room at the study clinic. Since 
the study involved young children, the process was done with their guardians. An 
informed consent form (Appendix 12 and 13), which was translated into Chichewa, the 
common local language in the district (Council., 2010), was read out to the guardian in the 
same language. At the end, the guardian was asked a few questions from the informed 
consent form to check the level of comprehension. Throughout the process, the guardian 
was encouraged to ask questions on areas she/he did not understand. If the person 
understood and voluntarily agreed to participate in the study, she/he was asked to sign the 
informed consent form. For illiterate guardians, the process was done in the presence of a 
witness who was a third person not associated with the study and the signing was done by 
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thumb printing. The original signed Informed Consent form was kept at the study clinic 
while the copy was given to the guardian for further reading at home. Guardians were 
encouraged to come back for clarification if they had any more questions. The Informed 
Consenting log was used to record the consenting process indicating time the process 
started and ended, whether participant was literate or not and whether the witness was 
available. Details of a person obtaining the informed consent from the guardian were also 
included.  
4.2.3.3 Confidentiality 
Each study participant was assigned a study number for identification. These numbers 
were generated by an independent person and were consecutively assigned to participants 
as they were enrolled. There were no unique differences in the numbering between HIV 
exposed and non-HIV exposed children. This was done deliberately in order not to 
influence the way study staff measured the study outcomes, as the two groups were 
different.  Participants’  names  and  any  personal  identifying  information  only  appeared  on  
the source documents which were always kept under lock and key. Access to these was 
limited to authorised study staff. No personal identifying information was used in data 
analysis as well as in any reports. Also, the two groups had separate informed consent 
forms. This was done so that HIV negative mothers (mothers of non-HIV exposed 
children) were not made aware of the HIV status of their counterparts (mothers of HIV 
exposed children) in order to minimise stigma and discrimination since they were residing 
in the same locations. 
4.2.3.4 Benefits 
Study participants had access to some medical services at the study clinic throughout their 
participation in the study. A dedicated Clinical Officer attended to study participants at 
every scheduled visit and at any point they presented to the clinic sick. The participants 
were closely monitored for any side effects related to cotrimoxazole prophylaxis. For all 
scheduled study visits, transport costs were reimbursed appropriately. 
4.2.4 Study Outcomes 
The primary outcome was the incidence of uncomplicated malaria defined as either 
confirmed uncomplicated malaria or uncomplicated malaria. Secondary outcomes were 
all-cause sick child visits, malaria specific hospital admission (severe malaria), all-cause 
hospital admissions and all-cause mortality as described in Table 4.3. 
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Table 4.3: Definitions of study outcomes and how they were assessed 
Outcome Definition Mode of assessment 
Incidence of 
uncomplicated 
malaria 
1. Confirmed uncomplicated malaria 
 History of fever within 24hours or 
no history of fever within 
previous 24 hours 
 Febrile on examination or patient 
not febrile 
 Presence of parasitaemia with 
mRDT or microscopy 
2. Clinical malaria  
 History of fever within 24hours or 
no information on the symptoms 
 Febrile on examination or not 
febrile 
 No confirmation or presence of 
parasitaemia with mRDT or 
microscopy 
 Malaria treatment was given 
 
Use of lab methods such 
as microscopy and 
malaria rapid diagnostic 
tests 
Use of health records 
from  the  child’s  health  
passport 
Use of medical history 
and clinical findings upon 
physical examination 
Incidence of all-
cause sick-child 
visits 
Any visit by the study participant to the 
study clinic with any type of sickness 
including malaria 
Use of health records 
from  the  child’s  health  
passport 
Clinical and physical 
examination findings 
Malaria specific 
hospital admission 
A hospital admission due to a confirmed 
diagnosis of malaria 
 
Health records from 
child’s  health  passport  
and source documents 
Past admission history 
All-cause hospital 
admission 
A hospital admission due to any other 
cause except malaria 
 
Health records from 
child’s  health  passport  
and source documents 
Past admission history 
All-cause mortality Death from any other causes Use of verbal autopsy 
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4.3 Results 
A total of 1000 children were enrolled during a 14-month period between June 2011 and 
August 2012. This was 2 months longer than the initial target of 12 months because of 
national fuel shortages that struck the country during the study period. Of the 1000 
children, 500 were HIV exposed (HIVex) and 500 were non-HIV exposed (HIVun). By the 
end of the follow-up period, five (1.0 %) HIVex children had sero-converted by their first 
birthday. Of the 10 participants who had withdrawn due to either permanent relocation 
outside the study catchment area or withdrawal of informed consent from the study, half 
(50%) were HIV exposed. There were a total of 18 deaths in the HIV exposed group and 8 
in the non-HIV exposed group during the study follow up period. The total observation 
time was 9,515 months for year 1 and 4,751 months for year 2. In comparison, HIVex 
children were followed up for a longer period (mean follow up of 10 months) than HIVun 
children (mean follow up of 5 months) with a mean difference of 5 month, (95% CI 1.6, 
11.2), p<0.001.  Year 1 covered the period from 6 weeks when the HIVex children started 
taking CPT to 14 months when they stopped taking CPT after HIV PCR results. In the 
second year, participants were followed from 15 to 24 months of age which henceforth is 
referred  to  as  their  ‘year-2’  in  the  analysis. 
4.3.1 Baseline characteristics of study participants 
The two groups were comparable in terms of sex, ethnicity, religion and other health and 
social demographic characteristics as presented in Table 4.4 and Table 4.5. Significant 
differences were observed in their age, anthropometric measurements, and parent 
characteristics such as age of mother, education of mother and job of both mother and 
father. On average, HIVun children were slightly older at enrollment than HIVex children 
with a mean difference in age of 3.5 days (95% CI 0.52, 6.39), p=0.02 reflecting that the 
HIVex child was recruited first followed by an HIVun child in the community. This could 
explain the significant differences observed in anthropometric measurements (weight, 
length and MUAC) between the two groups. Although about 8% of the children in both 
groups reported to have had suffered a febrile illness in the four weeks preceding the 
study, a small proportion (0.4%) had parasitaemia at enrollment (Table 4.4). The level of 
education of the mother was lower in the HIVex group (P=0.03), but the education levels 
of the fathers were comparable. In terms of household characteristics, HIVex children had 
slightly less access to safe drinking water but both groups were comparable in terms of the 
type of dwelling roofs of their houses (p=0.5) (Table 4.5).  
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Table 4.4: Child socio-demographic and health characteristics 
Characteristic HIV Exposed (HIVex) (N=500) 
Non-HIV Exposed 
(HIVun) (N=500) P-Value 
Child socio-demographic characteristics 
Age in days, mean (SD)1 35.9 (26.1) 39.4 (26.1) 0.021 
Sex, n (%) 
Males 
Females 
  
249 (49.8)) 
251 (50.2) 
  
223 (44.6) 
277 (55.4) 
  
0.1 
  
Ethnic Background, n (%) 
Yao 
Others 
157 (31.4) 
343 (68.6) 
  
165 (33.0) 
335 (67.0) 
  
0.701 
  
Religion, n (%) 
Moslem 
Christians 
  
75 (15.0) 
425 (85.0) 
  
90 (18.0) 
410 (82.0) 
  
0.208 
  
Child Health Characteristics     
Weight at enrolment, kg2 (SD) 4.4 (1.16) 4.7 (1.19) <0.001 
Length at enrolment, median, cm 
(range) 52 (36-66) 53 (38-69) 
<0.001 
MUAC3, median cm (range) 11 (8-17) 12 (8-17) <0.001 
Temperature, mean degrees Celsius 
(SD) 36.8 (0.54) 36.7 (0.59) 
0.002 
Haemoglobin level, mean g/dl (SD) 12.6 (3.0) 12.7 (2.80) 0.24 
Malaria parasitaemia, n (%) 2 (0.4) 0 (0.00) 0.157 
 Febrile illness in the preceding 4 
weeks, n (%) 41 (8.2) 42 (8.3) 
0.909 
Admission to hospital in the preceding 
4 weeks, n (%) 21 (4.2) 13 (2.6) 
0.163 
Current malaria treatment, n (%) 0.0 (0.0) 0.0 (0.0) - 
1SD: Standard Deviation; 2Kg: Kilograms; 3cms: centimetres; 4MUAC: Mid Upper Arm Circumference 
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Table 4.5: Parents' and Household characteristics  
Characteristic HIVex Group HIVun Group P Value 
Age of mother, median years 
(range) 29 (17-45) 23 (15-45) <0.001 
Marital Status, n (%) 
In marriage 
Not in marriage 
 
437 (87.4) 
63 (12.6) 
 
450 (90.0) 
50 (10.0) 
 
0.122 
Education: Mother, n (%) 
No formal education 
Primary Education 
Secondary Education 
Tertiary Education 
 
50 (10.0) 
273 (54.6) 
166 (33.2) 
11 (2.2) 
 
28 (5.6) 
281 (56.2) 
183 (36.6) 
8 (1.6) 
 
0.031 
Education: Father, n (%) 
No formal Education 
Primary Education 
Secondary Education 
Tertiary Education 
Unknown 
 
14 (2.8) 
180 (36.0) 
228 (45.6) 
47 (9.4) 
31 (6.2) 
 
16 (3.2) 
162 (32.4) 
256 (51.2) 
46 (9.2) 
20 (4.0) 
 
0.355 
Job Mother, n (%) 
Employed 
Not employed 
 
60 (12.0) 
440 (88.0) 
 
33 (6.6) 
467 (93.4) 
 
0.003 
Job Father, n (%) 
Employed 
Not employed 
Unknown 
 
361 (72.2) 
112 (22.4) 
27 (5.4) 
 
333 (66.6) 
149 (29.8) 
18 (3.6) 
 
0.01 
Use of Electricity, n (%) 
Uses electricity 
Does not use electricity 
 
136 (27.2) 
364 (72.8) 
 
115 (23.0) 
385 (77.0) 
 
0.057 
Main water Source, n (%) 
Tap 
Borehole 
Stream 
Unprotected well 
 
290 (58.0) 
155 (31.0) 
4 (0.8) 
51 (10.2) 
 
297 (59.4) 
180 (36) 
3 (0.6) 
20 (4.0) 
 
<0.001 
Dwelling roof type, n (%) 
Iron sheets 
Grass thatched 
Roof tiles 
 
310 (62.0) 
187 (37.4) 
3 (0.6) 
 
303 (60.6) 
196 (39.2) 
1 (0.2) 
 
0.524 
 
4.3.2 Use of ITNs and other malaria control measures at baseline 
No differences were observed in the number of mosquito nets in use in the home (net 
ownership) between the HIVex and the HIVun group. Four hundred and thirty-one (431) 
households reported owning  ≥1  mosquito  net  in  each  group.  In  terms  of  having  the  child  
sleep under a mosquito net the previous night, more HIVun children slept under any 
mosquito net (96.1% HIVun vs. 90.2% HIVex, p =0.001) compared to having a child sleep 
under an ITN which was used by a slightly higher proportion of HIVex children (88.7% 
HIVex vs. 86.9% HIVun, p =0.006). The most common reason for not using an ITN was 
forgetfulness. At household level, use of indoor residual spraying, mosquito repellent 
practices and traditional medications were uncommon in households for both HIVex and 
HIVun children (Table 4.6). 
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Table 4.6: Use of Insecticide Treated Nets for malaria prevention 
Malaria control indices HIVex HIVun Overall P-value 
Number of mosquito in use in the 
home, n (%) 
0 
>1 
 
 
69 (13.8) 
431 (86.2) 
 
 
69 (13.8) 
431 (86.2) 
 
 
138 (13.8) 
862 (86.2) 
 
 
0.47 
Are nets treated, n (%) 
Yes 
No 
 
391 (90.7) 
40 (9.3) 
 
395 (91.7) 
36 (8.4) 
 
786 (81.2) 
76 (8.8) 
 
0.631 
Child slept under a net the previous 
night, n (%) 
Yes 
No 
 
 
388 (90.2) 
42 (9.8) 
 
 
413 (96.1) 
17 (4.0) 
 
 
801(93.1) 
59(6.9) 
 
 
0.001 
Child slept under an ITN the previous 
night, n (%) 
Yes 
No 
Not known 
 
 
345(88.7) 
36(9.3) 
8.0(2.1) 
 
 
358(86.9) 
28(6.8) 
26(6.3) 
 
 
703(87.8) 
64(8.0) 
34(4.2) 
 
 
0.006 
How often is ITN treated, n (%) 
Never 
Once a year 
Once in 6 months 
Not known 
 
147 (31.1) 
49(11.4) 
20(4.6) 
215(49.9) 
 
126(29.2) 
41(9.5) 
22(5.1) 
242(56.2) 
 
273(31.7) 
90(10.4) 
42(4.9) 
457(53.0) 
 
0.26 
Reasons for child not 
sleeping under an ITN, n (%) 
Forgot 
Allergic to ITN 
Did not sleep at home 
Was used by others 
 
 
42(65.6) 
0.0(0.0) 
18(28.1) 
4.0(6.3) 
 
 
35(77.8) 
0.0(0.0) 
2.0(4.4) 
8.0(17.8) 
 
 
77(70.6) 
0.0(0.0) 
20(18.4) 
12(11.0) 
 
 
0.001 
Other malaria control measures 
IRS 
Mosquito repellent coils 
Body mosquito repellents 
Mosquito repellent spray 
Traditional medications 
 
2.0(0.4) 
37(7.4) 
1.0(0.2) 
25(5.0) 
2.0(0.4) 
 
1.0(0.2) 
50(10.0) 
0.0(0.0) 
16(3.2) 
2.0(0.4) 
 
3.0(0.3) 
87(8.7) 
1.0(0.1) 
41(4.1) 
4.0(0.4) 
 
0.355 
  
4.3.3 Uncomplicated malaria, all-cause sick visits and hospital admissions by year 
Overall, there were a total of 345 episodes of uncomplicated malaria during the follow up 
time,  278  (81%)  of  which  occurred  before  the  age  of  14  months  (‘year  1’).  These  numbers  
slightly lower (n=309) when only microscopy or RDT confirmed cases were used (Table 
4.8). The incidence rates in year 1 and year 2 were 35.3 and 17.0 per 100 child years 
respectively, p<0.001 for uncomplicated malaria and 32.0 and 14.5 per 100 child years for 
confirmed uncomplicated malaria, p<0.001. Comparison of microscopy between readers 
showed a good agreement of 91.2% between first and second reader (kappa statistic 0.687, 
95% CI: 0.57,0.80). The majority of uncomplicated malaria infections (99.4%) were due 
to Plasmodium falciparum. In terms of sick visits, 112.3 new sick visits per 100 child 
years were made to a health facility in year 1 compared to 60.8 in year 2. This pattern was 
similar for severe malaria (23.7 episodes of severe malaria in year 1 vs. 12.5 episodes in 
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year 2); all-cause hospital admissions (16.5 admissions per 100 child years in year 1 vs. 
12.5 admissions per 100 child years in year 2) and all-cause mortality (3.0 deaths per 100 
child years in year 1 vs. 0.5 deaths per 100 child years in year 2) (Table 4.8). The leading 
causes of death were pneumonia (27.8%) among HIVex children and gastrointestinal 
symptoms (37.5%) among HIVun children (Table 4.7).  
 
Table 4.7: Causes of deaths in HIVex and HIVun children 
HIVex Overall, n (%) N=26 
HIVex, n (%), 
N=18 
HIVun, n (%), 
N=8 
Respiratory Tract Infections 
(Pneumonia) 7 (26.9) 5(27.8) 2(25.0) 
Gastrointestinal symptoms 
(Malnutrition) 
  
7(26.9) 
  
4(22.2) 
 
3(37.5) 
Septicaemia 5(19.2)  4(22.2) 1(12.5) 
Malaria 1(4.0) 1(5.6) 0 
Haematological symptoms 
(Anaemia) 1(4.0) 1(5.6) 
  
 
0 
 
Unknown 4(15.0) 2(11.0) 2(25.0) 
Neurological 1(4.0) 1(5.6) 0 
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Table 4.8:Cumulative risk and incidence of uncomplicated malaria, sick visits and admissions by group and by year 
Outcome 1HIVex 2HIVun 8Overall IR/Yr 
 3Yr 4N 5CR 
% 
Person 
days 
Events 6IR/gr
p/Yr 
7IR/grp N CR 
% 
Person 
days 
Events IR/grp/
Yr 
IR/gr
p 
Uncomplicated 
malaria§ 
1 500 23.2 147817 116 28.7 24.8 500 32.4 139989 162 42.3 33.9 35.3 
2 473 7.2 73311 34 16.9 488 6.8 70344 33 17.1 17 
Confirmed 
uncomplicated 
malaria¶ 
1 500 21.2 147817 106 26.2 22.1 500 29.2 139989 146 38.1 30.4 32.0 
2 473 5.9 73311 28 14.0 488 5.9 70344 29 15.1 14.5 
Sick Visits 1 500 85.4 147817 427 105.5 90.8 500 91.6 139989 458 119.4 99.7 112.3 
2 473 26 73311 123 61.2 488 23.8 70344 116 60.2 60.8 
Severe malaria 1 500 22.6 147817 113 27.9 23.5 500 14.8 139989 74 19.3 16.3 23.7 
2 473 6.1 73311 29 14.4 488 4.1 70344 20 10.4 12.5 
Admissions 1 500 13 147817 65 16.1 16.2 500 13 139989 65 17.1 14.8 16.5 
2 473 6.1 73311 29 14.4 488 4.1 70344 20 10.4 12.5 
Deaths 1 500 3.4 147817 17 4.2 3 500 1.4 139989 7 1.8 1.4 3.0 
2 473 0.2 73311 1 0.5 488 0.2 70344 1 0.5 0.5 
 1HIVex: HIV Exposed; 2HIVun: non-HIV Exposed; 3Yr: Year; 4N: children at risk at start of observation period; 5CR: Cumulative Risk; 6IR/grp/Yr: Incidence rate per 100 child years per group per 
year; 7IR/grp: Incidence Rate per 100 child years per group; 8Overall IR/Yr: Overall Incidence Rate per 100 child years per year; Definitions: Year   1:   ≤14   months;;   Year   2:   15-24 months; 
Events/group: Events per HIVex/HIVun; IR/grp/yr: Incidence rate per group per year; Overall IR/yr: incidence Rate for each outcome for year 1 and for year 2. IR/grp: Incidence rate per group (HIVex 
or HIVun); Uncomplicated malaria§: uncomplicated malaria that includes both laboratory and clinically confirmed malaria;  Confirmed uncomplicated malaria¶: uncomplicated malaria that excludes 
clinically confirmed uncomplicated malaria. 
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4.3.4 Baseline characteristics associated with the incidence of uncomplicated malaria, 
in children during follow-up time in univariate analysis 
The univariate analysis with the primary outcome (incidence of uncomplicated malaria) 
revealed a significant association with socio-economic status indicator factors such as use 
of   electricity,   main   water   source,   dwelling   roof   type,   father’s   education   as   well   as  
occupation; and religion, body temperature, and presence of malaria parasites at baseline 
(Table 4.9). Having parasitaemia at baseline was significantly associated with a more than 
five-fold higher incidence of uncomplicated malaria (IRR 5.50, 95% CI 2.95, 10.28), 
p<0.001. Factors such as sex, anthropometric measurements including weight, length and 
MUAC;;   ethnicity,   mother’s   age   and   job   and   history   of   a   febrile   illness   were   not  
significantly associated with the incidence of uncomplicated malaria.  
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Table 4.9: Univariate association of baseline characteristics with the incidence of 
uncomplicated malaria 
Covariable IRR 95% CI P. Value 
HIV Exposure       
HIV Exposed  Reference Reference <0.001 
Non-HIV Exposed  2.91 2.05, 4.14   
Sex       
Male Reference Reference 0.585 
Female 1.08 0.81, 1.44   
Age at enrolment 1 0.99, 1.01 0.867 
Weight 0.97 0.98, 1.04 0.713 
Length 1.01 1.01, 1.02 0.573 
MUAC 1.03 0.93, 1.14 0.542 
Temperature 1.3 0.85, 1.39 0.037 
Haemoglobin level 1.01 0.99, 1.05 0.787 
History of febrile illness       
Yes Reference Reference 0.82 
No 0.93 0.50, 1.74   
Malaria parasites       
Negative Reference Reference <0.001 
Positive 5.5 2.95, 10.28   
Ethnicity       
Yao Reference Reference   
Other 1.17 0.86, 1.59 0.304 
Religion       
Moslem Reference Reference 0.012 
Christian 1.56 1.10, 2.21   
Use of electricity       
Yes Reference Reference <0.001 
No 2.28 1.63, 3.20   
Main water Source       
Tap Reference Reference <0.001 
Borehole 2.35 1.74, 3.16   
Stream 1.35 1.16, 11.47   
Unprotected well 1.72 1.10, 2.69   
Dwelling roof type       
Iron sheets Reference Reference <0.001 
Grass thatched 2.14 1.61, 2.85   
Roof tiles 0.28 0.05, 1.65   
Age of Mother 0.99 0.97, 1.02 0.464 
 
 
 
    
 Table continued 
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Mother’s  Education 
Table 4.9 continued 
None Reference Reference <0.001 
Primary 0.92 0.48, 1.76   
Secondary 0.61 0.31, 1.20   
Tertiary 0.2 0.71, 0.54   
Father’s  Education       
None Reference Reference 0.027 
Primary 0.89 0.61, 1.22   
Secondary 0.63 0.44, 0.88   
Tertiary 0.55 0.36, 0.84   
Mother’s  Job       
Employed Reference Reference 0.236 
Not employed 1.36 0.82, 2.26   
Father’s  Job       
Employed Reference Reference <0.001 
Not employed 1.13 1.00, 1.37   
 IRR: Incidence Rate Ratio; CI: Confidence Interval; HIVex: HIV Exposed; HIVun: non-HIV 
Exposed; MUAC: Mid-Upper Arm Circumference 
 
4.3.5 Univariate association of malaria control measures and the incidence of 
uncomplicated malaria  
In terms of malaria control measures, the number of mosquito nets available in the 
household (net ownership) was significantly associated with the incidence of 
uncomplicated malaria. Children living in households with one or more mosquito nets had 
a 40% lower incidence of uncomplicated malaria compared to households without a 
mosquito net (IRR 0.60, 95% CI 0.42, 0.86), p=0.005. ITNs were associated with 
decreased rates of malaria relative to untreated nets (IRR 0.65, 95% CI 0.44, 0.96), 
p=0.030. Treating the nets once in six months was associated with a 65% reduction in the 
incidence of uncomplicated malaria while treating them once a year yielded a 14% lower 
rate (IRR 0.35, 95% CI 0.17, 0.69) and (IRR 0.86, 95% CI 0.48, 1.52) respectively, 
p=0.027. Having a child sleep under either an untreated mosquito net or an ITN during the 
previous night was not significantly associated with the incidence of uncomplicated 
malaria (IRR 1.00, 95% CI 0.57, 1.76), p=0.996 and (IRR 1.38, 95% CI 0.90, 2.13), 
P=0.166 respectively in the univariate analysis (Table 4.10). 
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Table 4.10: Univariate association between use of malaria control measures and the 
incidence of uncomplicated malaria 
Covariable IRR 95% CI P Value 
Number of mosquito nets in use 
in the home, n (%)       
 0 Reference Reference   
≥1 0.6 0.42, 0.86 0.005 
 Mosquito nets treated with 
insecticides       
No Reference Reference 0.03 
Yes 0.65 0.44, 0.96   
 Frequency of net treatment       
Never Reference Reference 0.027 
Once in 6 months 0.35 0.17, 0.69   
Once in a year 0.86 0.48, 1.52   
Not known 0.79 0.53, 1.19   
Child slept under a net last night       
Yes Reference Reference 0.996 
No 1 0.57, 1.76   
Not known -  -   
Child slept under an ITN last 
night       
No Reference Reference 0.166 
Yes 0.72 0.47, 1.11   
Not known 1.1 0.56, 2.18   
Other malaria control measures       
IRS Reference Reference 0.109 
Mosquito repellent coils 4.55 0.86, 23.96   
Body mosquito repellents 14.87 1.77, 125.09   
            Mosquito repellent spray  2.47 0.42, 14.43   
Traditional Medicines 1.84 0.15, 22.42   
 
4.3.6 Effect of CPT on uncomplicated malaria, sick visits, severe malaria, admissions 
and mortality 
4.3.6.1 Uncomplicated malaria 
Overall, the crude incidence rate for uncomplicated malaria during the follow up period 
was lower in HIVex children compared to HIVun (24.8 vs. 33.9 episodes per 100 child 
years) P=0.004 (Table 4.8). Use of a confirmed uncomplicated malaria definition showed 
a similar trend (Table 4.8). Stratification by year and group showed that most of this 
difference occurred in the first year when HIVex were protected by CPT; (IRR 0.35, 95% 
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CI 0.25, 0.49), p<0.001, in multiple regression models adjusting for child factors such as 
presence  of   fever  and  parasitaemia  at  baseline  and  household  factors   including  mother’s  
education,  mother’s  job,  dwelling  roof  type  and  religion.    However,  the  incidence  rates  in  
year 2 for the HIVex were similar to that observed in the HIVun during the same period 
(IRR 0.94, 95% CI 0. 53, 1.68), P=0.839, thus there was no evidence for an excess risk of 
malaria in the HIVex group after the CPT was stopped. This difference in the observed 
IRR estimates in year-1 (0.35) and year-2 (0.94) was statistically significant (P-value 
interaction term, P=0.004) (Table 4.11). A similar picture was observed when a 
confirmed uncomplicated malaria definition was used. 
4.3.6.2 All-cause sick child visits (all cause-morbidity) 
During the follow-up time, the incidence of all-cause sick visits was slightly lower in 
HIVex group (90.8 compared to 99.7). However, in year-1, the incidence of all cause 
morbidity was 47% lower in the HIVex group compared to the HIVun group (IRR 0.53, 
95% CI 0.46, 0.60), p<0.001. Similar to the observations for uncomplicated malaria, the 
incidence in the HIVex group increased after stopping CPT (Table 4.11), but there was no 
evidence for an excess risk in year-2 after stopping CPT in the HIVex group as the rate 
remained slightly (not significant) lower relative to the HIVun group (IRR 0.84, 95% CI 
0.66, 1.08), p=0.171.  
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Table 4.11: The effect of before and after stopping CPT on the incidence of uncomplicated and severe malaria, sick visits, hospital 
admissions and mortality1 
Outcome   Year 1 (6 weeks to 14 months) Year 2 (15-24 months) Interaction Term for difference between 3HIVex and 4HIVun groups by year 
    IRR/RR 95% CI P value IRR 95% CI P value ITRIRR 95% CI P value 
Uncomplicate
d Malaria✚ 
  
Unadjusted 0.33 0.22,0.49 <0.000 0.93 0.44, 1.97 0.852 2.82 1.23, 6.47 0.014 
Adjusted 0.35 0.25,0.49 <0.001 0.94 0.53,1.68 0.839 2.66 1.38,5.15 0.004 
Confirmed 
uncomplicate
d Malaria★ 
 
Unadjusted 0.29 0.20,0.42 <0.001 0.89 0.41,1.62 0.867 2.80 1.19,6.59 0.020 
Adjusted 0.30 0.23,0.39 <0.001 0.91 0.43,1.93 0.841 2.64 1.35,5.16 0.006 
All-cause sick 
visits 
Unadjusted 0.54 0.48,0.62 <0.001 0.86 0.68, 1.10 0.236 1.59 1.22, 2.06 0.001 
Adjusted 0.53 0.46, 0.60 <0.001 0.84 0.66, 1.08 0.171 1.6 1.23, 2.09 <0.001 
Severe 
malaria 
  
Unadjusted 0.85 0.61, 1.19 0.349 1.56 0.79, 3.09 0.2 1.83 0.87, 3.84 0.11 
Adjusted 0.85 0.61,1.19 0.339 1.55 0.79, 3.07 0.206 1.83 0.87, 3.84 0.112 
All-cause 
admissions 
  
Unadjusted 0.47 0.26, 0.83 0.01 1.6 0.63, 4.08 0.328 3.42 1.41, 8.32 0.007 
Adjusted 0.46 0.26, 0.80 0.006 1.42 0.57, 3.56 0.444 3.12 1.32, 7.41 0.01 
All-cause 
mortality2 
Unadjusted 1.76 0.65, 4.82 0.267 - - - - - - 
Adjusted 1.73 0.65, 4.67 0.275 - - - - - - 
1Models  adjusted  for  HIV  exposure,  father’s  education,  frequency  of  net  treatment,  child  sleeping  under  an  ITN  in  the  previous night, temperature, malaria 
parasitaemia at baseline, age at enrollment, dwelling roof type, use of electricity, main water source, job of mother and religion 
2All cause mortality is estimated using log-binomial regression using a Risk Ratio as a measure of effect; 3HIVex: HIV exposed children; 4HIVun: non-HIV 
exposed children; IRR: Incidence Rate Ratio; RR: Risk Ratio, CI: Confidence Intervals, 
Definitions: Uncomplicated malaria✚: uncomplicated malaria that includes both laboratory and clinically confirmed malaria; confirmed uncomplicated malaria★: 
uncomplicated malaria that excludes clinically confirmed malaria 
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4.3.6.3 Hospital admissions 
In year-1, HIVex children on CPT had a 15% lower (not statistically significant) incidence 
of hospitalization due to severe malaria than their HIVun counterparts (IRR 0.85, 95% CI 
0.61, 1.19), p=0.339, and a significantly lower rate of all-cause hospitalisations (IRR 0.46, 
95% CI 0.26, 0.80), p=0.006. Following the discontinuation of CPT in year-2 the 
incidence rate appeared higher in HIVex group than in the HIVun group (malaria 
admission: IRR 1.55, 95% CI 0.79, 3.07, p=0.206; all-cause admissions: IRR 1.42, 95% 
CI 0.57, 3.56, p=0.444), but the differences between the groups were not statistically 
significant.   
4.3.6.4 All-cause mortality 
All cause mortality was estimated for the first year only because almost all events 
occurred during this period (24 out of 26 deaths). The log-binomial regression analysis 
showed a non-significant increase in the risk of mortality in the HIVex group in year 1 (RR 
1.73,   95%  CI   0.65,   4.67),   p=0.275   after   adjusting   for   age,  mother’s   education,   father’s  
occupation, having child sleep under an ITN and religion.  
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4.4 Discussion 
The primary objective for this chapter was to investigate whether HIV exposed children 
protected by CPT during their first year of life, have an excess risk of malaria (a rebound 
effect) after stopping CPT which might result from the potential for delayed acquisition of 
natural immunity to malaria (Osterbauer, 2012). Generally, uncomplicated malaria was 
markedly less common among the HIVex children while receiving CPT compared to HIVun 
children not receiving CPT during that same period (the 12.5 month period from 
approximately 6 weeks to 14 months of age). The effects estimates were much the same 
when all clinically suspected cases were included in the analysis versus an analysis that 
was restricted to the diagnostically confirmed malaria only (90% of the overall sample). 
The small differences reflected the scale up of the use of malaria rapid diagnostic testing 
in all health facilities. In addition, these were study participants who were constantly 
reminded at every contact to report to the study clinic whenever they were sick rather than 
other clinics not involved in the study. 
 
The chemo prophylactic effect of CPT was also associated with a significant decrease in 
the risk of all-cause sick-child clinic visits and hospital admissions. This study did not 
show evidence of increase in the incidence of uncomplicated malaria and all-cause 
morbidity (rebound effects) after CPT was stopped, although the rate of hospital 
admissions appeared higher in the HIVex than in the HIVun children, but this difference 
was not statistically significant and could be more related to HIV exposure as opposed to 
CPT since these children were born to HIV infected mothers. The higher mortality among 
HIVex children during the time they were taking CPT suggest that either CPT had no 
impact on all-cause mortality, or that the benefits were too small to outweigh the 
anticipated increased mortality in this high risk group relative to HIVun infants. Moreover, 
the mortality rate in this group falls below the general mortality reported among infants in 
Malawi in 2012 (UNICEF, 2013). 
 
A major limitation of the study is the non-randomized nature of the study arms and the 
observed differences in risk factors for malaria between the study groups at enrolment, 
which limits firm conclusions about a causal role of CPT and might have resulted in 
biased estimates of the effect size of CPT (under or overestimate). However, there are 
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good reasons to believe that the beneficial differences observed during the first year are, at 
least in part, due to CPT. The magnitude of the effect size makes it plausible that this 
finding is not due to chance and there is evidence that CPT is an effective intervention for 
malaria prevention in both children as well as adults (Mermin et al., 2006). A double-blind 
randomized placebo-controlled trial of HIV infected children in Zambia showed similar 
effects (Chintu, 2004). Hospital admission rates decreased by 23% in HIV infected 
children who received CPT (Chintu, 2004).  Cotrimoxazole’s  protective  efficacy  estimated  
against malaria ranged from 39% to 99.5% in previous studies conducted in different 
settings in Africa (Sandison, 2011, Gasasira et al., Dow, 2012, Thera et al., 2005). A meta-
analysis of five studies on the effect of CPT on the prevention of malaria in children in 
SSA presented in chapter three of this report has shown that CPT even in the high 
presence of antifolate resistance still achieved a 63% reduction in the risk of malaria in 
children.  
 
Our findings, in part, contrast with those from previous studies showing an increase in 
non-severe malaria and non-severe all-cause morbidity after the chemoprophylaxis is 
stopped (Aponte, 2007), but consistent with our results of higher hospital admissions. The 
lack of a rebound effect for uncomplicated malaria is perhaps surprising, because the high 
protective efficacy of CPT against uncomplicated malaria observed in this study (65%) 
might be sufficient to impair the development of naturally acquired immunity to malaria 
which is dependent on exposure to blood stage malaria infections (Doolan, 2009, 
Menendez et al., 1997). Compliance to CPT was closely monitored during the study and is 
unlikely the reason for the lack of rebound after a sustained period of malaria 
chemoprophylaxis. A possible explanation is that CPT alone provides incomplete 
protection and that even with CPT; children got exposed to some malaria infection 
allowing the acquisition of malaria specific immunity. This may be particularly the case in 
areas with high grade resistance to the antimalarial SP which is widespread in many parts 
of east and southern Africa including Malawi, which may partially impair the efficacy of 
CPT because of possible cross-resistance (Mbeye, 2014). However, the 65% protective 
effect observed in this study, contrasts with a more recent cotrimoxazole study in Uganda 
in which they got a lower protective effect of 39% in year one possibly due to very high 
prevalence of plasmodium genotypes associated with antifolate resistance (Sandison, 
2011). The extended (4 years) use of CPT in a randomized clinical trial in Uganda also 
found no evidence for a rebound effect (Homsy, 2014).  
 122 
 
The observed significant association of the incidence of uncomplicated malaria with 
baseline parasitaemia in the univariate analysis might be a reflection of a combination of 
factors such as high exposure to malaria infection due to location and household structure 
etc., as well as behavioral factors and host genetics.  
 
The lack of a rebound effect against non-severe disease also agrees with the pooled 
analysis of six IPTi trials that used SP in different African settings in which a sustained 
protection against malaria was not seen following the last dose of SP-IPTi at 9 month of 
age, and continued follow-up up to two years of age did not indicate a rebound effect in 
infants who were assigned to IPTi during their first year of life (Aponte, 2009). The nature 
of IPTi which involves administering the treatment at intervals alongside EPI vaccinations 
allowed some degree of exposure to malaria infection in between treatments thereby 
allowing the infants to acquire some levels of natural immunity to malaria (Bijker, 2012). 
The lower usage of bed nets reported in these IPTi trials could also have exposed the 
children to infective mosquito bites and consequently allowing acquisition of natural 
immunity to malaria. 
 
So how do we explain the lack of a rebound effect against uncomplicated malaria, yet 
there is some indication for higher rates of hospital admissions after CPT is stopped? This 
rebound scenario is similar to the one in a trial using IPTi-SP in Ghana which also showed 
no rebound of uncomplicated malaria but increased risk of severe malaria (Mockenhaupt, 
2007). Is it possible that partial protection impairs the acquisition of protective immunity 
against severe disease, while allowing for enough infections to break through to allow for 
the development of immunity against non-severe disease? This scenario is unlikely, 
because typically the development of protective immunity in young children results first in 
a reduced risk of severe disease, followed later by a reduction in uncomplicated episodes. 
Another possible explanation for the observed phenomenon is potential confounding by 
indication as the nature of being exposed to CPT was not at random hence the indication 
for CPT in the HIVex group may be related to the risk of future health outcomes, the 
resulting imbalance in the underlying risk profile between the HIVex and HIVun group may 
generate such results.  
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A major limitation of our study was the non- randomized design and use of a control 
group that a priori was likely to have less morbidity overall than HIVex children, at least in 
the absence of any intervention such as CPT. HIV exposure in HIVex but not infected 
children has been associated with increased congenital as well as maternally acquired 
neonatal infections which are thought to be caused by the increased shedding and high 
pathogen levels related to immunosuppression in the mother (Kuhn, 2005). It is plausible 
that this increased exposure to pathogens in HIVex children is sustained into the 2nd year 
and could explain some of the differences in severe morbidity in year-2. Nevertheless it 
remains unclear why these findings are only observed for the severe endpoints and not for 
non-severe disease. It is also possible that the increase in severe malaria in year two was 
simply due to chance as evidenced by lack of statistical significance. The decline in 
susceptibility to malaria infection during the time HIVex were receiving CPT may have 
contributed to an enhanced risk of severe disease when CPT had been stopped. This is 
suggested to affect the rate of the disease adversely by delaying the average of first 
infection thereby reducing the enhancement of the immunity that may be necessary for the 
maintenance of immunity to severe malaria (Gupta, 1999). Nevertheless, we cannot 
completely rule out the possibility of rebound effects considering that the follow-ups are 
on going and although not statistically significant, there is some evidence suggestive of 
increase in the incidence of uncomplicated malaria and all-cause morbidity as the effects 
were more diluted in year 2 after CPT was stopped. Although not ethically appropriate, 
randomizing HIVex children into receiving and not receiving CPT would have ensured an 
even distribution of participants in terms of baseline biological characteristics and 
therefore provide the true effect of cotrimoxazole prophylaxis on malaria, this is debatable 
as malaria incidence seemed to be reduced in the HIVex group compared to HIVun group. 
This may imply that HIV exposure may not significantly influence the measure of effect 
that was obtained. Furthermore, absence of significant differences in the malaria incidence 
in year 2 when HIVex children had stopped CPT and breastfeeding compared to their 
HIVun counterparts who continued breastfeeding until beyond the age of 12 months, 
contrasts with the findings from Tororo in Uganda, a high malaria transmission area which 
showed a significant reduction in the risk of getting malaria with breastfeeding in children 
aged six to 15 months (Vora et al., 2010). The small numbers in year 2 as the study was 
still on going might have contributed to the observed findings. 
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The lack of data of CD4+ counts for mothers of HIV infected children in this study limits 
the  interpretation  of  the  findings  since  maternal  CD4+  is  a  major  determinant  of  a  child’s  
health (Kuhn, 2002). However, the observed high protective efficacy of CPT in HIV 
exposed children would be linked to widespread use of antiretroviral drugs among 
mothers in the PMTCT programme which might have improved the health status of HIV 
infected mothers making it comparable with HIV negative mothers. However, the lack of 
performing an HIV test on all the mothers of children participating in this study to confirm 
their sero-status, could have led to misclassification of maternal HIV status which might 
have contributed to the observed findings. If more women were misclassified as HIV 
infected, the observed effect might be an overestimation of the effect of CPT in the HIVex 
and an underestimation of the effect in year 1 in HIVun if more women were misclassified 
as HIV negative. On the other hand, the overall shorter follow-up period in HIVun children 
might have affected the measurement of the primary outcome of interest in that lesser 
events might have been captured in the HIVun group compared to the HIVex group which 
was followed up for a relatively longer period of time. This limitation is likely to be 
addressed at the end of the study when all groups will have completed their study follow-
up time. Additionally, the inclusion of an offset in the analysis accounted for the 
differences in the follow up time hence the observed measure of effect might not have 
been affected by the differences in follow-up time. 
 
Interestingly, more HIVex children had access to safer water supply; better housing 
conditions and electricity, which were strong determinants of uncomplicated malaria in 
the univariate analysis. The strong association with better housing conditions including 
better water source, iron sheet or tile roofed houses and using electricity validates recent 
findings in a study in Korogwe, Tanzania where quality of housing significantly reduced 
the risk of malaria by one-third apparently due to the tendency of good quality houses to 
reduce number of malaria vectors (Liu, 2014) by restricting mosquito entry thereby 
reducing human exposure (Osterbauer, 2012). Other studies in Malawi (Wolff, 2001) and 
Burkina Faso (Ye, 2006) have found similar findings and across the region in Sri Lanka,  
Gamage-Mendis et al also observed that living in a house that was complete, built with 
bricks, plastered wall and roofed with tiles was a strong determinant of reduction in 
malaria risk compared to living in the poorest type of houses (Gamage-Mendis, 1991). 
Roof type is thought to determine indoor temperature, a parameter that is associated with 
malaria transmission (Ye, 2006). Although it is unlikely that housing conditions would 
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solely have affected the incidence of malaria in the present study because the whole study 
catchment area was semi urban with very minimal diversity in the form of housing, the 
finding is an important contribution to inform identification of interventions for malaria 
control in many settings in Malawi.  
 
ITN use has been associated with a reduction of malaria infection in people of all ages and 
this study also showed a protective association with ITN ownership and with the 
frequency of treating the nets with insecticides, although most households were using 
LLINs (MoH, 2012). This relationship could possibly explain the sustained protective 
effect of ITNs when a child slept under it in the previous night compared to sleeping in 
any net. The reasonably better ownership and utilization of mosquito nets in the present 
study surpassed national figures in which only 60% of the household owned at least one 
net and 56% of children aged under the age of five slept under an ITN in the previous 
night respectively (MoH, 2012).  The high figures observed in this study could be a good 
indicator of progress being made on the realization of the goals of 2011-2015 malaria 
strategic plan which set out to achieve universal access to malaria control interventions by 
2015 (MoH, 2011b). Moreover universal distribution of LLINs throughout the country 
preceded the current study.  
 
While some studies have reported association between anthropometry and malaria 
morbidity (Genton, 1998) most studies have reported inconclusive results (Deribew) 
suggesting lack of consensus on the effect of anthropometry on malaria.  The lack of 
association between the incidence of uncomplicated malaria and anthropometry in this 
study is in agreement with findings by Snow et al in which poor nutritional status was not 
associated with susceptibility to malaria in Gambian children (Snow, 1991). 
4.4.1 Summary of discussion 
Overall, we found that CPT was associated with marked reductions in the incidence of 
uncomplicated malaria and all-cause sick child clinic visits and hospital admissions. There 
was no evidence that the risk of malaria increased in the 2nd year after cessation of CPT at 
14 months of age. The present study is still ongoing, and the current analysis included 
only about 60% of the potential follow-up time in year 2. Although this is unlikely to 
impact on the findings in the first year, the interpretations of the findings in the second 
year should be made with caution. This is especially the case for the less frequent 
endpoints such as hospital admission and deaths for which the power of the existing 
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sample was still limited. Thus it remains to be determined whether the clear benefits 
observed with CPT in the first year are outweighed by a potential increase in the risk of 
hospital admissions in the 2nd year. More definitive results will be available following 
completion of the follow-up by August 2014.   
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CHAPTER 5 : LIVED EXPERIENCES OF HIV INFECTED MOTHERS 
ADMINISTERING DAILY COTRIMOXAZOLE TO THEIR HIV EXPOSED BUT 
UNINFECTED CHILDREN  
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5.1 Introduction 
5.1.1 The use of Cotrimoxazole prophylaxis in HIV exposed children 
Administered once daily, cotrimoxazole prophylaxis (CPT) has become an important 
component of HIV care and treatment package for HIV exposed children following WHO 
recommendations that all children exposed to HIV should receive this prophylaxis from 
about 4 to 6 weeks of age until they stop breastfeeding and HIV infection is excluded 
(WHO, 2006b). This is an antimicrobial drug that prevents the development of serious, 
often fatal Opportunistic Infections (OIs), notably Pneumocystis jiroveci pneumonia 
(PCP) in young HIV-infected infants (WHO, 2006b). Most importantly, CPT has 
previously been found to be an effective antimalarial in both adults and children (Mermin 
et al., 2006, Sandison, 2011). In chapters three and four of this report, the use of CPT in 
children showed a more than two-thirds reduction in new malaria infections in children. 
Other studies have shown that its effectiveness remains even with the presence of 
widespread background resistance to it (Sandison, 2011). This is especially important 
given the numbers of children dying of malaria in Africa. In 2013, more than three-
quarters of all the malaria deaths in Africa occurred in children under five years of age 
(WHO, 2013b). In order to achieve optimal benefits from CPT, strategies for adherence 
and coping with various challenges associated with long-term treatments must be 
achieved. However, it is not known how the long-term administration of CPT would 
impact on the lives of HIV infected women with HIV exposed but not infected children.  
Benefits to be realized from CPT are particularly important in resource-limited settings 
where access to effective services for prevention of mother-to-child transmission of HIV, 
effective infant-feeding interventions, early diagnostic services and antiretroviral therapy 
(ART) for children remain limited yet despite the fact that countries have developed and 
put in place policies to support the scale up and implementation of CPT for infants and 
children, and that it is inexpensive, life-saving, safe and theoretically simple to deliver, a 
few children (8%) exposed to HIV were initiated on CPT by two months of age in 2008 
(WHO, 2010d), a situation that could affect health outcomes in these children. 
Understanding the experiences of mothers administering CPT to their HIV exposed but 
uninfected children would provide an understanding of how mothers cope in terms of 
ensuring compliance to the intervention as well as how they deal with any situations that 
arise eventually leading to improved uptake of the interventions. 
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5.2 Study Objectives 
1. To establish a narrative of the lived experiences of HIV infected women 
administering daily CPT to their HIV exposed children 
2. To explain   how   HIV   infected   women’s   lived   experiences,   attitudes   and   life  
circumstances impact on their behaviours towards administering CPT to their HIV 
exposed but not infected children.  
3. To identify factors associated with uptake of CPT in HIV exposed but not infected 
children 
5.3 Methods 
Narrative approach was used to understand lived experiences of HIV infected mothers 
administering CPT to their children who are not infected with HIV. The use of open-
ended questions and probing of their initial responses were used to enable them to respond 
in their own words ultimately providing stories that explain their experiences and from 
these stories; society, family and household dynamics related to administering CPT in 
HIV exposed children were identified using grounded theory approaches to build a theory 
that explains CPT adherence in children.  
 
5.3.1 The narrative approach 
The narrative approach is a process of gathering information through story telling 
(Chataika, 2005). This approach was chosen because it gives insights into the experiences 
and realities of people being studied (Goodley, 2000) hence forms the central component 
of experience and reality. It is understood as an approach that includes a temporal ordering 
of events and the researcher makes an effort to make points out of those events 
(Sandelowski, 1991). The narrative framework allows researchers to have special access 
to the human experience of a situation (Sandelowski, 1991) and is concerned with the 
storied nature of an experience from an insider view point (Bruner, 1986). In narrative 
analysis, the coding is typically of the narratives as a whole, unlike other methods that use 
different elements within the narratives. The coding strategy revolves around reading the 
stories and classifying them into general patterns. 
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5.3.2 The Grounded theory approach 
In this study, grounded theory techniques were partially applied to explain how the 
women’s   lived   experiences,   attitudes   and   life   circumstances   impact   on   their   behaviours  
towards administering CPT to their HIV exposed but not infected children. Grounded 
theory methodology is an approach in which the researcher first goes into the field and 
builds a theory from the findings as they go along in the research (Straus, 1998). It is most 
commonly used in research areas that have hardly been explored. It seeks to guide 
researchers   in  producing   theory   that   can  explain   the  “patterns  of   actions   and   interaction 
between   and   among   various   types   of   social   units”   (Strauss and Corbin, 1998, Straus, 
1998). The theory construction operates within the framework of the specific context and 
is thus flexible and fluid to realise that situations change and each situation is unique and 
requires fresh exploration. Ultimately, grounded theory will build a theoretical explanation 
of the poor or good adherence to CPT by helping us understand the conditions necessary 
to give rise to these phenomena, how it expresses itself through action and interaction and 
the consequences that result from them. There has been a lot of debate in the literature on 
the approach to grounded theory since the divergence in views on approach by Glaser and 
Strauss, the two pioneers of grounded theory (Glaser, 1992, Strauss, 1990) occurred.  
 
Since this study aimed at eliciting experiences with administering CPT to HIV exposed 
children  who  are  ‘presumably  healthy  children,’   the  Glaserian  approach  seemed  suitable  
to explore this area that has hardly been explored. The Glaserian approach allowed natural 
observation and elicitation of this information from the stories told by the HIV infected 
women administering CPT to their HIV exposed but not infected infants and allowed for 
the development of patterns of their experiences and concepts that explain such a 
situation. This being an area that has never been researched, the combination of narrative 
and grounded theory approaches allowed the mother to tell their experiences from which 
theoretical concepts explaining actions adopted by mothers administering daily CPT to 
their children emerged in contrast to the commonly used framework approach which lacks 
the ability to generate social theory (Gale, 2013). 
5.3.3 Study participants and Sampling 
 
The study participants were HIV infected women with young children participating in a 
large cohort study aimed at investigating the effect of stopping CPT on malaria, other 
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morbidities and mortality. Participants were randomly selected from three groups: a group 
that had just started administering CPT; another group in the middle of giving CPT and 
the third one at end of the CPT period. These participants were purposively sampled from 
a cohort of mothers who had their children participating in a large cohort in order to reach 
the targeted sample size quickly considering the limited academic time and financial 
constraints.  Every two months, study participants were visited in their homes for a refill 
of CPT for their children as well as counseling on adherence to treatment. However, as 
data collection progressed, the selection of participants for IDIs followed a theoretical 
sampling suggested by Glaser and Strauss. Theoretical sampling aims at including 
participants on the basis of an understanding of the context, emerging concepts from on-
going   data   analysis   and   a   deliberate   attempt   to   ‘test’   such   concepts   (Crabtree, 1999). 
Firstly, participants for FGDs were selected using purposive sampling as explained above. 
However, as data was being collected and concepts begun to emerge, there was need to 
sample more educated mothers to aid saturation of data as majority of women in the FGDs 
had primary education (Crabtree, 1999). Consequently, more women who attained 
secondary school education were sampled for the IDIs (Table 2). The interview guides 
were constantly modified based on the responses from the interviews. This was made 
possible within a short period of time because all the participating women were part of an 
on-going large cohort study of cotrimoxazole prophylaxis and malaria (Chapter 4) in 
which they had provided informed consent at the onset to be included in the qualitative 
study. In addition, before taking part in the qualitative study, all participants were 
individually reminded of their participation in the FGDs and IDIs and were informed 
about the nature of the questions to be discussed which were likely to disclose their HIV 
status to other participants (especially for FGDs) and what was expected of them. 
Participants were free to withdraw from participation at any point they wanted. 
 
As this is a qualitative study the sample size for the narrative cohort was 17 mothers of 
HIV exposed children. There were three FGD cohorts of between 6-12 women each which 
is a reasonable number to hold a discussion (Watts, 1982). 
5.3.4 Ethical Considerations 
This being part of the large cohort study from which the women came from, ethical 
approvals were sought together with the cohort study. The women were informed during 
the consenting process at the beginning of the cohort study about the likelihood of being 
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selected for this (qualitative) study at a later date implying that providing informed 
consent for the cohort study also meant consenting for this study hence ethical approvals 
for this specific study felt not to be required. 
5.3.5 Data collection topic guides 
Two separate data collection guides (Appendix 14 and Appendix 15) using open-ended 
questions were developed to guide In-depth interviews and FGDs respectively. A 
deductive approach based on ecological theory of perception influenced the formulation of 
the structured questions used in this study. The ecological theory was used because it is a 
general theory of the perception and control of behavior as it aspires to describe, explain 
and predict perception and action by all animals in all situations (CEHD, 2014) It focuses 
on the perception and behavior that occur naturally (CEHD, 2014). In addition to these 
questions, some thematic topic areas of exploration were evolving alongside the process 
of data collection throughout the interviews. In order to avoid inaccuracies, the data 
collection tools were translated into the local language, Chichewa. An independent person 
who did not participate in Chichewa translation did the back translation from Chichewa to 
English. This was done to ensure that the meaning was correct. Adjustments to the data 
collection topic guides were constantly made throughout the data collection process 
depending on the nature of discussions. 
5.3.6 Data Collection methods 
In this study, two data collection methods were used: In-depth Interviews and Focus 
Group Discussions. The combination of these two methods complimented each other in 
generating   concepts   and   understanding   participants’   experiences,   views,   perceptions,  
values, beliefs and expectations about CPT adherence in HIV exposed children (Patton, 
2002b, Robinson, 1999).  
 
Demographic characteristics such as age, educational status, area of residence and 
occupation of the mothers of HIV exposed children were extracted from the cohort study 
of CPT and malaria database in which HIV exposed children were participating. Note 
taking and tape recording were used to collect and record the data respectively. 
5.3.6.1 In-depth Interviews 
Boyce C., et al, defines In-depth interviewing as a qualitative research technique that 
involves conducting intense individual interviews with a small number of respondents to 
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explore their perspectives on a particular idea, program or situation (Boyce, 2006). IDIs 
allow the interviewer to dig in deeply into social and personal matters. This makes it more 
advantageous than FGDs where digging deeply into an individual is prevented because of 
its public nature where an interviewer is only allowed to get a wider range of experiences 
from a group (Watts, 1982). IDIs were conducted with individual HIV infected mothers of 
HIV exposed children taking part in the large on-going cohort study of CPT and malaria.  
5.3.6.2 Focus Group Discussions 
Focus Group Discussions on the other hand involve a group of about 6-12 people who 
have similar experiences or concerns who come together to discuss a specific issue with 
the help of a facilitator in a setting where participants feel comfortable enough to engage 
in a dynamic discussion for one or two hours usually consisting of a mixed group of 
participants from different social backgrounds who do not know each other (Liamputtong, 
2011, Green, 2014). This method allows researchers to uncover aspects of understanding 
that often remain hidden in the more conventional in-depth interviewing method 
(Liamputtong, 2011). In this study, FGDs were conducted with HIV infected women who 
had their children participating in an on going large cohort study of CPT and malaria with 
the aim of understanding their experiences with giving daily CPT to their children who are 
not infected with HIV but were still breastfeeding. For each FGD, there was one 
facilitator,  a  note  taker  and  a  researcher.  The  facilitator’s  responsibility  was to guide the 
discussion using appropriate probes for depth and clarification throughout the process and 
ensured that tape-recording of the discussion was being done. The note taker concentrated 
on taking note of any non-verbal communication and gestures while the researcher was 
writing memos from the data to start building concepts for the development of the theory. 
The researcher constantly liaised with each one of the other team members as necessary to 
ensure that appropriate information was being collected.  
5.3.7 Interviewing 
One-on-one IDIs with mothers of HIV exposed children were conducted in a private room 
away from traffic to ensure privacy. Questions were asked using the local language in a 
non-judgemental manner and mothers were allowed to speak freely in the local language. 
Each IDI was completed between 30-45 minutes while each FGD lasted for about 1 hour 
and 45 minutes. Information on household decision-making on health issues, experiences 
with providing CPT to a child, perceptions about CPT provision to a child, and sources 
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and mode of provision of information on CPT was solicited. All discussions were tape-
recorded accompanied by note taking of important highlights. 
5.3.8 Data Analysis 
A mixture of qualitative data analysis approaches was used to analyse the data. Themes 
were developed through a framework approach in which a systematic search for patterns 
to  generate  full  descriptions  of  HIV  infected  women’s  experiences  of  giving  daily  CPT  to  
their children was done. This helped to provide narratives that answered the question of 
the impact of the CPT programme on the women. Grounded theory approach was 
simultaneously applied to constantly develop emerging concepts from the themes and 
narratives across the women in order to refine the themes and develop a social theory 
explaining   factors   related   to   women’s   behavior   related   to   administering   CPT   to   their  
children. Furthermore, an inductive approach allowed for the unexpected and more 
socially located responses from the participants. 
 
Although framework approach was used to identify emerging themes from the data, 
theoretical concepts to explain how the upcoming/emerging themes influenced some 
behaviors were identified simultaneously with data collection. Furthermore, as data was 
being collected, it was immediately being transcribed and analysed (Jones, 2011). Coding 
of important topics relevant to the subject was done in order to build a list of relevant 
topics that arose from both IDIs and FGDs (Jones, 2011). This process resulted in a series 
of categories and codes that helped build the phenomena arising from the study. All newly 
collected data was constantly compared with data collected previously. The analysis was 
aided with the use of N Vivo software version 10.0 (International, 2010). Meanwhile, 
classification and categorization of different categories were being made. 
5.3.9 Trustworthiness of the data 
Trustworthiness of the data is achieved when the research data is credible, transferable, 
dependable and confirmable (Lincoln, 1985). In this study, trustworthiness was achieved 
through triangulation by: (a) use of two approaches of data collection – IDIs and FGDs 
which provided the opportunity to look at emergence of different concepts from both 
individual and societal perspectives; (b) use of different researchers with different 
experience to conduct the one-on-one interviews and moderate FGDs. The comparison of 
interviews showed similarity in the issues that were emerging that reflects both 
dependability and confirmability of the data. The FGDs and IDIs were conducted by 
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individuals employed to work in the cohort study but with no direct interaction with study 
participants. These included Laboratory Technicians, Data Officer and a research intern 
working on quality assurance for other studies within the institution. These were trained 
and assigned to carry out the interviews in the local language, Chichewa. However, the 
responses were transcribed using English by the main researcher and the intern. During 
this process, the main researcher reviewed the type of probing and responses that were 
obtained. At a very early stage and throughout the data collection process, the main 
researcher engaged interviewers/moderators in discussions on proper probing on various 
topics. A sub-set of the translated transcripts was translated back in to Chichewa by an 
independent person and was compared with the original transcripts to identify any 
problems with translation. An independent expert social scientist reviewed some of the 
transcripts at random and provided support and guidance on the coding framework. 
5.4 Results 
5.4.1 Characteristics of study participants  
5.4.1.1 Participants for Focus Group Discussions 
Three FGDs were conducted with mothers of HIV exposed children receiving daily CPT 
taking part in an on-going large cohort study of CPT and malaria in HIV exposed children. 
In total, twenty-six women participated in the FGDs. Of these, five had attained secondary 
school education while the rest attained primary education (PE). The age of participants 
taking part in the FGDs ranged from 20-41 years. In terms of employment, the majority 
(24 out of 26) were unemployed (Table 5.1).  
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Table 5.1: Details of respondents who participated in FGDs 
Focus Group Discussion 1 
FGD No. Age Location Education Level Occupation 
1 23 Mikuyu Primary Security Guard 
2 21 Mikuyu Primary Unemployed 
3 20 Thabwani Primary Unemployed 
4 38 Magumba Primary Unemployed 
5 26 Chidzalo Primary Unemployed 
6 31 Seven miles Primary Unemployed 
7 28 Mpunga Secondary Business 
8 31 Maonga Primary Unemployed 
9 41 Six miles Primary Unemployed 
10 27 Six miles Primary Unemployed 
11 22 Magumba Primary Unemployed 
12 28 Nambesya Secondary Unemployed 
Focus Group Discussion 2 
1 34 Chiphola Primary Unemployed 
2 40 Thabwani Primary Unemployed 
3 23 Mpunga Primary Unemployed 
4 29 Thom Allan Secondary Unemployed 
5 29 Chikowi Primary Unemployed 
6 24 Chikanda Primary Unemployed 
Focus Group Discussion 3 
1 30 Mtiya Secondary Cleaner 
2 38 Cobbe Barracks Primary Unemployed 
3 32 Chikanda Primary Business 
4 36 Six miles Primary Unemployed 
5 35 Chinamwali Primary Unemployed 
6 34 Namarika None Unemployed 
7 36 Six miles Secondary Unemployed 
8 33 Chikanda Primary Unemployed 
 
5.4.1.2 Participants for In-depth interviews 
Seventeen IDIs with mothers of HIV exposed children receiving daily CPT were 
conducted   to   obtain   information   on   factors   that   influence   adherence.   The   participants’  
ages ranged from 17-39 years. These participants were slightly younger than those in 
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FGDs. In addition, the majority of IDI participants (11 out of 17) were more educated 
having attained up to secondary education (SE) (Table 5.2).  
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Table 5.2: Details of respondents who participated in IDIs 
IDI No. Age Location Educational level Occupation 
1 24 Njonjo Secondary Unemployed 
2 17 Nkoloma Secondary Unemployed 
3 34 Namonde Secondary Unemployed 
4 31 Chongo Secondary Unemployed 
5 35 Chikanda Secondary Unemployed 
6 39 Saile Secondary Unemployed 
7 31 Peter Mtende Secondary Unemployed 
8 33 Nkhalola None Unemployed 
9 23 Cobbe Barracks Secondary Business 
10 33 Kazembe Primary Unemployed 
11 35 Chongo None Unemployed 
12 33 Mpakati Primary Unemployed 
13 20 Chizalo Primary Unemployed 
14 29 Mpakati Secondary Unemployed 
15 24 Kazembe Secondary Unemployed 
16 29 Prison lines Secondary Unemployed 
17 31 Saidi Primary Unemployed 
 
5.4.2 Participant narratives of their lived experiences of administering daily CPT to 
their HIV exposed children 
This section presents mothers’ narratives of their experiences with administering CPT to 
their young children. The narratives reveal the impact of being in the programme and its 
influence on household dynamics; impact of access to information as a result of 
participating in the study (the main cohort study) and how it influences household and 
individual decision making on health; strategies HIV infected mothers with HIV exposed 
children employ to continue administering CPT to their HIV exposed children; motivating 
as well as deterring factors for continued administration of CPT and the role of support 
systems in the whole process. In addition, factors that influence adherence as well as a 
theoretical explanation of adhering to PMTCT interventions such as administering to daily 
CPT in HIV exposed but not infected children has been presented.  
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5.4.2.1 Impact of the PMTCT Programme on household dynamics 
Impact on health decision-making powers in the household 
Being in the PMTCT programme where women were administering daily CPT to their 
HIV exposed children modified decision-making powers within their households. 
Although most mothers indicated their spouses, parents and themselves as decision 
makers on health issues in general, in most instances decisions were made jointly between 
the spouses although there is an indication from the data that the influence in decision 
making was being dominated by those with economic power within the household with 
ten participants citing men as having more decision-making powers by virtue of being 
household heads. One married woman described how health-related decisions were made 
and implemented in her household: 
 
“When  the  spouse  is  there,  he  encourages  you  to  go  to  the  hospital. As it is, it is the 
mother who takes the child to the hospital, the father just speaks of what ought to be 
done but he does not go with you. An exception only applies to loving husbands who 
may accompany you but it is women three quarters of the time” (Respondent 010, 
IDI) 
 
As would have been expected in most African settings where some men shun away from 
household health issues, it was interesting to note the reversal of this cultural norm in 
some households where male partners were not detached from household health issues as 
they actively participated in ensuring that their child was healthy as demonstrated in the 
quotation below. 
 
“Ah,  only  that  his  father  is  very  attentive.  Usually  when  the  child,  say  coughs,  he  
instructs me to go with him to the  clinic” (Respondent 014, IDI) 
 
Moreover, the quotation above clearly demonstrates the decision-making power by the 
husband while the wife plays the role of an implementer. However, in certain instances 
women disrespect these role boundaries and execute decisions without the knowledge of 
the husband. The woman in the quotation below narrates how she makes decisions on 
health and informs the husband afterwards:  
 
“Anything  that  may  happen  to  me  or  the  child  has  to  be  reported  to  the  spouse  
because he has to  know  since  we  are  a  family…  When  am  back  I  tell  him  that  the  
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child is sick and I took him to the clinic, likewise when it is me, I call him and may 
tell  him  that  I  went  to  the  hospital  because  I  have  malaria” (Respondent 011, IDI) 
 
When asked as to whether the household decision maker on health issues influenced 
participation in the PMTCT programme and eventually the process of administering CPT 
to the child, participants unanimously indicated that they do not influence this process. 
Some women mentioned that if their spouses were to tell them not to give their child CPT, 
they would be doing it covertly without their knowledge. The dialogue in Table 5.3 
illustrates the determination of one woman to continued administration of CPT 
irrespective of what the spouse said.  
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Table 5.3: Participant views on decision-making on health issues (Respondent 010, 
IDI) 
Interviewer Respondent 
………………. Am not affected negatively 
What if your husband decides that 
you should stop? 
I would not bend to that 
Why? Stopping the administration of 
Bactrim§ (CPT) is tantamount to 
inviting problems 
Why not, it is the decision maker 
who has spoken? 
He cannot speak like that 
What if he does? 
 
Then I can always give him when my 
husband has left 
 
 
Four participants who stated that they were responsible for making decisions on health 
issues in their households, they were either not married or their spouses were not 
concerned about health issues of the household. Two of IDI participants indicated that 
their parents were the primary decision makers because they were dependent on them.   
5.4.2.2 Impact of access to health information on household decision-making 
Households look up to Health workers for information on CPT 
Most study participants explained that they received adequate information regarding 
administering CPT to their children from health workers. They pointed out that the 
frequent reminders each time they interfaced with medical personnel at the study clinic 
enabled them to comply with interventions for their HIV exposed children such as 
administering CPT on daily basis. Some clients stated that they were visited once every 
two months while others mentioned that they visited the clinic themselves once in a while 
for drug refills when the Research Assistants (RAs) did not visit them on their scheduled 
date. However, under normal circumstances visits to the clinic were made either when the 
child was ill or the study clinic had requested them to do so as per the CPT and malaria 
study protocol.  
 
“The  information  is  enough  …….  we  receive  it  every  time.  When  the  doctors  visit  
us,  they  remind  us,  ‘do  you  give  this  child  the  treatment?’  Then  we  respond  saying,                                                          
§ Bactrim is a brand name for Cotrimoxazole (sulfamethoxazole-trimethoprim) 
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‘yes,  we  give  him,’  and  sometimes  they  also  add  onto  the  treatment.” (Participant 
003, FGD 2, Age 23, PE, Mpunga, Unemployed).  
 
The three most preferred sources of CPT information mentioned by study participants 
included study clinic or the hospital; the media and home visits by health workers. These 
were also listed as main sources where the women got CPT information. Some people 
indicated community leaders and community groups, leaflets and telephones as potential 
sources of CPT information.  
 
“The  only  way  I  can  help  my  child  is  by  coming  to  the  clinic  on  the  dates  that  have  
been allocated for me.  …  no  other  better  place  than  the  hospital.  …the  nurse,  she  is  
the  one  I  can  trust.” (Respondent 011, IDI). 
Adequacy and usefulness of information on CPT supports household decisions on 
health 
Looking at perceptions about CPT information provided by health personnel, participants 
mainly perceived the information to be adequate as described below.  
 
“The  information  is  adequate,  but  at  first  we  were  not  certain  that  bactrim  was  
helpful  for  children.  But  as  soon  as  they  had  informed  us,  “We  are  providing  this 
bactrim  for  this  child  so  that  he  doesn’t  get  sick  regularly,”  we  accepted  the  
information and made use of it, and now we have seen that this thing is very 
powerful.” (Participant 003, FGD 2, Age 23, PE, Mpunga, Unemployed). 
 
In terms of its usefulness, the women mainly considered that CPT information equipped 
them with appropriate knowledge and skills for safeguarding and protecting their children 
from various illnesses and HIV infection. Study participants also indicated that the 
information did not only allow them to make informed decisions about the wellbeing of 
their children in terms of making health-related choices, it also encouraged them to seek 
medical care from formal healthcare facilities in the event that the child was ill. Lastly, 
frequent provision of CPT information was perceived to act as reminders to parents when 
they had forgotten something related to CPT.  
 
“Most  of  us  forget  and  when  we  watch on Television we are reminded. I have 
benefited because in those times  I  was  forgetting,  it  was  there  to  remind  me.” 
(Respondent 009, IDI) 
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“This  information  has  helped  me  because  when  I  go  for  ANC  visits,  I  see  how  well  
the  child  is  gaining  weight  because  he  is  receiving  the  proper  care”. (Respondent 
011, IDI) 
 
5.4.2.3 Motivation for continued administration of CPT to young children 
A  child’s  good  health  as a motivation for continued administration of CPT  
Looking at what made women continue administering CPT to the HIV exposed child who 
was not infected, most participants indicated that they find this necessary because 
breastfeeding was ongoing. They continued providing CPT to their children in order to 
help prevent transmission of HIV from the mother through breastfeeding. Interestingly, 
respondents indicated that a true HIV status of a child could only be determined two years 
after birth hence stopping CPT would have meant exposing the child to risks of infections 
at  a  time  when  the  parent  is  not  sure  of  the  child’s  true  HIV  serostatus  as  described  below.   
 
 “I  continue  because  even  though  he  can  be  HIV  negative,  he  is  still  at  risk  of  being  
infected [with HIV] because he is breastfeeding. Then I continue with bactrim so 
that  he  should  renew  his  strength.” (Respondent 008, IDI) 
 
The mothers felt it was necessary to provide CPT to a child who was HIV exposed but not 
infected in order to preserve good health of the child. There were fears that stopping 
administering  CPT  to  a  child  may  increase  the  child’s  vulnerability  to  diseases.   However, 
one respondent indicated that it was not necessary to provide CPT to a child who is not 
infected with HIV yet, but did not provide reasons for this.  
 
Most participants perceived the administration of CPT to a child as very important. The 
main reason provided was that CPT did not only improve immunity of the child but it also 
allowed the child to enjoy a good health. Participants felt that with CPT, the child did not 
fall sick frequently but it also made the illness less severe. Administering CPT was 
perceived to protect the child from infections including HIV infection, malaria, 
pneumonia, diarrhoea and cough as the two women narrated:  
 
“The  bactrim  helps  us  to  protect  our  children  from  getting  ill  often.  Even  coughs  
stay away from them; they are never frequently sick from them. Even when they 
are attacked by a cough, it never seriously gets them down. It is moderately 
different  from  someone  who  is  not  taking  bactrim;;  it  comes  a  bit  harder.” 
(Participant 002, FGD 3, Age 38, PE, Barracks, Unemployed) 
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“It  is  important  because  for  a  child  who  is  on  bactrim;;  He  is  not  frequently  
attacked  by  malaria  and  for  the  pneumonia  that  was  common  before,  he  wasn’t  
affected.  Even the diarrhoea that accompanies teething, he did not have any. This 
is how I can explain  the  importance  of  bactrim.” (Respondent 013, IDI) 
 
The women provided testimonies that their children were growing as healthy as those of 
HIV negative women. Some observed that there was a big difference in terms of good 
health between their children and those belonging to other HIV positive women who were 
not receiving CPT.  
 
“The  child  equally  grows  like  those  who  are  not  from  infected  mothers  and  you  
cannot  even  differentiate  their  health.  …administering  bactrim  to  my  child  is  very  
important. To begin with, bactrim protects the child from contracting the virus 
from the mother or even the prevention of being attacked by these other different 
insignificant  diseases.” (Respondent 004, IDI) 
 
Participants also indicated that it was important to administer CPT to their children in 
order to improve their health. Providing CPT was equated to protecting the life of the 
child from HIV and thus improving longevity. Finally, some women indicated that CPT 
was saving the time and resources the parent would have spent by frequently visiting the 
hospital every time the child was ill. 
 
 “You  are  saved  from  frequenting  the  hospital  because  of  the  child’s  constant  illness  
as  is  the  case  with  the  other  children  who  may  even  suffer  from  serious  illnesses.” 
(Respondent 004, IDI) 
Demonstration of compliance to medical advice/instructions 
Continued provision of CPT to an HIV exposed child was also done to demonstrate 
compliance to the instructions provided by health care workers. Women were therefore 
merely acting upon the instructions given and were unable to act differently without 
receiving instructions to do so by the healthcare providers. To some, this compliance was 
reinforced   by   the   fear   of   being   humiliated   once   they   go   against   healthcare   workers’  
instructions. However, to others, being shouted at by the healthcare provider was not an 
issue to worry about if instructions have not been adhered to.  The quotations below 
described how women trusted instructions from health professionals:  
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“You  have  to  keep  on  offering  the  child  bactrim  even  though  he  is  seemingly  healthy  
because the medical  people  haven’t  told  you  about  the  situation  of  his  health.  You  
can  stop  only  when  medical  people  have  instructed  to  do  so.” (Participant 002, FGD 
3, Age 38, PE, Barracks, Unemployed) 
  
“No  one  will  stop  [a  child]  being  on  the  treatment  unless  you  instruct her to do so. 
On  her  own,  she  can’t  make  that  decision.  She  wants  to  hear  from  your  [providers]  
mouth  saying,  “You  should  now  stop  offering  the  child  [bactrim].” (Participant 006, 
FGD 3, Age 34, PE, Namarika, Unemployed).  
Trust in healthcare providers 
Most participants indicated that they trusted and followed instructions provided by health 
providers. Continued interaction with health providers reinforced the need to adhere to 
treatment as described by one respondent in a group discussion. 
 
“We  follow  the required procedure which they give us at the hospital. We should 
not make the child skip [treatment]. We need to administer bactrim, half pill, to 
him daily, every morning. So, we implement the instruction from the hospital. If 
they tell us [something],   we   follow   it.” (Participant 008, FDG 3, Age 33, PE, 
Chikanda, Unemployed) 
Willingness to improve health of the child 
Some participants indicated that they adhered to CPT in order to protect their children 
from diseases. One participant in particular, indicated that she adhered to giving CPT to 
her child because she was still breastfeeding. She therefore felt that discontinuing 
treatment or non-adherence to treatment would increase the chances of her child acquiring 
HIV infection. CPT was thus viewed to protect the child from an HIV infection as 
narrated in the quote below:  
 
“Because   the   child   is   still   breastfeeding,   I   don’t   know   how,   but   there   is   a   risk   of  
transmission  so  the  bactrim  protects  him  from  contracting  the  virus.” (Respondent 
004, IDI) 
Peer Influence and support 
Peers and friends in the same study encouraged each other to continue adhering to CPT 
for their infants. This was reinforced by good health that the child enjoyed.  
 
“When   you   are   chatting,   you   are   able   to   encourage   one   another,   saying,   “This  
child   looks  great.  You   shouldn’t   change.  …but   there  are  other   children  who  are  
not receiving bactrim. Their bodies do not look healthy; they are skinny. But on the 
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part  of   those  who  receive  bactrim,  they  look  fine.  They  are  healthy.” (Participant 
005, FGD 2, Age 29, PE, Chikowi, Unemployed) 
 
“I   explained   to  my   pastor….   “With   this   pregnancy   you   are   seeing,   I   have   been  
found  with  the  infection,  I  am  positive.”    He  told  me,  “don’t  despair.  We  should  be  
praying  but  also  you  shouldn’t  stop  taking  the  treatment.”  Right  now,  whatever  the  
little  he  finds,  he  shares  it  with  me.  Whether  it  is  flour,  he  gives  it  to  me,  “Here  is  
Likuni  flour,  use  it  for  making  porridge  for  the  child.”  Because  of  that  I  thank  my  
pastor   for   the   support   rendered   to   us.” (Participant 008, FDG 3, Age 33, PE, 
Chikanda, Unemployed) 
5.4.2.4 Deterrents from continuing with PMTCT interventions in children  
Fear of stigma and discrimination 
Study participants were asked to discuss some of the challenges that they encountered 
when administering CPT to the child as one of the PMTCT interventions in HIV exposed 
children. The first challenge was fear of discrimination by other family members as well 
as community members if they discovered the child was taking daily prophylaxis. This 
worry emerged because of the perceived and existing association between CPT and having 
HIV.  
 
“…  other  people  will  ask  you,  “You  always  give  this  child  bactrim,  what  is  it  for?”  
You see? So, it becomes difficult for you to answer because there is a group of 
people.   …there   are   other   people   who   begin   to   ridicule   you   behind   your   back,  
saying,  “You  shouldn’t  take  her  for  her  looks;;  she  takes  ARVs.  ‘Amamwatu’  (she  
heavily   takes   ARVs).”   That’s   the   Chichewa   that   is   there   now,   ‘amamwa’.  
‘Amabwila’  (vernacular  term  used to describe the act of chewing large quantities 
of  powdery  or  crystal  foods)  daily.  …  when  they  have  known  about  you,  it  will  be  
the same talk. They will just wait for you to move away so they can discuss you. 
“Along  this  entire  line  [compound],  all  are sick. There is no one who is alive may 
be   just   one   or   two   people.”   (Participant 002, FGD 1, Age 21, PE, Mikuyu, 
Unemployed). 
 
Since mothers in this study were part of the large cohort study that followed up 
participants in their homes for study follow up procedures, some mothers experienced that 
their peers discriminated them against when the study staff visited them in their homes. 
Basing on this experience, they were afraid of being ridiculed if other people knew they 
were administering CPT to their children. One woman described her experience as 
follows: 
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 “One   day,   this   child   got   sick   and   three   of   us   women  went   to   a   hospital.   So,   a  
certain  man  asked,  “Are  you  going   to   the  hospital?”  The  other  man  said,  “This  
one who was diagnosed with the disease (HIV), her   child   is   sick.”   So,   I,   the  
infected  one,   felt   concerned   in  my  heart.”   (Participant 005, FGD 1, Age 26, PE, 
Chidzalo, Unemployed) 
 
Participants in a focus group discussion narrated that some community members 
considered the study as part of a satanic cult. They therefore discouraged the women from 
taking part in the study by stating that their children would die as demonstrated in the 
quote below.  
 
“There  are  others  who  discourage  us  from  this  research  in  which  we  have  enrolled  
our  children.  They  say,  “They  are  satanic.  You  will   lose   the  children  because  of  
what  you  have  enrolled  in.”  When  the  project  car  visits  you,  they  say,  “What  type  
of medical people   are   they   who   visit   people   in   their   homes?”   “These  
doctors…what   type   of   doctors   are   they   who   are   just   visiting   [people]   in   their  
homes?”  the  first  day  this  one  picked  us  up,  “Visiting  people  in  their  homes  with  
expensive fuel this time around. They are satanic, you are going to sell out the 
children.”  (Participant 004, FGD 1, Age 38, PE, Magumba, Self-employed) 
A  child’s  intolerance  of  CPT 
Some participants indicated that their children usually vomited the drugs during 
administration. They were therefore forced to re-administer the drugs but feared 
overdosing their children because they were not certain on the quantity that had been 
swallowed. They described this dilemma as follows:  
 
“The  challenge  we  encounter,  some  of  the  children  vomit  the  drug  when we give it 
to  them.  Nonetheless,  we  try  all  we  can  so  that  they  take  [the  drug].  But  that’s  the  
major   challenge,   vomiting   the   treatment.” (Participant 9 FGD1, Male, 41year, 
Std7, Six Miles, Unemployed,) 
 
“He  does  spit  out  everything.  He  can  just  spit  a  little bit and swallow the rest so 
fearing that I may overdose him, I do not re-administer.” (Respondent 016, IDI) 
 
There were opposing views on the steps to be taken after the child had vomited the 
medication as one woman suggested that re-administering the drugs was safe after 30 
minutes from the previous administration of the drugs while another woman indicated that 
it was not advisable to re-administer drugs after the child vomited.  However, some study 
participants indicated that they devised certain techniques to address the problem of child 
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vomiting the medication by either giving the child sugar or breast milk soon after 
administering the drugs to counteract its bitterness thereby preventing the vomiting.  
 
“If  it  is  the  challenge  of  other  children  spitting  out  [the  treatment],  because  of  the  
bitterness of the treatment, to prevent the child from spitting out, we should coax 
him   taking   sugar.   When   the   child   takes   the   treatment,   you   give   him   sugar.”  
(Participant 002, FGD 1, Age 21, PE, Mikuyu, Unemployed) 
 
“We   entice   the   child  when  we  want   to   give   him   the   treatment;;   you   take   out   the  
breast and offer it to him. Then he opens the mouth and you swiftly give him [the 
treatment]  and  then  you  give  him  the  breast.” (Participant 5, FGD 1, Age 26, PE, 
Chidzalo, Unemployed) 
 
Only one woman suspected that her child developed side effects after receiving CPT as 
she explained in this statement.  
 
“…but  one  incident  in  particular;;  He  had  diarrhoea  and  he  vomited  and  I  came  to  
the study clinic and was given medication, he improved and  then  later  worsened.” 
(Respondent 017, IDI) 
 Forgetfulness 
Although most of the participants mentioned that nothing would prevent them from 
ensuring that they adhere to CPT for their children, some cited a few reasons that 
encouraged non-adherence to CTP. The main reason given was forgetfulness on the part 
of the parent to administer CPT to the child. Participants stated that they sometimes forgot 
to give the medication to the child or carry the drugs with them when they were travelling. 
These incidents were said to happen infrequently. 
 
 “There are things that lead to failure, you might forget, the same forgetfulness we 
were talking about. You may have forgotten to give the child the treatment. This is 
one thing that also leads to failure to provide the treatment   to   a   child…” 
(Participant 004, FDG 2, Age 29, PE, Thom Allan, Unemployed) 
Spousal disagreements, lack of food and shortage of drugs 
Some of the issues mentioned that resulted into non-adherence to CPT included existing 
problems between partners in a family, lack of drugs, lack of food and lack of follow-up 
visits from health providers. In terms of relationship problems, the lack of understanding 
from a spouse and the absence of peace in the household were said to interfere with 
administration of CPT to the child. This has been illustrated in the quote below. 
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 “…   when   there   are   disagreements   and   arguments   between   me   and   my   spouse  
where my husband would want me to stop. Other than this I do not see anything 
else  that  can  make  me  fail.” (Respondent 004, IDI) 
 
With reference to the lack of drugs, participants indicated that they failed to adhere to CPT 
treatment for their infants when their drugs run out without realizing or because when 
supply of fresh stock has not been done through home visits by study personnel as 
described by one woman.  
 
“When   the   treatment   has   ran   out   it   becomes   a   problem  because   those  who   visit  
and  give  us  the  treatment  make  a  date  with  us,  “we  will  be  coming  on  such  a  day,”  
but  you  find  that  they  haven’t  come  on  that  day.  So,  it becomes a problem because 
you  wait  thinking  that  the  treatment  will  find  you.” (Participant 008, FDG 3, Age 
33, PE, Chikanda, Unemployed) 
 
Finally, some participants indicated that lack of food in the household was a reason why 
they sometimes failed to give CPT to their children. They perceived that giving a child 
medication on an empty stomach would make the child weak as described in the quotes 
below. 
 
“If  you  don’t  have   food,  you   fail   to  give   the  child   the  bactrim  …  when   the  child  
reaches 6 months of age at which point the child needs to eat anything, but then 
you  are   found   to  have  no   food.  Then  you  wonder,  “Should  I   take   the  medication  
and  give   it   to   the  child  when  I  don’t  have   food?”  Then  you   just  say,  “Perhaps  I  
should  wait  until  the  evening,”  because  there  is  no  food  [laughs]…” (Participant 
007 FDG 1, Age 22, PE, Magumba, Unemployed) 
 
“It  is  really  true  because  you  can’t  give  the  treatment  to  a  child  before  eating.  The  
child   might   become   frail…   Also,   when   you   go   to   the   hospital,   they   advise   you  
“Take   this   treatment   after   you   have   eaten.   When   you   have   eaten   is   when   you  
should  take  it.”    So  people  draw  a  lesson  from  that.” (Participant 011, FDG 1, Age 
28, SE, Mpunga, Business) 
 Religious influence 
On influence of religious and traditional beliefs, almost all participants stated that these 
did not influence their decisions or actions when giving treatment to their children. 
However, some pointed out that there were some religions that influenced them to avoid 
seeking treatment or defaulting on going treatment.  One woman indicated that religion of 
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her spouse made her worry about continuing administering CPT to the child. 
 
“My  husband  strongly  believes  that  God  exists  so  whenever  I  am  giving  bactrim  he  
says that am torturing the child but I should leave him alone because God is in 
control and he is the one who gave us the child. It starts bothering me but I do not 
give  up  because  I  go  to  the  hospital  and  follow  the  instructions  given.”  (Respondent 
004, IDI) 
5.4.2.5 Strategies for continued provision of CPT to their children   
Reminders for CPT administration  
The data shows that parents have a number of strategies that they use to remind 
themselves to administer CPT to their children. Their spouses and some household 
members including parents, siblings and older children reminded them to give CPT to 
their children. In addition to these, they used their daily routine activities as reminders for 
providing CPT to their child. These included: time for taking their ARVs, time for bathing 
the child, time for changing nappies, time for feeding the child and time when the sun 
rises. One woman described bathing and feeding of the child as a reminder for 
administration of CPT as stated below: 
 
“What  makes  me  remember….   is   that  every  morning, the moment I bathe him and 
feed him porridge, I remember to administer bactrim. It is automatic, porridge is 
followed  by  bactrim.” (Respondent 014, IDI) 
 
One mother stated that she used an alarm on her phone as a reminder to give CPT to the 
child.   Below,   another   woman   explained   how   timing   for   taking   her   ARV’s   helped   her  
remember to give CPT to her child as well:  
 
“I  remember  because  when  I  am  taking  the  drugs,  when  it  is  6  o’clock,  I  know  that  
the   child   should  also   take   the   treatment….   I   remember   to   [give   the  drugs   to   the  
child]   when   I   am   taking   my   treatment.” (Participant 006, FDG 2, Age 24, PE, 
Chikanda, Unemployed) 
 
Some women indicated that they conditioned their memory to remember administering 
CPT without any reminders. Also, some mothers kept drugs where they could easily see in 
their house and were reminded each time they saw the drugs. Here, a woman described 
how keeping CPT visible assisted her to remember administering the drugs to the child: 
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“My  ‘pillar’  [reminder]  is  that  I  leave  the  drugs  on  a  visible  place  so  that  I  don’t  
forget  them.”  (Participant 003, FDG 2, Age 23, PE, Mpunga, Unemployed) 
Carrying cotrimoxazole every time  
A number of women indicated that they always carried the medication with them in case 
they travelled and this helped them ensure that the child adhered to treatment.  
 
 “Whenever  I  am  going  away,  I  put  bactrim  in  his  bag  and  I  try  my  best  to  find  time  
to give him the bactrim. I have never forgotten because whenever I am going away, I 
start   packing   the   medication   and   his   health   passport   before   anything   else.” 
(Respondent 010, IDI) 
5.4.2.6 Managing concomitant medications with CPT 
On personal experiences on administration of CPT when the child was required to take 
other prescribed medication, participants indicated that they allowed the child to be on 
concurrent treatments. When asked what they did when a child got ill and required to be 
given other medications, respondents to this question showed that they continued 
administering CPT to their children even when they were required to take other 
medications. One participant demonstrated this in the quote below: 
 
“I   do   not   stop.   I   still give him say cough medicine when he has a cough or 
medication  for  fever  if  he  has  a  temperature.”  (Respondent 003, IDI) 
 
However, they understood that giving all of the different medications at once might be 
hazardous to the child. And therefore, they developed strategies to manage concurrent 
treatments for the child on CPT. Some of the women described how they managed giving 
different medications simultaneously to their child.  
 
 “I   do   not   stop   administering;;   I   administer   in   the   morning   when   feeding   him  
porridge. If he is on another treatment, then I give him that treatment at 10 am.” 
(Respondent 009, IDI) 
 
“When  I  have  more  drugs  to  give  the  child  …I  feel  like  the  combination  will  make  
him weak, I alternate. I give him the other drugs at 6.00am and then Bactrim say 
at 8 am or 9 am  to  give  space  between  the  medications.” (Respondent 010, IDI) 
 
Data above shows the diversity in coping mechanisms in reference to the timing of 
concurrent medications to the child.  Despite lack of standard guidelines to guide parents 
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on how to deal with such situations, most mothers still identified ways of ensuring the 
child took both treatments as one woman narrates.  
 
“….   what   I   do   now   is   to   space   bactrim   and   other   drugs   within   a   few   hours.”  
(Respondent 011, IDI) 
 
However, some of the women made enquiries from the study clinic about the dangers of 
giving simultaneous treatment to the child before administering the medications as 
described in the quote below: 
 
“I  asked  about  this  the  last  time  I  was  admitted  when  he  was  taking niverapine and 
I  was   told   that   there  was  no  problem  and  he  could  continue.”   (Respondent 012, 
IDI) 
 
The majority of mothers of HIV exposed children in this study explained that they 
continued providing CPT to their children even when the children were required to take 
other medications because they were motivated by the information and instructions 
provided by healthcare providers. This helped the women to be able to isolate the purpose 
of each of the medication given to the child and hence valued the need to ensure that the 
child took both or all medications. 
 
“I  already  have  the  instructions  from  the  doctors  to  continue  administering.  This  is  
why  I  continue  until  they  tell  me  to  stop.” (Respondent 002, IDI) 
 
Furthermore, women trusted that healthcare providers would not do anything to harm their 
children because they always checked the health passport book of the child before they 
provided a new prescription. One participant related this with her experience of being on 
ART where sometimes she had to take multiple drug regimens and felt this was supposed 
to be the same with children. She therefore did not have worries about giving CPT 
together with other medication as described below: 
 
“There   are   no  worries,  when  we   fall   sick,  we   are   given   different  medications say 
Artemether Lumefantrine (AL) or others which we take simultaneously hence it is the 
same  case  with  the  child.” (Respondent 014, IDI) 
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5.4.2.7 The role of support systems in influencing uptake of PMTCT interventions in 
young children 
Support systems mentioned in this study included support healthcare providers, family and 
the community (Table 5.4). 
Support from healthcare providers 
Most participants felt that the healthcare providers regularly supplied them with the drugs 
right in their homes during home visits for the CPT and malaria study consequently 
reducing the number of visits they would have to made to the hospitals to collect the 
medications. The constant interaction with these healthcare providers as they visited them 
was seen by most mothers as an opportunity to learn more on the medications. As such, 
the information gained assisted them to adhere to treatment in order to achieve its 
optimum benefits.  Furthermore, the women felt supported with the reception they were 
given when they visited the study clinic either with a sick child or to collect more 
medications. Table 5.4 below   includes  women’s   narratives   on   how   they   perceived   the  
support they received from healthcare providers, family and community. 
Support from family members 
Some participants had disclosed their HIV status to family members who they believed 
would support them. These included very close relatives mainly spouses, parents and 
siblings. However, some mothers said that they were cautious on informing some relatives 
about CPT considering high levels of stigma and discrimination as described by 
respondent 010, IDI (Table 5.4) who felt betrayed after her nephew disclosed her status to 
other members of the community.  
 
Most participants valued the role of family relations in providing support in the 
administration of CPT. They narrated that support from close relatives is in the form of 
encouragement to continue providing CPT to their children, reminding them the time to 
give the child medication and helping in administering CPT to the child when the primary 
caregiver was away. Some indicated that they informed relatives about their participation 
in the malaria and cotrimoxazole study so that they were aware of what was happening. 
Informing relations was viewed as security for continued administration of CPT to the 
child in case the primary caregiver was incapacitated. However, one woman (Respondent 
017, IDI) described that she informed relatives that she had joined the malaria and 
cotrimoxazole study to avoid suspicion that she had HIV and only disclosed her status to a 
relative who was also infected with HIV. 
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Support from the Community  
Most women indicated that it was not proper to involve community members and 
religious institutions to provide social support to women who are providing CPT to their 
children. They stated that it was difficult to divulge confidential information to other 
people in the community for fear that they might use it against them. The excerpt for 
participant 008, FGD 3 in Table 5.4 describes why it was not advisable to inform 
community members about their HIV status. Most mothers indicated that they did not 
receive adequate support from community groups. Only two participants indicated to have 
obtained some kind of support from the two community-based organizations that 
implemented HIV-related activities in the district. This may explain why most of the 
participants felt that no external support from the community was required to support 
women in the administration of CPT. Here; one participant described why it is not 
advisable to inform community members about their HIV status: 
 
 “It   is   really   essential   to   inform  relatives  but   you   should   know  which   relative   to  
inform   and   be   certain,   “If   I   inform   this   person,   won’t   I   hear   the   story   at   the  
[communal]  tap?”  You  need  to  choose  who  to  inform.  So,  when  you  notify   them,  
you then explain to them and they keep privacy for you. But there are other 
relatives whom if you tell them, you will hear the story   at   the   tap.” (Participant 
001, FDG 2, Age 34, PE, Chiphola, Unemployed) 
 
As a result of fearing negative consequences, some parents were forced to secretly 
administer CPT to their babies while fearing that they might be seen doing that by some 
members of the community. Some had to lie that the drugs were paracetamol as it is not 
associated with HIV. Fear of having their child bewitched by other people was another 
reason why some women did not want any involvement of the community members. Table 5.4 highlights what the women said about support from community members on 
administration of CPT to their infants 
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Table 5.4: Views of mothers of HIV exposed infants on the support systems for CPT provision 
Women’s  views  about  support  from  
healthcare providers 
Women’s  views  about  support  from  family  members Women’s  views  about  support  from other 
members of the community 
“I  am  just  thankful  for  a  programme  like  this  one,  
for  our  children’s  participation  in  the  research  
about bactrim. We are just grateful [and ask you] 
not to stop here. Do the same even to our friends 
who are coming because we have followed the 
instructions that you give us. And we have seen 
that our children are growing up well with good 
health and not falling sick frequently because we 
have been following what you have been 
instructing us. So, we are asking you that this 
programme should proceed. It should not end 
here.”  (Participant 007, FDG 3, Age 36, SE, Six 
Miles, Unemployed) 
“…  because  the  child  lives  with  my  younger  sister  when  I  go  
to  work.  I  advise  her,  “You  first  cook  porridge  for  the  child.  
After you have cooked the porridge then feed the child with it. 
After feeding with the porridge, you should then take bactrim 
and  give  it  to  the  child.”  This  is  happening  because  when  I  
check  the  pills  I  find  that  they  are  decreasing.”  (Participant 
007, FDG 1, Age 22, PE, Magumba, Unemployed) 
“What  I  am  afraid  is that once people become aware, 
other  people  don’t  speak  politely,  ‘You  see  that  
woman?  She  is  on  treatment.’  In  that  way,  you  feel  
depressed by the mockery. So, to prevent being 
mocked, I told my child to keep a secret for me so 
that am not looked down and disheartened when I go 
out. When people see me, they should find me to be 
the same as they are (Participant 008, FDG 3, Age 
33, PE, Chikanda, Unemployed) 
“It  is  fine  because  when  we  go  to  the  hospital,  the  
doctors welcome us with the usual courtesies, 
attends  to  the  child  and  gives  us  medicine.” 
(Respondent 010, IDI) 
 
”There  are  some  relatives  that  I  explained  to;;  I  told  them  that  
I joined the malaria study group from Zomba so they visit me 
and bring me medication for the child. They sometimes call 
me and I go there to get medicine that I administer to the 
child. Perhaps when they see the doctors they just suspect 
and do not ask, particularly my brother. But for the other 
relative I was explaining to, he is also on medication like 
me.”  (Respondent 017, IDI) 
“No,  they  can’t  help  us…religious  people,  community  
members/neighbors  or  our  relatives.  They  can’t  
manage because these drugs are very expensive. 
They  can’t  afford  to  buy  them.  You  the  medical  
people are the ones who could help us. You should 
not  get  tired  of  us.  Help  us  until  the  end  of  our  lives.” 
(Participant 008, FDG 3, Age 33, PE, Chikanda, 
Unemployed) 
“…  I  always  give  him  away  from  the  
people, for example, in the house or in my 
bedroom. When they see me outside, I tell 
them that it is panado [Paracetamol] and 
the child needs it because he has fever or a 
cold but not many know because I have not 
spoken  to  them.” (Participant 004, IDI) 
“I  would  say  it  has  an  advantage  because  life  is  too  short.  If  I  
died, my child may be taken care of by relatives who may not 
know my status. They will not continue with bactrim and 
something  bad  may  happen  to  the  child.”  (Respondent 016, 
IDI) 
 
I relate to them as normal as possible but they 
wonder why the doctors frequently visit me at home. I 
tell them that I joined malaria study but my child has 
not been found with malaria since. They then ask why 
the doctors come when the child has no malaria and I 
tell them that the doctors will stop when the child is 
diagnosed  with  malaria.” (Participant 007, IDI) 
 If they know then it might be this other day where I had an 
argument with my nephew, that is when he started calling me 
“…they  might  see  you  giving  the  child  the  treatment.  
Then they will think that the child has an infection. 
 157 
names and I believe people heard because it was in the 
evening and the calm of the night may have made us the only 
loud sound to be heard because in the morning some 
community members asked me what the commotion was all 
about.”  (Respondent 010, IDI) 
Then they could do their own things and the child 
could  mysteriously  become  ill  until  the  he  dies.” 
(Participant 005, FDG 2, Age 29, PE, Chikowi, 
Unemployed) 
 
 “You  also  need  to  keep  privacy  for  yourself  because,  even  if  
you inform your relatives, there are other relatives who do 
not know how to keep your confidentiality. They will inform 
another person, another person will inform another person. 
Then the story will have grown. When we get tested as we are 
doing, they scorn us. They feel that as you are taking the 
treatment,  you  are  done.”  (Participant 002, FDG 2, Age 40, 
PE, Thabwani, Unemployed) 
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5.4.2.8 Participants’  worries  about  administering daily CPT 
Most participants indicated that they did not have concerns about administering CPT to 
their children. However, the most cited worry raised by some was the burden of 
continuously giving the child medication and the possibility of inviting side effects from 
the medication.  Here, mothers were worried about side effects of CPT to their babies. 
 
 “Usually  it   is   feeling  sorry  for   the  child  that  he  has  to  endure  daily medication just 
because he was born from an infected mother but nothing big because I know the 
medication  has  been  given  by  doctors  who  know  their  trade.” (Respondent 004, IDI) 
 
“Since  he   is   young  and  he   is   taking  bactrim  daily,   I   sometimes   think   that this might 
affect  his  mental  capacity.” (Respondent 003, IDI) 
 
The other worry raised by one woman was that the baby might sero-convert later on. The 
other one feared that health problems might emerge to the baby in the future once CPT 
was discontinued.  
 
 “Sometimes   I   just   think  about   the  pros  and  cons  of  medication,   I   think   if   I   stop  
then problems will surface.”  (Respondent  002,  IDI) 
5.4.3 Paediatric CPT uptake theory proposition and factors associated with CPT 
adherence 
This study also aimed at providing   an   explanation   of   how  HIV   infected  women’s   lived  
experiences, attitudes and life circumstances impact on their behaviours towards 
administering CPT to their HIV exposed but not infected children. This has been 
explained using application of some of the concepts from the Health Belief Model and 
Ecological theory of perception. Furthermore a diagrammatic presentation that follows, 
explains how different factors narrated by women influence adherence to CPT in HIV 
exposed children. 
5.4.3.1 A theoretical explanation of paediatric CPT adherence 
The theory being proposed combines aspects of both the Health Belief Model as well as 
the ecological theory of perception: 
Understanding and acceptance of the present situation 
The practice of adherence to long-term treatment in HIV disease in young children is 
influenced by both internal and external factors.  It begins with the acceptance of the HIV 
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status by the mother and/or family during pregnancy and the value that the mother 
attaches to the life of her child coupled with her perceptions on severity of HIV, perceived 
susceptibility of the child to an HIV infection, perceived benefits of the interventions such 
as good health of the child, and perceived disincentives or barriers to uptake of the 
interventions like shortage of drugs.  
Taking appropriate action-steps 
In this phase, the understanding and acceptance of the situation prepares the mother to 
take appropriate actions to prevent HIV transmission to her newborn child.  During 
pregnancy, the mother conforms to antenatal care, and Prevention of mother to child 
transmission of HIV (PMTCT) interventions and discloses her status to significant family 
members who render their support throughout. The mother remains cautious on how far 
she could disclose her status for fear of negative influence through rebuke, stigma and 
discrimination. After the child is born, the mother remains determined to protect her 
newborn child from contracting HIV. Although the child remains at a higher risk of 
getting  infected  with  HIV  during  breastfeeding,  the  mother’s  self  determination  motivates  
her to take appropriate steps to ensure her child has access to preventive interventions. The 
mother sets out to obtain relevant information on available interventions and breaks 
boundaries of male domination in decision-making on health issues in order to access 
these interventions.  
The prevailing environment 
Family harmony, supportive family members and other forms of support, presence of 
reminders, adequate information, evident benefits from the intervention, trust in health 
care providers and rising above stigma and discrimination in HIV disease are some of the 
catalysts for determination to achieve better adherence to long-term treatments in young 
children (Figure 5.1). In contrast, lack of appropriate interventions like drugs and an 
inefficient health care system in general, lack of food, reminders and succumbing to 
stigma and discrimination are the factors fueling non-adherence to long-term interventions 
in children in resource-limited settings.  
5.4.3.2 Factors associated with CPT adherence in HIV exposed children 
Figure 5.1, illustrates how different factors work to influence adherence to CPT in HIV 
exposed children. Factors above the thick arrow leading to better adherence are obstacles 
to adherence. The presence of one or a combination of these factors deters these women 
from giving cotrimoxazole to their children. However, the arrows that point upwards 
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towards the thick arrow counteract this force and push the thick arrow along the double 
dotted arrow towards better adherence. The thick arrow moves downwards and upwards 
along the dotted double arrow between better and poor adherence depending on whether 
there are obstacles or promoters of adherence. For a sustained and better adherence, the 
thick arrow must remain in its current position. Improving  and  maintaining  the  ‘promoters  
of  adherence’  below  this  arrow  could  achieve  this. 
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Figure 5.1: Factors associated with adherence to cotrimoxazole prophylaxis in children 
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5.5 Discussion 
 
This study sought to unveil the lived experiences of HIV infected women participating in a 
large cohort study on the impact of administering daily CPT to their HIV exposed children. It 
further aimed at establishing how these experiences impact on their behaviours in relation to 
continued administration of CPT. Finally; it isolated factors that influence paediatric CPT 
adherence.  
 
The participation of women in the ‘cohort  study’  had an influence on the way the decisions 
about giving CPT were made at the household level. As much as men being heads of 
households are mostly viewed as decision makers on most matters including health, women in 
this study rose above this phenomenon and took the right decisions to have their children 
access PMTCT interventions most especially CPT. In addition, being in the cohort study 
enabled these women to have access to information on CPT and develop strategies to ensure 
adherence among their children.  The women depended on health workers for information 
about their children which empowered them to take appropriate decisions but also develop 
ways for compliance to interventions. Adequate information about the medication and on-
going interaction between caregivers and the health care providers also reminded caregivers 
to administer cotrimoxazole to their children. Although few studies have shown that provider-
patient-communication can improve the way communication is done during doctor-patient 
consultations and health and patient outcomes, there has been minimal and contradictory 
evidence on the effect of this communication on patient health care behaviour like adherence 
(Munro, 2007). Interestingly, this study shows that with good communication, women have 
access to adequate information about importance of the drug, its side effects and how it must 
be used. This information helps them to clear any misconceptions that might arise regarding 
the use of the drug and promotes trust between patients and providers. However, 
communication was not used in isolation to influence adherence because the women needed 
food, family support and the drugs themselves to ensure adherence. This concurs with a 
suggestion (Munro, 2007) that communication alone may not succeed in improving long-term 
adherence. 
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Only women participating in an on-going study were selected for the study due to time and 
financial constraints considering that if women from the community not participating in the 
on-going cohort study were to be recruited, it would have meant seeking ethical approvals and 
permissions from the local authorities all over again which would have required 
transportation from one place to the other and additional time. Those who were lost to follow 
up in the cohort study were not included in this study because they had either relocated to 
areas outside the study catchment area or had refused participation in the study. However, this 
must have been accounted for by how women were selected for this study. Inclusion of 
women at the beginning (2 months) of administering CPT would imply that some of the 
women who would eventually withdraw from participation during the course of the study 
participated in the qualitative study.  
 
Secondly, this study sought to develop a theoretical explanation from the concepts that 
emerged from the narratives and the literature as an important ingredient to foster 
understanding of the experiences of parents/guardians of children on long-term treatment in 
chronic diseases in resource limited settings. The concepts emerging from the women’s lived 
experiences show partial alignment to the ecological theory of perception and the Health 
Belief Model. The proposed theoretical explanation of CPT adherence therefore takes into 
account derivatives of the two theories.  From an ecological perspective, the women 
themselves, their families, the communities in which they lived and the health care system 
were separate territories which related and influenced each other through social interaction 
and passing of information across the territories. This social interaction and information 
sharing played a role in influencing actions either positively or negatively. Depending on the 
nature of these processes, some might have been motivators such as a supportive family that 
helped someone to take a positive action and some might have been deterrents whose negative 
remarks and actions inhibited other people to take appropriate actions. The data in this study 
demonstrated that despite negative influences that might have arisen at any level, the 
determination of the individual to take a health-related action and the realisation that the 
recommended action would prevent any negative outcomes motivated the women to believe 
that they could successfully do something to prevent any negative health outcome. The 
women in this study used all available alternatives to ensure the child did not miss his 
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medications. This feature is a strong indicator of the Health Belief Model in which an 
individual feels that a negative health condition can be avoided by taking the appropriate 
health action. 
 
Furthermore, the study has revealed many factors that influence CPT adherence in HIV 
exposed children in a semi-urban setting in southern Malawi (Figure 5.1). Lack of drugs at 
the health facility emerged as one of the reasons for non-adherence. This was attributed to 
inability by field workers to supply drugs to participants in their homes. In addition, informal 
conversations with most participants revealed that sharing of drugs between mothers and 
children due to stock outs in public health facilities (which were responsible for supplying 
CPT to the general population) contributed to lack of drugs for the child. This factor 
negatively affected adherence to CPT in children. The findings of a placebo-controlled study 
in Zambia, showed that despite high levels of adherence that were observed using objective as 
well as subjective adherence assessments, drops in adherence at certain time points were 
associated with running out of medications in between study visits (Walker, 2009). As cited 
by Shah A.C. this is one of the health care delivery related factors that influence adherence 
negatively (Shah, 2007). Issues of forgetfulness, inadequate information, travelling away 
from home and taking concomitant medications in the present study were also found to 
influence adherence negatively in the Zambian study (Walker, 2009). Gitta and others have 
also isolated travelling away from home and forgetfulness as some of the factors that 
influenced missing of cotrimoxazole prophylaxis in both HIV infected and HIV exposed 
children in Uganda (Gitta, 2007).  
 
Although many studies on long-term adherence in paediatric HIV disease have focused on 
adherence to ART, the factors that influence adherence are similar to those influencing 
cotrimoxazole adherence. One explanation is that in both, children depend on caregivers for 
their medications hence any factors associated with HIV that affect the caregiver, would 
likely affect adherence for both ART and cotrimoxazole prophylaxis. In this study, HIV 
disclosure  and  accepting  one’s  HIV  status  seemed  to  have  positive  influence on adherence in 
that women who accepted their status during pregnancy, took appropriate steps to prevent 
transmission of the virus to their children and would therefore adhere to cotrimoxazole for the 
benefit of their child irrespective of existing obstacles. Likewise, a study in Ethiopia in older 
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children, found that complete parental disclosure of HIV status to the child helped to motivate 
HIV infected children to adhere to their daily treatment regimes as they understood the 
infection and interpreted its implications thereby appreciated the importance of adherence 
(Biadgilign, 2008).   Improvement   in   child’s   health   status in Uganda fostered adherence to 
CPT among both infected and exposed children (Gitta, 2007). This was also the case in the 
present study where evident health benefits like sustained good health of the child motivated 
women to continue giving CPT to their children. 
 
Fear of stigma and discrimination as a factor that deterred women from uptake of PMTCT 
interventions such as CPT in this study corroborates the findings of a study in India where 
women were not able to disclose their status to some of their family members for fear of 
isolation (Paranthaman, 2009). This negatively impacted on adherence as some women opted 
not to give medications to their children in the presence of other family members 
(Paranthaman, 2009). In the present study, the majority of women were skeptical about 
disclosing their status but also letting others know that their child was taking daily CPT for 
fear of rebuke and discrimination.  
 
5.5.1 Possible limitations in interpretation of the study findings 
Several factors must be considered when interpreting the findings. The study took place in 
Zomba, a semi urban district largely among women with low education levels and low social 
economic status hence the results presented cannot be applied to women in urban areas with 
higher education levels as well as socio-economic status. Views other than these would have 
been elicited if the study included women of higher educational levels, socio-economic status 
and those residing in urban areas. This is regarded as an important constraint because the 
interpretation of events surrounding administering CPT to HIV exposed children may be 
related to educational level, socio-economic status as well as residing in urban areas where 
health facilities are more closely distributed and sources of information are many. In addition, 
understanding of instructions, perceptions of illness and cultural positions may be different 
between urban and semi-urban dwellers. 
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Although educational level and age of participants for both FGDs and IDIs were presented, 
responses were not categorised by either age or educational level. This could have been done 
by categorising responses into primary and secondary education but also into age categories 
of for example <25 years and >25 years.  This is an important limitation because adherence 
experiences may be different by age group as well as education category. Furthermore, the 
study population consisted of HIV infected women who were participating in a cohort study 
where they had access to information and their continued interaction with the study workers, 
might have influenced their behaviors regarding giving CPT to their children as well as their 
perception regarding PMTCT interventions in general. In addition their adherence to CPT 
might be related to the reasons for wanting to be in the PMTCT programme in the first place. 
These results therefore cannot be generalized to HIV infected women with HIV exposed but 
not infected children not participating in the study. Their being in the cohort study at the time 
of the interviews may limit generalization of the findings to women who withdrew from 
participation because their reasons for withdrawing might be related to uptake of CPT 
interventions. 
 
Additionally, since most of these women (in the cohort study) were recruited from the 
PMTCT clinics, they were willing to have their children initiate and complete PMTCT and 
aware of the importance of adhering to CPT hence the responses provided in this study might 
be related to their initial intentions and not necessary asa result of the experiences during the 
study. 
 
Although both IDIs and FGDs were conducted at a neutral venue away from the study clinic 
where these women regularly brought their children for clinical care, there is a possibility that 
the women knew what this study was looking for and this might have influenced their 
responses. In recognition of this, additional measures were followed to minimize such effects 
that included use of non-clinical staff to conduct the interviews.  
 
The study focused more on the patient and the emerging concepts were largely patient related. 
More information on healthcare provider and health facility related factors would have been 
solicited if interviews were done with health care providers and pharmacy records were 
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checked respectively. Lastly,  the  researcher’s  medical  background  might have influenced the 
direction of the research to focus more on patient related perspectives to adherence ignoring 
health providers and health facilities. 
5.5.2 Summary of Discussion 
The discussion of this chapter highlights the experiences with administering CPT to HIV 
exposed children and how these affect household dynamics and coping strategies. It also 
presents the theoretical explanation of different aspects of adherence and factors that 
influence adherence to CPT in HIV exposed children.  
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CHAPTER 6 : GENERAL DISCUSSION, RECOMMENDATIONS AND 
CONCLUSIONS  
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6.1 Introduction 
6.1.1 Summary of the findings 
 
The studies in this thesis show a more than 60% reduction in the incidence of uncomplicated 
malaria associated with the use of CPT with no evidence of increase in uncomplicated malaria 
after CPT was stopped.  HIV  infected  women’s  participation  in  the  cohort  study  empowered  
them to make better decisions for the health of their children and develop appropriate 
strategies for compliance. These findings are based on the three studies included in this thesis. 
A systematic review and a meta-analysis (chapter 3) reviewed the effect of cotrimoxazole 
prophylaxis on malaria and mortality in children living in sub-Saharan Africa, and showed a 
63% reduction in the risk of clinical malaria and 43% in all-cause mortality. Our subsequent 
prospective cohort study in Malawi showed a 65% reduction in the incidence of 
uncomplicated malaria (chapter four). There was no evidence of increase in the incidence of 
uncomplicated malaria after CPT was stopped (i.e. no rebound effect). Finally, a qualitative 
study explored the experiences of HIV infected mothers administering daily CPT to their 
HIVex children enrolled in the cohort study (chapter five). HIV infected women with HIVex 
but not infected children were motivated to continue administering CPT to their children 
because of the evident health benefits in their children.  
6.1.1.1 CPT is highly effective in preventing uncomplicated malaria, severe malaria and 
other comorbidities in children  
The 63% and 65% reduction in malaria incidence obtained from the meta-analysis and the 
cohort study respectively, is an indication that CPT provides effective chemo-prophylactic 
effect against malaria. Although highly heterogeneous, the findings of the review have 
important clinical implications. The review shows that CPT has a strong impact on preventing 
malaria despite widespread resistance to it (chapter 3). This has been supported by the 
findings of the cohort study (chapter 4) evaluating the effect of CPT on the incidence of 
uncomplicated and severe malaria. The overall incidence of uncomplicated malaria appeared 
higher in year 1 than in year 2 but multiple regression analysis on the effect of group showed 
a 65% lower risk in HIVex children in year 1 compared to their HIVun counterparts consistent 
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with previous findings of studies evaluating the effectiveness of CPT on malaria prevention 
(Sandison, 2011).  
6.1.1.2 Stopping CPT in HIV exposed children does not increase the risk of the incidence 
of uncomplicated malaria in HIV exposed children (malaria rebound effect) 
In contrast to previous observations showing an increase in the incidence of malaria after 
stopping malaria chemoprophylaxis (Greenwood et al., 1995), there was no evidence of 
malaria rebound effects in this study as the incidence was similar between the HIVex and 
HIVun group in year 2 after CPT had been stopped. This is one of the first studies to 
investigate malaria rebound after stopping CPT. However, this finding represents only 60% of 
the follow up time as the study is still on-going but significant changes after completion of the 
study are unlikely considering that a more recent RCT in Uganda did not also find any 
malaria rebound effects when CPT was extended for four years (Homsy, 2014).  
6.1.1.3 Evidence of increase in the incidence of severe malaria after stopping CPT in the 
HIV exposed group 
Surprisingly, an increase in the incidence of severe malaria was observed after stopping CPT 
in the HIVex group. Although not statistically significant and not expected considering the 
lack of rebound with uncomplicated malaria, it is not necessarily inconsistent with existing 
epidemiological data (Mockenhaupt, 2007). The decline in susceptibility to malaria infection 
during CPT may have resulted in enhanced risk of severe disease when the children were first 
exposed to malaria infection in year 2 after CPT had been stopped. Such a scenario is 
suggested to affect the rate of the disease adversely by delaying the average of first infection 
thereby reducing the enhancement of the immunity that may be necessary for the maintenance 
of immunity to severe malaria (Gupta, 1999). Moreover, the exposure to HIV in utero and 
during   the   breastfeeding   period   might   have   affected   development   of   the   infant’s   immune  
system resulting in immunological abnormalities and increased susceptibility to morbid 
events and hospitalisations as evidenced by a lack of significant decrease in all-cause sick 
visits and increase in the rate of hospital admissions in HIVex children after CPT was stopped.  
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6.1.1.4 Stopping CPT does not show real evidence on impact on all-cause mortality 
Although a meta-analysis on the effect of CPT on mortality in children was not possible due 
to small number of studies, an RCT in the systematic review demonstrated substantial 
reductions in mortality with the use of CPT (chapter 3). Surprisingly, the observational study 
(chapter 4) was not able to show protective effect of CPT on all-cause mortality. Although 
year 2 estimates were not statistically significant, they have important clinical implications 
and worth consideration in the clinical management of these children. 
6.1.1.5 Women’s  perceptions  on  administering  CPT  to  their  HIV  exposed  children   
The qualitative study revealed the impact of participating in the CPT programme and/or a 
research study on household parameters such as decision making as well as social support 
regarding administering daily CPT to HIV exposed children. In addition, both deterring and 
facilitating factors for continuing to administer CPT in HIV exposed children in southern 
Malawi were highlighted in this study. Although there is lack of evidence on the influence of 
home study follow-ups on uptake of long-term interventions for HIV exposed children, this 
study shows that the household visits acted as reminders for continued administration of CPT. 
In addition, the information HIV infected women received through the participation of their 
HIV exposed children in the cohort study empowered them to make appropriate decisions 
about the health of their children and develop strategies that they found helpful for the 
continued administration of CPT to their children. The improved health outcomes of their 
children further motivated them to continue with the available interventions for their children.  
6.1.1.6 Theoretical perspective   of   women’s  motivation   to   continue   administering   CPT   to  
their HIV exposed children 
The proposed theory outlines the interrelatedness of several processes that eventually 
influence paediatric CPT adherence in HIVex children. The key message is the influence of 
these processes on paediatric medication adherence. The women present a rare character 
where they rose above the boundaries of male-dominated household decision making on the 
health of their children in situations where the male partner seemed resistant to seek care for 
their children. The proposed theory amalgamates the experiences these women go through in 
their daily lives to present an understanding of how such processes can influence adherence to 
long term HIV associated medications such as CPT in HIVex children. 
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6.2 Recommendations  
6.2.1 General Recommendations 
As the increase in the number of HIV infected pregnant women having access to improved 
PMTCT interventions results in fewer new HIV infections in infants born to these women, the 
need for appropriate services and improved delivery of the same for HIV exposed children 
cannot be ignored.  The increase in the number of HIV exposed children is a call to strengthen 
the capacity of health facilities to provide quality and long term services for this population 
while taking into consideration the effects of such services. Since HIVex children are more 
susceptible to childhood illnesses compared to HIVun children due to their nature of being 
HIV exposed (Slogrove, 2010, Hygino, 2008, Mussi-Pinhata, 2007), overall child survival 
should continue to be a priority. One of the key interventions that require special attention is 
the use of CPT for the prevention of HIV opportunistic infections. In addition, gaining a 
deeper understanding of the impact of this intervention on the children and their families is 
crucial to providing better care. Surveillance for adverse events in these infants as well as 
more robust systems to capture consequences resulting from interruption of these 
interventions are a priority to fully understand the outcomes of this intervention and thereby 
develop effective strategies to prevent any health risks resulting from such. This is 
particularly important in poor resource settings where parasitic infections, malnutrition and 
other comorbidities are more common and in which monitoring capacity is limited.  Table 6.1 
contains a list of summarized recommendations.  
Table 6.1: Key Messages and summary of recommendations 
 CPT remains an effective intervention for HIV exposed children for both general morbidity as 
well as malaria and is an important programme that needs to be strengthened and scaled up 
through:  
o Maintenance of CPT stocks in all health facilities,  
o Continued counselling for HIV infected women with young children to promote 
uptake,  
o Involvement of spouses and significant family members for social support.  
 Stopping CPT at 12 months after cessation of breastfeeding and confirmation of a negative 
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HIV test is safe, as it does not increase the risk of the incidence of uncomplicated malaria as 
previously postulated implying that HIV exposed can stop CPT without increasing their risk 
of malaria.  
 Participation in PMTCT programmes empowers the women to develop useful strategies that 
promote positive heath outcomes in their children. The following are recommended: 
o Strengthening of available support groups of HIV infected women to promote 
information sharing and peer motivation 
On-going counselling to promote positive health behaviour 
 
 
6.2.2 Future Research  
The non-significant evidence of a rise in the incidence of uncomplicated malaria and other 
outcomes observed in year 2 in the cohort study raises a number of questions such as whether 
the cessation of CPT is a contributing factor for this increase or is it a consequence of 
immunological challenges associated with exposure to HIV in utero as well as during 
breastfeeding. Since the present study was not designed to investigate these factors, future 
studies should focus on assessing whether long term and sustained use of CPT interrupts 
acquisition of natural immunity to malaria and whether duration of breastfeeding and 
nutritional status have any role in the findings observed in this study.  
The systematic review and meta-analysis presented in this thesis are the first to assess the 
effect of cotrimoxazole on the prevention of malaria in children in sub-Saharan Africa. Since 
it mainly focused on children, future research should investigate whether the effect is the 
same in adults and HIV infected pregnant women. More evidence on HIV uninfected 
populations is needed in order to answer the question whether cotrimoxazole should become 
an option in the control of malaria among the general population in sub-Saharan Africa. 
More field research is required to test the proposed theoretical explanation of CPT adherence 
in HIV exposed children in order to prove it scientifically. More research on measuring 
adherence in this population must also involve healthcare providers and review of pharmacy 
records in order to understand concepts that affect adherence from these perspectives. 
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Additionally, quantitative research methods would help establish associations and isolate the 
factors that are significantly related to adherence.  
6.3 Limitations 
The general limitations for this project included the use of restricted dataset, which included 
all of the first year follow-up but only about 60% of the second year follow-up, which was 
still ongoing by the time the thesis had to be submitted. It is unknown at this point whether 
this will have implications for the interpretation of the findings for this study. For example, if 
the effect estimates themselves remain similar, the potential increase in severe malaria 
observed in this preliminary analysis may become statistically significant when the full study 
is completed. In addition, the limited funding that was available for the study limited 
inclusion of other groups of women in the qualitative study like those who did not participate 
in the cohort study and those who were lost to follow up thereby limiting generalization of the 
study findings.  
 
6.4 Conclusions  
This being the first known study to review the malaria protective efficacy of CPT in children 
in SSA, investigate malaria rebound effects following cessation of CPT in HIVex children and 
also the first one to explore experiences of HIV infected mothers administering CPT to their 
HIV uninfected children, it contributes a large body of knowledge to the limited data on the 
pooled effect of CPT on malaria but also provides cutting edge information on the effect of 
stopping CPT in HIV exposed children after cessation of breastfeeding and determination of 
their HIV status. Furthermore, it provides a narrative of the experiences of administering a 
long-term treatment to children who are  presumably  “healthy”.  This  knowledge  gap  could  be  
a possible reason for unavailability of guidelines in Malawi and elsewhere on the 
management of these children when they are taking CPT and after they have stopped. Given 
this reality, the findings of this study may contribute to the debate on the possible 
interventions suitable for these children. Despite the highly heterogenous estimates observed 
from the meta-analysis, the findings obtained in both studies (meta-analysis and cohort 
studies) have important clinical implications. Finally, HIV infected women benefit from 
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regular contacts with health professionals from which they obtain information that guides 
their decisions about the health of their children. 
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Appendix 2: Data Extraction form for Systematic review and meta-analysis 
 
In HIV infected and exposed children, does cotrimoxazole prophylaxis reduce malaria 
incidence and mortality compared to children not receiving cotrimoxazole?: 
A Systematic Review and Meta-Analysis 
Article Title:  
 
 
 
First Author: 
 
Data Extracted by: 
 
Journal:  Date Completed: 
Year of Publication: Calendar time study was conducted: 
Author contacted:   
 Yes (date) ___________________ 
 No 
 Responded (date)______________ 
Email: 
Study Design: 
Observational Study  
Randomized Controlled Trial  
 
Country: 
Final Status:  
 Included 
 Excluded (reasons): 
 
STUDY CHARACTERISTICS 
Characteristic Response 
Yes   No 
Type of Publication  
 
 
 
 
 
 
 
 
 
 
 
 
Journal Paper 
Dissertation 
Unpublished paper 
Other 
Study Setting  
 
 
 
 
 
 
 
Urban 
Rural 
Not Able to tell 
Institution Please tick Please tick 
 
Teaching Hospital 
Health Centre 
PMTCT Program 
Referral Hospital 
District/provincial hospital 
Research Institution 
Community 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
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Other Specify  
______________________ 
 
______________________ 
No of participants 
 Cotrimoxazole Group No cotrimoxazole group 
 
 
(insert number here) 
 Not able to tell 
(insert number here) 
 Not able to tell 
Sex 
Males 
Females 
Not Able to tell 
 
 
 
 
 
 
 
 
Age  
 
 
 
 
 
 
 
 
 
 
 
 
 
Age 
Median Age 
Mean Age 
Age Range 
IQR 
 
Not Able to tell 
HIV Status  
 
 
 
 
 
 
 
 
 
HIV Infected 
HIV exposed 
HIV Negative 
Not Able to tell 
Follow Up Period   
Overall 
Mean 
Median 
Range 
IQR 
Not Able to tell 
 
 
 
 
 
 
 
 
 
 
Treatment dosage and 
duration 
Cotrimoxazole: 
 
Placebo/comparison 
treatment: 
 
 
Other malaria interventions  Insecticide Bed Nets 
 Impregnated curtains 
 Intermittent preventive 
treatment in infants (IPTi) 
 Indoor Residual Spraying 
(IRS) 
 Other chemoprophylaxis 
 Not able to tell 
 Insecticide Bed Nets 
 Impregnated curtains 
 Intermittent preventive 
treatment in infants (IPTi) 
 Indoor Residual Spraying 
(IRS) 
 Other chemoprophylaxis 
 Not able to tell 
Use of Antiretroviral 
Treatment 
Yes 
 No 
 Not able to tell 
Yes 
 No 
 Not able to tell 
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Study Outcomes Cotrimoxazole Group 
 
 
 
 
 
No Cotrimoxazole 
 
 
 
 
 
Malaria 
Number of Events 
Overall Incidence 
Unadjusted IRR (95% CI) 
 
Adjusted IRR (95% CI) 
Mortality  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Number of Events 
Overall Incidence 
Unadjusted HR (95% CI) 
Adjusted HR (95% CI) 
 
No adjusted analysis 
performed 
Confounding factors   
 (tick all that apply) 
 age 
 sex 
 HIV status 
 Breastfeeding 
 Living in urban vs. rural 
areas 
 use of mosquito net 
 use of other antimalarial 
chemoprophylaxis 
Previous episode of 
malaria 
 other confounders 
List:  
 no adjusted analyses 
performed 
 
(tick all that apply) 
 age 
 sex 
 HIV status 
 Breastfeeding 
 Living in urban vs. rural 
areas 
 use of mosquito net 
 use of other antimalarial 
chemoprophylaxis 
Previous episode of 
malaria 
 other confounders 
List:  
 no adjusted analyses 
performed 
 
Prevalence of dhps and dhfr 
gene mutations  
Mutant Gene: 
 
 
 
 
 
 
 Not reported 
Prevalence 
 
 
 
 
 
 
 Not reported 
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Appendix 3: Enrollment Case Report Form (Visit 1) 
 
Malaria rebound in HIV exposed children after stopping cotrimoxazole prophylaxis 
        
Form Completed by   (Initials)  
Client Initials    (Initials)  
Date Completed   /  /  (dd/mm/yy)  
Type of Client    1=HIV exposed, 2=non-HIV exposed  
 
LAB INVESTIGATIONS (before history taking, collect blood samples and send for 
processing)          
 
Finger prick for malaria smear 1=Yes, 2=No     Filter paper 1=Yes, 2=No, Hb 1=Yes, 
2=No    
   
DEMOGRAPHIC DATA 
1. Date of birth  /  / (dd/mm/yy)  (DO NOT LEAVE BLANK)  
2. Is birth weight available from the health passport?         1=Yes, 2=No                 
If available, record .  kgs 
3. Sex     1=Male 2=Female     
4. Ethnic origin  1=lomwe, 2= Yao,   3=   Chewa,   4=Sena,   5=Mang’anja,6=Tumbuka,7=  
Ngoni , 
                      8=Unknown,   9= other specify_____ 
5. Religion  1=Catholic, 2= Moslem, 3=Prot Major, 4=Prot Adventist, 5= Pentecostal                       
                   6=unknown, 7=other, specify 
6. Age of mother (years)      
Is it Estimated or Actual  1= Estimated, 2= Actual  
7. Education:Mother   1=No formal Education, 2=primary, go to primary, 3=secondary, go  
 to sec  4= tertiary  
If Primary  1= Able to read and write, 2= Not able to read and write 
If Secondary  1=Form 1, 2=Form 2, 3=Form 3, 4=Form 4    
8.  Job Mother  1=employed, 2=not not employed   
     If employed specify: 1=Yes, 2=No, self employed 1=Yes, 2=No, white 
collar job 1=Yes, 2=No,   Farming 1=Yes , 2=No, part time piece works 
 1=Yes, 2=No, Driver 1=Yes, 2=No, Domestic 1=Yes, 2=No, Other 
 job specify___________________ 
9. Marital Status  1= married, 2=widowed, 3=Divorced, 4=Separated, 5=Not married, If 
not married, SKIP TO QUESTION 12 
If married,  1= Partner alive, 2=Cohabiting with partner,   
10. Job Father  1=employed, 2=not not employed  
If yes, employed specify: self employed 1=Yes, 20=No, white collar job  1=Yes, 
  2=No, Farming  1=Yes, 2=No, part time piece works 1=Yes, 2=No, Driver   
1=Yes, 2=No   Domestic, Other job specified________________  
11. Education Father:   1=No formal Education  2=primary, go to primary, 3= secondary,  
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       go to sec , 4=tertiary  
If Primary  1= Able to read and write, 2= Not able to read and write  
If Secondary  1=Form 1, 2=Form 2, 3=Form 3, 4=Form 4  
12. Does the family have the following? Cattle  1=Yes, 2=No, bicycle  1=Yes, 2=No, 
TV 
          1=Yes, 2=No, Radio/CD 1=Yes, 2=No, Land  1=Yes, 2=No, car/motorbike  
             1=Yes, 2=No  
13. Number of siblings:  Alive      Dead (only same mother and father) 
 
HOUSEHOLD CHARACTERISTICS 
14. Use of Electricity 1=Yes, 2= No      
 (For questions 15 & 16, tick all that apply) 
15. Water Source                    
   tap  1=Yes, 2=No  
Borehole     1=Yes, 2=No  
Stream        1=Yes, 2=No  
Well           1=Yes, 2=No  
Other specify_____________________________________  
16. Dwelling roof type    
Iron sheets 1=Yes, 2=No 
  Grass thatched        1=Yes, 2=No  
Tiles            1=Yes, 2=No  
Not known   1=Yes, 2=No 
 
 MOTHER’SHEALTH  STATUS           
17.  Is the mother on any long term treatment  1=Yes, 2= No   if no, go to Q19 
If yes   (tick ALL that apply)  
      ART 1=Yes, 2=No   TB treatment 1=Yes, 2=No   Cotrimoxazole 
prophylaxis 1=Yes, 2=No     Vincristine 1=Yes, 2=No   Antihypertensives 
1=Yes, 2=No      ant asthmatics 1=Yes, 2=No, ant-epileptics , 1=Yes, 2=No   ant 
fungal ,1=Yes, 2=No   diabetes drugs  1=Yes, 2=No Other Specify 
______________________  
(For questions 18 & 19, check in health passport or mothers HIV care records)                                            
18. Is the CD4 Count of mother available  1=Available, 2=not available 
If available, record   /mm3        Date / /  (dd/mm/yy) 
19. Is the Viral Load of Mother available  1=Available, 2=not available 
If the Viral Load available is it detectable?   1= Detectable, 2=Not Detectable 
If detectable, record  copies/ml Date / /
(dd/mm/yy) 
 
 MALARIA CONTROL MEASURES  
20. How many mosquito nets are in use in the home  1=0,  2=≥1, if 0, SKIP TO Q25 
21. Are the nets treated with insecticide  1=yes, 2=no  
22. When did you last treat the nets  1= Last month, 2=Two months, 3=6 months, 4=Not  
       Remember. 
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23. How often do you treat mosquito nets  1= never, 2=0nce a year, 3=once in 6 months, 
4=not known.  
24. Did child sleep under a mosquito net last night?  1=Yes, 2=No  (No, go to Q25) 
If yes; is net treated with insecticide?  1=Yes, 2=No, 3=Not known    
If no, specify reason (tick ALL that apply) 
Forgot 1=Yes, 2=No, Allergic to ITN 1=Yes, 2=No, did not sleep at home 
1=Yes, 2=No, was used by others 1=Yes, 2=No, other specify 
_____________________ 
25. Do you use any of the following malaria control measures (tick ALL that apply) 
Indoor Residual Spraying (IRS)  1=Yes, 2=No 
Coils         1=Yes, 2=No  
Body repellents    1=Yes, 2=No  
       Sprays e.g. Doom             1=Yes, 2=No  
Traditional medication     1=Yes, 2=No       
None         1=Yes, 2=No       
                                 Others specify __________________                                              
26. When you suspect that your child has malaria, what action do you take? (Tick ALL that 
       apply)                                                        
Go to the hospital 1=Yes, 2=No,    Buy medication from pharmacy/shops 1=Yes, 
 2=No, Do tepid sponging 1=Yes, 2=No, Traditional medication 1=Yes, 2=No, 
 
PREVIOUS MEDICAL HISTORY 
(Use  child’s  health  passport  if  available)   
27. Has child suffered any febrile illness before? 1=Yes, 2=No 
28. Has child been admitted before?  1=Yes, 2=No, IF NO, SKIP TO QUESTION 29 
If yes, How many times has child been admitted?   Time/s (indicate number in box) 
Please give details of the last two admissions below: 
Previous Admissions 1 1=Yes, 2=No  If   ‘yes’   Specify   date / /  
(dd/mm/yy)  If  ‘yes’  Specify  diagnosis      ____________   
       Previous Admissions 2 1=Yes, 2=No  If   ‘yes’   Specify   date:  /  / 
 (dd/mm/yy) If  ‘yes’  Specify  diagnosis  ________________   
29. Is child currently on Antibiotics Yes, 2= No, IF NO, SKIP TO QUESTION 30 
If yes specify name:        start date                             Duration  
    Amoxycillin                    /  /  (dd/mm/yy) days  
Erythromycin                  /  /  (dd/mm/yy) days  
Augmentin                      /  /  (dd/mm/yy) days  
Cholramphenicol            /  /  (dd/mm/yy) days  
Ceftriaxone                     /  /  (dd/mm/yy) days  
Gentamycin                    /  /  (dd/mm/yy) days  
Benzyl Penicillin            /  /  (dd/mm/yy) days  
Other Specify __________________                    
30. Is the child currently on malaria treatment?  1=yes, 2=no, IF NO, SKIP TO  
Section G 
If yes, specify type:    Date  prescribed  duration in days  
       Artemether Lumafantrine (AL)   /  /  (dd/mm/yy) days  
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    Sulphadoxine Pyrimethamine(SP)  /  /  (dd/mm/yy) days  
                               Quinine Sulphate  /  /  (dd/mm/yy) days  
                      Traditional medication  /  /  (dd/mm/yy) days 
   Other specify_______________________________________________ ___    
  
CURRENT MEDICAL STATUS 
31. Is your child having any complaints?             IF NO, SKIP TO QUESTION 32 
Fever       1= Yes, 2=No.   If  ‘yes’,  duration    days  
Cough        1=Yes 2=No.  If  ‘yes’,  duration    days  
Vomit        1=Yes, 2= No.  If  ‘yes’,  duration    days  
Diarrhoea   1=Yes, 2=No.  If  ‘yes’,  duration    days 
Rash           1=Yes 2=No       If  ‘yes’,  duration    days  
Other specify __________________________________________________           
32. Is child having any of the following?        IF NO, SKIP TO QUESTION 33 
Bloody stool     1=Yes, 2=No    
Bloody urine     1=Yes, 2=No    
Jaundice history     1=Yes, 2=No    
Respiratory distress    1=Yes, 2=No             
Coma         1=Yes, 2=No   
Convulsing          1=Yes, 2=No  
 
CLINICAL EXAMINATION 
33. Anthropometric measurements 
Weight .   kg length .   cm   MUAC .   cm           
 
34. Vital signs 
Pulse rate    beats/min  
Temperature   .   ºC     
Respiratory rate           /min   
 
35. Other Signs 
a) Chest signs       1=Yes, 2= No (If no, go to b) 
If yes, specify               (tick ALL that apply) 
Chest recessions  1=Yes , 2=No 
Crepitations          1=Yes, 2=No    
Tachypnea            1=Yes, 2=No     
Hyperinflation     1=Yes, 2=No  
Wheezing      1=Yes, 2=No    
b) Oedema   1=Yes, 2= No.     .  
c) Lymphadenopathy  1=yes, 2=no, If no, go to (d) 
If yes,   1=Regional, 2=General 
d) Pallor:    Conjunctival  1=present, 2= absent, if no, go to (e) 
If Conjunctival= present,  1=Mild/moderate, 2= Severe 
e) Dehydration   1=yes, 2= no, if no, go to (f)    
If yes    1=Mild, 2= Moderate, 3= Severe,   
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f) Spleen     cm  
g) Liver    cm      
h) ENT/mouth abnormal    1=Yes, 2= No.        If  yes, specify : Thrush  1=yes, 2= No 
sores  1=yes, 2=No                  If other, please specify   ________________________ 
i) Jaundice?                 1=Yes, 2=No 
 
LAB INVESTIGATIONS : Please complete visit 1 laboratory form  
Hb .  g/dl 
Malaria slide  1=positive, 2= negative  
If positive, severity  1=1+, 2=2+, 3=3+, 4=4+                   
 
J.  DIAGNOSIS  
    35) a)  Presenting diagnosis 1             code and Specify   ___  
     b) Presenting diagnosis 2             code and Specify   ___  
      K. TREATMENT 
Anti-malarials given?  1=Yes, 2=No 
Antibiotics given?         1=Yes, 2=No 
CPT        1=Yes, 2=No  
Other drugs given?      1=Yes, 2=No  
Drug details of anti-malarials, antibiotics and other drugs given 
Drug Dose (mgs/tablets) & 
frequency 
Duration (days) 
   
   
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix 4: Community Follow up Case Report Forms  (Visits 2-11) 
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Form Completed by   (Initials)  
Date Form Completed  /  /  (dd/mm/yy)  
Client Initials    (Initials)  
Type of Visit     1=Visit 2,2= Visit 3,3=Visit 4,4=Visit 5, 5=Visit 7, 6=Visit 8, 
7=Visit  
                                           9, 8=Visit 10, Visit 11. 
Type of Client    1=HIV exposed, 2=non-HIV exposed  
If the subject is HIV exposed go to Section A, if non-HIV exposed go to SECTION B  
   
SECTION A: HIV Exposed 
 
MOTHER’S  HEALTH  STATUS 
1. Is the mother alive?  1=Yes, 2=No If yes GO TO QUESTION 2       
If No, Did death occur since last visit?  1=Yes, 2=No     
If yes, indicate date:  / /  and SKIP TO QUESTION 4 
2. Is the mother on any long-term treatment?  1=Yes, 2=No    if no, SKIP TO QUESTION 
3   If yes   (tick ALL that apply)     
ART   1=Yes, 2=No, TB treatment 1=Yes, 2=No, Cotrimoxazole prophylaxis 
1=yes, 2=No, Vincristine 1=Yes, 2=No, Antihypertensives 1=Yes, 2=No, ant 
asthmatics 1=Yes, 2=No, ant-epileptics 1=Yes, 2=No, ant fungals 1=Yes, 
2=No diabetes drugs 1=Yes, 2=No, Other Specify ____________ 
 
MALARIA CONTROL MEASURES  
3. How many mosquito nets are in the home since last visit  1=0,  2=≥1. If answer is 0, 
GO TO Q5 
4. Did child sleep under a mosquito net last night?  1=Yes, 2=no  (No, go to Q4b) 
 If yes; is net treated with insecticide?  1=Yes, 2=No, 3=Not known   
If no, specify reason    (tick ALL that applies) 
Forgot                              1=Yes, 2=no   
Allergic to ITN                1=Yes, 2=no   
Did not sleep at home        1=Yes, 2=no   
Was used by others                   1=Yes, 2=no   
Other specify __________________________________ 
5. Do you use any of the following malaria control measures (tick ALL that apply) 
Indoor Residual Spraying (IRS)  1=Yes, 2=No 
Coils         1=Yes, 2=No  
Body repellents    1=Yes, 2=No  
       Sprays e.g. Doom           1=Yes, 2=No  
Traditional medication     1=Yes, 2=No       
None         1=Yes, 2=No       
                                 Others specify __________________                                              
6. When you suspect that your child has malaria, what action do you take? (Tick ALL that  
     apply)                                                        
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Go to the hospital 1=Yes, 2=No,    Buy medication from pharmacy/shops 
1=Yes,2=No, Do tepid sponging 1=Yes, 2=No, Traditional medication 1=Yes, 
2=No, 
 
CHILD’S  MEDICAL  &  NUTRITIONAL  HISTORY 
7. Is the child still breastfeeding?  1=Yes, 2=No 
If no, when did child stop breastfeeding / /  (dd/mm/yy)  
Estimate duration of breast-feeding, or time since stopped? in weeks     
(Not relevant if have date stopped)                             
Specify reasons for stopping breastfeeding    (tick ALL that apply) 
 Child stopped  1Yes, 2=No, Child has mouth sores 1=Yes, 2=No, Started 
formula 1=Yes, 2=No, Mother busy 1=Yes, 2=No, Fear of stigma & 
discrimination 1=Yes, 2=No, Stopped cotrimoxazole  1=Yes, 2=No, Mother sick 
 1=Yes, 2=No Mother died  1=Yes, 2=No 
Specify other reasons for stopping breast-feeding _________________________ 
 8. Is child taking added feeds  1=Yes, 2=No 
      If yes name type of feeds: 
Plain Porridge  1=yes, 2=No, Fortified Porridge  1=yes, 2=No,  Formula milk 
 1=yes, 2=No,  Any other Milk  1=yes, 2=No,  Normal Diet  1=yes, 
2=No, Other Specify __________________________   
9. Is child taking cotrimoxazole prophylaxis  1=Yes, 2=No  (if yes GO TO Q10 –  IF no 
continue) 
If no, specify reason (tick ALL that apply) 
                Child refuses 1=Yes, 2=No, forgot 1=Yes, 2=No,  Side effects  1=Yes,     
                2=No, fear of stigma & discrimination  1=Yes, 2=No, Cot out of stock  1=Yes,  
                2=No, tired of giving child medication  1=Yes, 2=No, Child stopped 
breastfeeding,  
                Specify other reasons for not taking cotrimoxazole _____________ 
10. Have you visited another health facility since last study contact?  1=Yes, 2=No 
 If yes, indicate date / /  specify the diagnosis_______________ 
11. Was child admitted during this time?   1=Yes, 2=No  
12. Were any laboratory tests done on your child?  1=Yes, 2=No 
If   yes, specify    MPs  1=Yes, 2=No Hb  1=Yes, 2=No Full Blood Count  1=Yes, 
2=No 
         Urine  1=Yes, 2=No 
        Malaria results      1=Positive, 2= Negative 
        Other laboratory test done ___________________________     
13. What treatment did your child receive? 
Anti-malarials given?  1=Yes, 2=No,  1=Yes, 2=No if yes which one? 
Artemether Lumafantrine (AL)  1=Yes, 2=No    Sulphadoxine Pyrimethamine 
 (SP) 1=Yes, 2=No Quinine   Sulphate  1=Yes, 2=No      Amodiaquine  
Artesunate 1=Yes, 2=No 
14. Antibiotics given? 1=Yes, 2=No, if yes tick that apply 
            Amoxycillin      1=Yes, 2=No Chloramphenicol     1=Yes, 2=No    
          Erythromycin     1=Yes, 2=No           Augmentin     1=Yes, 2=No 
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            Ceftriaxone      1=Yes, 2=No   Benzyl Penicillin   1=Yes, 2=No  
            Gentamycin      1=Yes, 2=No                    
Other drugs given?      1=Yes, 2=No                   if yes specify drug details 
Drug details of other drugs given 
Drug Dose (mgs/tablets) & 
frequency 
Duration (days) 
   
   
   
   
15. Is child currently sick?  1=Yes, 2=No                    
If yes, advise to take the child to study clinic 
16. Anthropometric measurements 
Weight  .  Kg        length .  Cm  MUAC   cm   
 
SECTION B: NON-HIV EXPOSED 
 
MOTHER’S  HEALTH  STATUS 
1. Is the mother alive?  1=Yes, 2=No If yes GO TO QUESTION 16       
If No, Did death occur since last visit?  1=Yes, 2=No     
If yes, indicate date:  / /  and SKIP TO QUESTION 17 
2. Is the mother on any long-term treatment?  1=Yes, 2=No    if no, SKIP TO QUESTION 3   
If yes   (tick ALL that apply) 
 TB treatment 1=Yes, 2=No, Antihypertensives  1=Yes, 2=No, anti asthmatics 
1=Yes, 2=No, anti-epileptics  1=Yes, 2=No, ant fungals 1=Yes, 2=No, 
diabetes drugs  1=Yes, 2=No.   Other Specify _____ 
 
MALARIA CONTROL MEASURE 
3. How many mosquito nets are in the home since last visit  1=0,  2=≥1, If answer is 0,  
GO TO Q19 
4. Did child sleep under a mosquito net last night?   1=Yes, 2=no  (No, go to Q2b) 
If yes; is net treated with insecticide?         1=Yes, 2=No, 3=Not known  
If no, specify reason    (tick ALL that applies) 
Forgot                      
Allergic to ITN                  
Did not sleep at home         
Was used by others                    
Other specify _____________________________ 
5.  Since the last visit have you used any of the following malaria control measures (tick ALL 
that apply) 
Indoor Residual Spraying (IRS)  1=Yes, 2=No 
 Coils           1=Yes, 2=No 
  Body repellents       1=Yes, 2=No 
  Sprays e.g. Doom     1=Yes, 2=No  
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  Traditional medication   1=Yes, 2=No 
None                1=Yes, 2=No  
Others specify __________________                                                                                                                                                                                                                                                               
6. When you suspect that your child has malaria, what action do you take? (Tick ALL that 
apply)                                                        
Go to the hospital 1=Yes, 2=No,    Buy medication from pharmacy/shops 1=Yes, 
 2=No, Do tepid sponging 1=Yes, 2=No, Traditional medication 1=Yes, 2=No, 
 
CHILD’S  MEDICAL  &  NUTRITIONAL    HISTORY 
7. Is the child still breastfeeding?  1=Yes, 2=No 
If no, when did child stop breastfeeding / /  (dd/mm/yy) 
Estimate duration in weeks    
(Not relevant if have date stopped)                               
Specify reasons for stopping breastfeeding    (tick ALL that apply) 
Child stopped  1=Yes, 2=No, Child has mouth sores  1=Yes, 2=No, Started 
formula  1=Yes, 2=No, Mother busy 1=Yes, 2=No, Mother sick 1=Yes, 
2=No, Mother died 1=Yes, 2=No  
Specify other reasons for stopping breast-feeding _______________________ 
8. Is child taking added feeds  1=Yes, 2=No 
If yes name types of feeds 
Plain Porridge  1=Yes, 2=No, Fortified Porridge  1=Yes, 2=No, Formula milk 
 1=Yes, 2=No, Any other Milk 1=Yes, 2=No, Normal Diet  1=Yes, 2=No 
Other Specify _______________   
9. Have you visited another health facility since last study contact?  1=Yes, 2=No 
 If yes, indicate date / /  specify the diagnosis _____________  
10. Was child admitted during this time? 1=Yes, 2= No 
11. Were any laboratory tests done on your child?  1=Yes, 2=No 
If   yes, specify  1= MPs, 2= Hb, 3= Full Blood Count, 4= Urine  
Malaria test result 1=positive, 2=negative 
  Other laboratory test done ___________________________     
12. What treatment did your child receive? 
  Anti-malarials given?       1=Yes, 2=No, if yes tick that apply  
Artemether Lumafantrine (AL)  1=Yes, 2=No,    Sulphadoxine Pyrimethamine (SP) 
1=Yes, 2=No, Quinine   Sulphate   1=Yes, 2=No,     Amodiaquine Artesunate 1=Yes, 
2=No 
13. Antibiotics given?     1=Yes, 2=No if yes tick that apply 
            Amoxycillin     1=Yes, 2=No, Chloramphenicol  1=Yes, 2=No,       
         Erythromycin   1=Yes, 2=No,        Augmentin       1=Yes, 2=No,   
             Ceftriaxone    1=Yes, 2=No, Benzyl Penicillin    1=Yes, 2=No,   
         Gentamycin       1=Yes, 2=No     
Other drugs given?    1=Yes, 2=No if yes specify drug details 
Drug details of other drugs given 
Drug Dose (mgs/tablets) & 
frequency 
Duration (days) 
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14. Is child currently sick?  1=Yes, 2=No If yes, advise to take the child to study clinic 
15. Anthropometric Measurements 
Weight .  Kg            Length .  Cm  MUAC  cm    
 
SECTION C  
 
OUTCOME: Action taken  1 = Admission, 2 = Rx + extra FU, 3 = Rx +no FU, 4 = No 
action, 5= Completed  
Outcome  1= Continuing, 2= Study End, 3= Withdrawn, 4=Dead,   
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Appendix 5: Clinic follow up Case Report Form (visit 6 for HIV exposed children) 
 
Malaria rebound in HIV exposed children after stopping cotrimoxazole prophylaxis 
 
Form Completed by   (Initials)  
Date Form Completed  /  /  (dd/mm/yy)  
Client Initials    (Initials)  
Type of Visit     1=Visit 2,2= Visit 3,3=Visit 4,4=Visit 5, 5=Visit 7, 6=Visit 8, 
7=Visit  
                                           9, 8=Visit 10, Visit 11. 
Type of Client    1=HIV exposed, 2=non-HIV exposed  
If the subject is HIV exposed go to Section A, if non-HIV exposed go to SECTION B  
   
SECTION A: HIV Exposed 
 
MOTHER’S  HEALTH  STATUS 
1. Is the mother alive?  1=Yes, 2=No If yes GO TO QUESTION 2       
If No, Did death occur since last visit?  1=Yes, 2=No     
If yes, indicate date:  / /  and SKIP TO QUESTION 4 
2. Is the mother on any long-term treatment?  1=Yes, 2=No    if no, SKIP TO QUESTION 
3   If yes   (tick ALL that apply)     
ART   1=Yes, 2=No, TB treatment 1=Yes, 2=No, Cotrimoxazole prophylaxis 
1=yes, 2=No, Vincristine 1=Yes, 2=No, Antihypertensives 1=Yes, 2=No, ant 
asthmatics 1=Yes, 2=No, ant-epileptics 1=Yes, 2=No, ant fungals 1=Yes, 
2=No diabetes drugs 1=Yes, 2=No, Other Specify ____________ 
 
MALARIA CONTROL MEASURES  
3. How many mosquito nets are in the home since last visit  1=0,  2=≥1. If answer is 0, 
GO TO Q5 
4. Did child sleep under a mosquito net last night?  1=Yes, 2=no  (No, go to Q4b) 
 If yes; is net treated with insecticide?  1=Yes, 2=No, 3=Not known   
If no, specify reason    (tick ALL that applies) 
Forgot                                1=Yes, 2=no   
Allergic to ITN                1=Yes, 2=no   
Did not sleep at home        1=Yes, 2=no   
Was used by others                   1=Yes, 2=no   
Other specify __________________________________ 
5. Do you use any of the following malaria control measures (tick ALL that apply) 
Indoor Residual Spraying (IRS)  1=Yes, 2=No 
Coils         1=Yes, 2=No  
Body repellents    1=Yes, 2=No  
Sprays e.g. Doom            1=Yes, 2=No  
Traditional medication     1=Yes, 2=No       
None         1=Yes, 2=No       
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                                 Others specify __________________                                              
6. When you suspect that your child has malaria, what action do you take? (Tick ALL that 
apply)                                                        
Go to the hospital 1=Yes, 2=No,    Buy medication from pharmacy/shops 
1=Yes,2=No, Do tepid sponging 1=Yes, 2=No, Traditional medication 1=Yes, 
2=No, 
 
CHILD’S  MEDICAL  &  NUTRITIONAL  HISTORY 
7. Is the child still breastfeeding?  1=Yes, 2=No 
                   If no, when did child stop breastfeeding / /  (dd/mm/yy)  
       Estimate duration of breast-feeding, or time since stopped? in weeks     
         (Not relevant if have date stopped)                             
        Specify reasons for stopping breastfeeding    (tick ALL that apply) 
 Child stopped  1Yes, 2=No, Child has mouth sores 1=Yes, 2=No, Started 
formula 1=Yes, 2=No, Mother busy 1=Yes, 2=No, Fear of stigma & 
discrimination 1=Yes, 2=No, Stopped cotrimoxazole  1=Yes, 2=No, Mother sick 
 1=Yes, 2=No Mother died  1=Yes, 2=No 
            Specify other reasons for stopping breast-feeding _________________________ 
8. Is child taking added feeds  1=Yes, 2=No 
If yes name type of feeds: 
Plain Porridge  1=yes, 2=No, Fortified Porridge  1=yes, 2=No,  Formula milk 
 1=yes, 2=No,  Any other Milk  1=yes, 2=No,  Normal Diet  1=yes, 
2=No, Other Specify __________________________   
9. Is child taking cotrimoxazole prophylaxis  1=Yes, 2=No  (if yes GO TO Q10 – IF no 
continue) 
If no, specify reason (tick ALL that apply) 
                Child refuses 1=Yes, 2=No, forgot 1=Yes, 2=No,  Side effects  1=Yes,     
                2=No, fear of stigma & discrimination  1=Yes, 2=No, Cot out of stock  1=Yes,  
                2=No, tired of giving child medication  1=Yes, 2=No, Child stopped 
breastfeeding,  
                Specify other reasons for not taking cotrimoxazole _____________ 
10. Have you visited another health facility since last study contact?  1=Yes, 2=No 
 If yes, indicate date / /  specify the diagnosis_______________ 
11. Was child admitted during this time?   1=Yes, 2=No  
12. Were any laboratory tests done on your child?  1=Yes, 2=No 
If   yes, specify    MPs  1=Yes, 2=No Hb  1=Yes, 2=No Full Blood Count  1=Yes, 
2=No 
         Urine  1=Yes, 2=No 
Malaria results      1=Positive, 2= Negative 
Other laboratory test done ___________________________     
13. What treatment did your child receive? 
Anti-malarials given?  1=Yes, 2=No,  1=Yes, 2=No if yes which one? 
Artemether Lumafantrine (AL)  1=Yes, 2=No    Sulphadoxine Pyrimethamine 
 (SP) 1=Yes, 2=No Quinine   Sulphate  1=Yes, 2=No      Amodiaquine  
Artesunate 1=Yes, 2=No 
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Antibiotics given? 1=Yes, 2=No, if yes tick that apply 
            Amoxycillin      1=Yes, 2=No Chloramphenicol    1=Yes, 2=No    
          Erythromycin     1=Yes, 2=No           Augmentin    1=Yes, 2=No 
             Ceftriaxone     1=Yes, 2=No   Benzyl Penicillin  1=Yes, 2=No  
            Gentamycin      1=Yes, 2=No                    
Other drugs given?      1=Yes, 2=No                   if yes specify drug details 
Drug details of other drugs given 
Drug Dose (mgs/tablets) & 
frequency 
Duration (days) 
   
   
   
   
14. Anthropometric measurements 
Weight  .  Kg        length .  Cm  MUAC   cm   
 
15. HIV Testing 
Blood Sample for HIV PCR testing collected?  1=Yes, 2=No 
If No, Specify 
reasons:____________________________________________________________________
_____ 
HIV Rapid testing result  1=positive, 2=Negative 
 
16. Has mother been given Carbergoline?  1=Yes, 2=No 
If No, Specify reason:_________________________________________________________ 
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Appendix 6: Clinic follow up Case Report Form (visit 7 for HIV exposed children) 
 
Malaria rebound in HIV exposed children after stopping cotrimoxazole prophylaxis 
 
Form Completed by   (Initials)  
Date Form Completed  /  /  (dd/mm/yy)  
Client Initials    (Initials)  
Type of Visit     1=Visit 2,2= Visit 3,3=Visit 4,4=Visit 5, 5=Visit 7, 6=Visit 8, 
7=Visit  
                                           9, 8=Visit 10, Visit 11. 
Type of Client    1=HIV exposed, 2=non-HIV exposed  
If the subject is HIV exposed go to Section A, if non-HIV exposed go to SECTION B  
   
SECTION A: HIV Exposed 
 
MOTHER’S  HEALTH  STATUS 
1. Is the mother alive?  1=Yes, 2=No If yes GO TO QUESTION 2       
If No, Did death occur since last visit?  1=Yes, 2=No     
If yes, indicate date:  / /  and SKIP TO QUESTION 4 
2. Is the mother on any long-term treatment?  1=Yes, 2=No    if no, SKIP TO QUESTION 
3   If yes   (tick ALL that apply)     
ART   1=Yes, 2=No, TB treatment 1=Yes, 2=No, Cotrimoxazole prophylaxis 
1=yes, 2=No, Vincristine 1=Yes, 2=No, Antihypertensives 1=Yes, 2=No, ant 
asthmatics 1=Yes, 2=No, ant-epileptics 1=Yes, 2=No, ant fungals 1=Yes, 
2=No diabetes drugs 1=Yes, 2=No, Other Specify ____________ 
 
MALARIA CONTROL MEASURES  
3. How many mosquito nets are in the home since last visit  1=0,  2=≥1. If answer is 0, 
GO TO Q5 
4. Did child sleep under a mosquito net last night?  1=Yes, 2=no  (No, go to Q4b) 
 If yes; is net treated with insecticide?  1=Yes, 2=No, 3=Not known   
If no, specify reason    (tick ALL that applies) 
Forgot                              1=Yes, 2=no   
Allergic to ITN                1=Yes, 2=no   
Did not sleep at home        1=Yes, 2=no   
Was used by others                   1=Yes, 2=no   
Other specify __________________________________ 
5. Do you use any of the following malaria control measures (tick ALL that apply) 
Indoor Residual Spraying (IRS)  1=Yes, 2=No 
Coils         1=Yes, 2=No  
Body repellents    1=Yes, 2=No  
Sprays e.g. Doom            1=Yes, 2=No  
Traditional medication     1=Yes, 2=No       
None         1=Yes, 2=No       
                                 Others specify __________________                                              
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6. When you suspect that your child has malaria, what action do you take? (Tick ALL that 
apply)                                                        
Go to the hospital 1=Yes, 2=No,    Buy medication from pharmacy/shops 
1=Yes,2=No, Do tepid sponging 1=Yes, 2=No, Traditional medication 1=Yes, 
2=No, 
 
CHILD’S  MEDICAL  &  NUTRITIONAL  HISTORY 
7. Is the child still breastfeeding?  1=Yes, 2=No 
                   If no, when did child stop breastfeeding / /  (dd/mm/yy)  
 Estimate duration of breast-feeding, or time since stopped? in weeks     
         (Not relevant if have date stopped)                             
 Specify reasons for stopping breastfeeding    (tick ALL that apply) 
 Child stopped  1Yes, 2=No, Child has mouth sores 1=Yes, 2=No, Started 
formula  
  1=Yes, 2=No, Mother busy 1=Yes, 2=No, Fear of stigma & 
discrimination 
            1=Yes, 2=No, Stopped cotrimoxazole  1=Yes, 2=No, Mother sick  
1=Yes,  
                 2=No  Mother died  1=Yes, 2=No 
            Specify other reasons for stopping breast-feeding _________________________ 
8. Is child taking added feeds  1=Yes, 2=No 
If yes name type of feeds: 
Plain Porridge  1=yes, 2=No, Fortified Porridge  1=yes, 2=No,  Formula milk 
 1=yes, 2=No,  Any other Milk  1=yes, 2=No,  Normal Diet  1=yes, 
2=No, Other Specify __________________________   
9. Is child taking cotrimoxazole prophylaxis  1=Yes, 2=No  (if yes GO TO Q10 – IF no 
continue) 
If no, specify reason (tick ALL that apply) 
                Child refuses 1=Yes, 2=No, forgot 1=Yes, 2=No,  Side effects  1=Yes,     
                2=No, fear of stigma & discrimination  1=Yes, 2=No, Cot out of stock  1=Yes,  
                2=No, tired of giving child medication  1=Yes, 2=No, Child stopped 
breastfeeding,  
                Specify other reasons for not taking cotrimoxazole _____________ 
10. Have you visited another health facility since last study contact?  1=Yes, 2=No 
 If yes, indicate date / /  specify the diagnosis_______________ 
11. Was child admitted during this time?   1=Yes, 2=No  
12. Were any laboratory tests done on your child?  1=Yes, 2=No 
If   yes, specify    MPs  1=Yes, 2=No Hb  1=Yes, 2=No Full Blood Count  1=Yes, 
2=No  
         Urine  1=Yes, 2=No 
Malaria results      1=Positive, 2= Negative 
  Other laboratory test done ___________________________     
13. What treatment did your child receive? 
Anti-malarials given?  1=Yes, 2=No,  1=Yes, 2=No if yes which one? 
Artemether Lumafantrine (AL)  1=Yes, 2=No    Sulphadoxine Pyrimethamine 
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 (SP) 1=Yes, 2=No Quinine   Sulphate  1=Yes, 2=No      Amodiaquine  
Artesunate 1=Yes, 2=No 
Antibiotics given?       1=Yes, 2=No, if yes tick that apply 
            Amoxycillin      1=Yes, 2=No Chloramphenicol     1=Yes, 2=No    
          Erythromycin     1=Yes, 2=No           Augmentin     1=Yes, 2=No 
            Ceftriaxone      1=Yes, 2=No   Benzyl Penicillin  1=Yes, 2=No  
            Gentamycin     1=Yes, 2=No                    
Other drugs given?     1=Yes, 2=No                   if yes specify drug details 
Drug details of other drugs given 
Drug Dose (mgs/tablets) & 
frequency 
Duration (days) 
   
   
   
   
14. Anthropometric measurements 
Weight  .  Kg        length .  Cm  MUAC   cm   
 
15. HIV PCR RESULTS 
HIV PCR Results  1- Positive, 2=Negative 
If Negative, has child stopped cotrimoxazole  1=Yes, 2=No 
If Positive, has child been referred to ART Clinic  1=Yes, 2=No 
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Appendix 7: Sick Visit Case Report Form 
Malaria rebound in HIV exposed children after stopping cotrimoxazole prophylaxis 
 
Form Completed by   (Initials 
Patient Initials   (Initials)  
Date of Visit    /  /  (dd/mm/yy)  
Type of Case    1=HIV exposed, 2=non-HIV exposed 
 
CHILD’S  MEDICAL  &  NUTRITIONAL  HISTORY 
1. Is the child still breastfeeding?            1=Yes, only breastfed, 2=Yes & added feeds, 
2=No  
If no, specify reason    (tick ALL that apply)    
Child stopped  1=Yes, 2=No, Child has mouth sore  1=Yes 2=No, Started 
formula  1=Yes        2=No Mother busy  1=Yes 2=No, Fear of stigma & 
discrimination  1=Yes 2=No Mother sick  1=Yes 2=No, Mother died  1=Yes 
2=No; Other specify Other specify ____________________ 
2. Is child taking cotrimoxazole prophylaxis  (FOR HIV Exposed ONLY)  1=Yes, 2=No 
(IF YES GO TO Q3, IF no continue) 
If no, specify reason (tick ALL that apply)  
 Child refuses    1=Yes 2=No   forgot  1= Yes, 2=No Side effects 1=Yes 2= 
No fear of stigma & discrimination   2=No 1=Yes CPT out of stock  1=Yes 
2=No, tired of giving child medications  1=Yes, 2=No, Child stopped breastfeeding 
 1=Yes 2=No, Specify other reasons for not taking cotrimoxazole 
_________________  
3. Have you visited another health facility since last study contact?  1=Yes, 2=No (if no go 
to CURRENT MEDICAL HISTORY)  
If yes, specify type of facility   
Health Centre     1=Yes, 2=No   
Private Clinic     1=Yes, 2=No   
Traditional healer   1=Yes, 2=No    
Other specify ___________________________________ 
(Check health passport for details and complete the following) 
Indicate date / /  specify diagnosis ______   
4. Was child admitted during this time?   1=Yes, 2=No  
5. Were any laboratory tests done on your child?  1=Yes, 2=No  
If   yes, specify 1= MPs, 2= Hb, 3=Full Blood Count, 4= Urine  
 Other laboratory test done ___________________________    
Malaria test results  1=Positive, 2=Negative  
6. Did child receive any treatment  1=Yes, 2=No  
if No go to Section B: Current Medical History 
Anti-malarials given?     1=Yes, 2=No if yes tick that apply  
 1=Artemether Lumafantrine (AL) 2=Sulphadoxine Pyrimethamine (SP), 3= 
Quinine   Sulphate   4= Amodiaquine Artesunate   
Antibiotics given?   1=Yes, 2= No if yes tick that apply 
   Amoxycillin      1=Yes, 2=No       Chloramphenicol    1=Yes 2=No 
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   Erythromycin   1=Yes, 2=No                 Augmentin     1=Yes 2=No  
      Ceftriaxone   1=Yes, 2=No         Benzyl Penicillin 1=Yes   2=No  
   Gentamycin      1=Yes, 2=No  
Other drugs given?          1=Yes, 2=No if yes specify drug details 
           Drug details of other drugs given  
Drug Dose (mgs/tablets) & 
frequency 
Duration (days) 
   
   
   
 
CURRENT MEDICAL HISTORY 
7. Presenting problems  a)  Code and Specify ____ 
         b)  Code and Specify   _____ 
Symptoms 
Fever        1=Yes 2=No  for how long?  days   
Cough      1=Yes 2=No  for how long?  days   
Vomiting   1=Yes 2=No             for how long?  days   
Diarrhea    1=Yes 2=No             for how long?  days  
Fitting       1=Yes 2=No  for how long?  days  
Respiratory distress   1=Yes 2=No               for how long?  days  
Rash               1=Yes 2=No  for how long?  days  
Other (please specify) _____                          for how long?  days  
 
CLINICALEXAMINATION  
8. Anthropometric measurements 
Weight .   Kg; Height .   cm MUAC .  cm 
 
9. VITAL SIGNS 
Temperature .  °C Respiratory rate  /min Pulse Rate  b/min          
 
10. OTHER  SIGNS 
Loss of consciousness  1=Yes, 2=No                Lymph nodes    1=Yes, 
2=No  
Convulsions     1=Yes, 2=No  Jaundice              1=Yes, 2=No 
Mouth ulcers    1=Yes, 2=No Skin Rash      1=Yes, 2=No  
Chest signs       1=Yes, 2=No Fungal  infection  1=Yes, 2=No        
Dehydration      1=Yes, 2=No                 
Pallor                1=Yes, 2=No     
Spleen                cm  
              Liver     cm  
 
LAB INVESTIGATIONS : Please complete Appropriate  laboratory form  
          Hb                                     .  g/dl  
          Malaria RDT  1=positive, 2= negative 
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          Malaria slide   1=positive, 2=negative 
 If positive, Severity    1=1+, 2=2+, 3=3+, 4=4+                                                        
          Filter paper                   1= Collected, 2= Not Collected 
 
DIAGNOSES 
Presenting diagnosis 1    Code and Specify_________ 
Presenting diagnosis 2 Code and Specify   ________ 
 
TREATMENT 
Anti-malarials given?  1=Yes, 2=No  
Antibiotics given?  1=Yes, 2=No  
      Other drug  given?      1=Yes, 2=No  
Drug details of anti-malarials, antibiotics and other drugs given 
Drug Dose (mgs/tablets) & frequency Duration (days) 
   
   
   
 
VISIT OUTCOME 
Action taken  1 = Admission, 2 = Rx + extra FU, 3 = Rx +no FU, 4 = No action, 5= 
Completed  
Outcome  1= Continuing, 2= Study End, 3= Withdrawn, 4=Dead, 5= Discontinue 
study drugs 
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Appendix 8: Laboratory Form 
Malaria rebound in HIV exposed children after stopping cotrimoxazole prophylaxis 
Form completed by   (Initials) 
Date     /  /   
Client’s  Initials    
Type of client               1=HIV exposed, 2= non-HIV exposed   
Visit                                        visit 1=1 sick visit=2, visit 12=3 
 
Samples  
 Thick film 1=Yes, 2=No, (if no, specify reason ____) 
Thin film 1=Yes, 2=No (if no specify reason ______) Filter paper 1=Yes, 2=No, (If 
no, specify reason ________)   
 
Form completed by    (in the Laboratory) 
Samples received in Laboratory    
Thick Film    1=Yes, 2=No  (if no, specify reason_____)  
Thin film      1=Yes, 2=No (if no, specify reason______)  
Filter Paper   1=Yes, 2=No, (If no, specify reason______) 
Blood film result 
Malaria Parasite Density 
 First reader  parasites/200wbc    Initials   
 Second reader  parasites/200wbc Initials   
Malaria microscopy  1=positive, 2=negative 
Malaria Rapid Test   1=positive, 2=negative 
Malaria species:        1=P. falciparum, 2= P. malariae, 3= P. ovale, 4=P. vivax 
Filter Paper done    1=Yes, 2=No 
 
IF APPLICABLE, 
Full Blood Count: 
WBC (total)  .  103/μL  MCV  .  fL 
RBC .   106/μL   MCHC .   g/dL 
Hb .   g/dL   RDW  .   % 
Hct .   %   Plt    103/μL 
        MCH  .   g/dL 
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Appendix 9: Last study visit Case Report Form (visit 12) 
 
Malaria rebound in HIV exposed children after stopping cotrimoxazole prophylaxis 
 
Form Completed by     (Initials)  
Date Form Completed    /  /  (dd/mm/yy)  
Client Initials                  (Initials)  
Type of Client                 1=HIV exposed, 2=non-HIV exposed  
                                                      
MOTHER’S  HEALTH  STATUS 
1. Is the mother alive?  1=Yes, 2=No If yes GO TO QUESTION 2       
If No, Did death occur since last visit?  1=Yes, 2=No     
If yes, indicate date:  / /  and SKIP TO QUESTION 3 
2. Is the mother on any long-term treatment?  1=Yes, 2=No    if no, SKIP TO QUESTION 3   
If yes   (tick ALL that apply)     
ART 1=Yes, 2=No, TB treatment  1=Yes, 2=No,  Cotrimoxazole prophylaxis 
1=Yes, 2=No,    Vincristine 1=Yes, 2=No,  Antihypertensives 1=Yes, 2=No,    
ant asthmatics 1=Yes, 2=No, ant-epileptics 1=Yes, 2=No, ant fungals 1=Yes, 
2=No, diabetes drugs 1=Yes, 2=No,       Other Specify 
________________________ 
(For questions 3 & 4, check in health passport or mothers HIV care records for HIV 
 exposed only)  
3. Was CD4 Count of mother measured since last visit?    1=Yes, 2=no (if no, GO TO Q4) 
If yes, record   /mm3        Date / /  (dd/mm/yy) 
4. Was Viral Load of Mother measured since the last visit?   1= Yes, 2=No (if No, GO TO 
Q5)  If Yes, Is it detectable?  1= Detectable, 2=Not Detectable 
If detectable, record   copies/ml Date / /  (dd/mm/yy) 
 
MALARIA CONTROL MEASURES 
5. How many mosquito nets are in use in the home since last visit?  1=0,  2=≥1, If 
answer is 1, GO TO Q10 
6. Did child sleep under a mosquito net last night?   1=Yes, 2=no  (No, go to Q9) 
If yes, is net treated with insecticide?    1=Yes, 2=No, 3=Not known 
7. When was the last time net was treated since enrolment into the study?    
1=never, 2=past three, 3=past six months, 4=past 9 months, 5= past year, 5=Other 
Specify__________________________________ 
8. How often do you treat mosquito nets  1= never, 2=0nce a year, 3=once in 6 months, 
4=not known 
If no, specify reason    (tick ALL that applies) 
Forgot                  1=Yes, 2=No   
  Allergic to ITN               1=Yes, 2=No    
Did not sleep at home       1=Yes, 2=No          
  Was used by others                  1=Yes, 2=No   
Other specify_____________________ 
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9. Since the last visit have you used any of the following malaria control measures (tick ALL 
that apply) 
Indoor Residual Spraying (IRS)                             1=Yes,2=No     
Coils                                                                        1=Yes, 2=No     
Body repellents                                                      1=Yes, 2=No  
Sprays e.g. Doom                                                    1=Yes, 2=No      
Traditional medication                                           1=Yes, 2=No 
None                                                                        1=Yes, 2=No       
10. When you suspect that your child has malaria, what action do you take? (Tick ALL that 
apply) 
Go to the hospital                        1=Yes, 2=No 
Buy medication from pharmacy/shops        1=Yes, 2=No 
Do tepid sponging                                    1=Yes, 2=No     
Traditional medication                                  1=Yes, 2=No 
CHILD’S  MEDICAL  &  NUTRITIONAL    HISTORY 
11. Is the child still breastfeeding?                         1=Yes, 2=No  
If no, when did child stop breastfeeding / /  (dd/mm/yy) 
Estimate duration in weeks  (Not relevant if has date stopped) 
       Specify reasons for stopping breastfeeding    (tick ALL that apply) 
Child stopped,   1=Yes, 2=No      Child has mouth sores 1=Yes, 2=No  
Started formula  1=Yes, 2=No      Mother busy 1=Yes, 2=No     
Fear of stigma & discrimination 1=Yes, 2=No Stopped cotrimoxazole  
1=Yes, 2=No, Mother sick 1=Yes, 2=No    Mother died  1=Yes, 2=No  
Specify other reasons for stopping breast feeding_______________________ 
12. Is child taking added feeds  1=Yes, 2=No  
If yes name type of Feeds 
Plain porridge 1=Yes, 2=No, Fortified Porridge 1=Yes, 2=No  
Formula milk  1=Yes, 2=No,    Any other Milk     1=Yes, 2=No  
Normal diet    1=Yes, 2=No,  
Other Specify __________________________   
(If non-HIV exposed GO TO Q15) 
13. Is child taking cotrimoxazole prophylaxis  1=Yes, 2=No (if yes GO TO Q15    IF no 
continue) 
If no, specify reason (tick ALL that apply) 
Child refuses  1=Yes, 2=No, forgot  1=Yes, 2=No Side effects  1=Yes, 
2=No  fear of stigma & discrimination  1=Yes, 2=No   CPT out of stock  1=Yes, 
2=NoChild HIV PCR negative   1=Yes, 2=No, tired of giving child medications  
1=Yes, 2=No         Child stopped breastfeeding     1=Yes, 2=No  Specify other 
reasons for not taking contrimoxazole ________________ 
14. Have you visited another health facility since last study contact?  1=Yes, 2=No 
 If yes, indicate date / /  specify the diagnosis ________Code
  Was child admitted during this time? 1=Yes, 2=No 
15. Were any laboratory tests done on your child?  1=Yes, 2=No 
If   yes, specify  1=MPs 2=Hb 3= Full Blood Count 4= Urine 
 Other laboratory test done ___________________________     
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16. What treatment did your child receive? 
Anti-malarials given? 1= Yes, 2= No    if yes tick that apply  
 1=Artemether Lumafantrine (AL), 2=Sulphadoxine Pyrimethamine (SP), 
3=Quinine Sulphate, 4=Amodiaquine Artesunate   
Antibiotics given?  1=Yes, 2=No    if yes tick that apply 
Amoxycillin 1=Yes, 2=No Chloramphenicol  1=Yes, 2=No, Erythromycin  
1=Yes, 2=No, Augmentin 1=Yes, 2=No   Ceftriaxone 1=Yes, 2=No, Benzyl  
Penicillin  1=Yes, 2=No   Gentamycin  1=Yes, 2=No,  
Other drugs given?  1=Yes, 2=No     if yes specify drug details 
Drug details of other drugs given 
Drug Dose (mgs/tablets) & 
frequency 
Duration (days) 
   
   
CURRENT MEDICAL STATUS 
Is your child having any complaints?  1=Yes, 2= No, IF NO, SKIP TO CLINICAL 
EXAM 
Fever     1=Yes, 2=No, If ‘yes’,  duration    days  
Cough     1=Yes2=No, If ‘yes’,  duration        days  
Vomit                1=Yes, 2=No, If ‘yes’,  duration      days 
Diarrhoea    1=Yes, 2= No, If ‘yes’,  duration      days 
Rash    1= Yes, 2=No,  If  ‘yes’,  duration           days 
Other specify____________ 
             
CLINICAL EXAMINATION  
17. Anthropometric Measurements 
Weight .  Kg            Height .  cm  MUAC    cm    
18. Vital signs 
Pulse rate   beats/min   
Temperature  .   ºC      
Respiratory rate  /min 
19. Other Signs 
a) Chest signs       1=Yes, 2=No (If no, go to b) 
If yes, specify   (tick ALL that apply) 
Chest recessions  1=yes, 2=No       
Crepitations        1=Yes, 2=No       
Tachypnea          1=yes, 2=No      
Hyperinflation    1=Yes, 2=No        
Wheezing    1=Yes, 2=No  
b) Oedema   1=Yes, 2=No.       
c) Lymphadenopathy 1=yes, 2=no, If no, go to (d) 
If yes,   1=Regional, 2=General 
d) Pallor:    Conjunctival  1=present, 2= absent, if no, go to (e) 
If Conjunctival  present:  1=Mild/moderate,2=Severe 
e) Dehydration  1=yes, 2= no, if no, go to (f)    
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If yes    1=Mild, 2=Moderate, 3= Severe,   
f) Spleen     cm   
g) Liver    cm  
h) ENT/mouth abnormal    1=Yes, 2=No. If  yes, specify: Thrush 1=Yes, 2=No  
Sores         1=Yes, 2=No 
If other, please specify ________________ 
i) Jaundice?   1=Yes, 2=No 
 
20. Lab Investigations: Please complete laboratory form 
Hb .  g/dl 
Malaria RDT  1=positive, 2=negative 
Malaria slide  positive, 2= negative  
If positive, severity  1=1+, 2=2+, 3=3+, 4=4+  
Filter paper malaria  1=Yes, 2=No  
 (If non-HIV exposed go, to Diagnosis)               
HIV Rapid Test  1= positive, 2=negative  
 
21. Diagnosis  
a) Presenting diagnosis 1___________  code and Specify   _________  
b) Presenting diagnosis 2___________  code and Specify   _________ 
 
22. Treatment  
Anti-malarials given?       1=Yes, 2=No   
Antibiotics given?            1=Yes, 2=No  
Other drugs given?           1=Yes, 2=No  
Drug details of anti-malarials, antibiotics and other drugs given 
Drug Dose (mgs/tablets) & 
frequency 
Duration (days) 
   
   
   
VISIT OUTCOME 
Action taken    1 = Admission, 2 = Rx + extra FU,  3 = Rx +no FU,  4 = No action, 5= 
Completed Study 
Outcome   1= Continuing, 2= Study End, 3= Withdrawn, 4=Dead, 5= Discontinue 
study drugs   (if 2: complete summary form, if 3: complete withdrawal form, if 4:fill in 
verbal autopsy form) 
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Appendix10: COMREC Approval letter 
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Appendix 11: LSTM Ethics approval 
 
 
 
 232 
Appendix 12: Informed Consent Form for HIV exposed 
 
Malaria rebound in Cotrimoxazole prophylactic HIV exposed children 
  
Participant Information  
This study is being conducted by the College of Medicine of the University of Malawi in 
collaboration with the University of Liverpool. We invite you and your child to take part in 
this study. Before you decide it is important for you to understand why the research is being 
done and what it will involve.  
 
What is the purpose of this study?  
The aim of this study is to learn more about malaria, other diseases and practices associated 
with the use of cotrimoxazole which is used for prevention of HIV related illnesses in 
children whose mothers are HIV infected. We want to find out whether after stopping 
cotrimoxazole a child born from an HIV infected mother who remains HIV negative will be at 
higher risk than normal children of suffering from malaria. This is because it is believed that 
cotrimoxazole which also treats malaria may be protecting your child from getting malaria. 
We know that a little malaria for young children is good for the child to build up its 
immunity. We do not know whether cotrimoxazole which also treats malaria is hindering the 
development of this immunity. We therefore want to compare children who are born to HIV 
infected mothers and have been on cotrimoxazole for prevention of HIV related illnesses 
against those that are born to HIV negative mothers and not been on cotrimoxazole for 
prevention of HIV related illnesses. A few mothers/guardians will also be asked of their 
experiences of giving their child cotrimoxazole which prevents HIV related illnesses over the 
course of the study.  
 
Why has your child been chosen?  
Your child has been chosen because he/she is born from an HIV infected mother, is 
breastfeeding and on daily cotrimoxazole for prevention of HIV related illnesses. Your child 
will be among 1000 children who will be participating in this study if you choose that your 
child participate in this study. 
 
What will happen to your child if he/she takes part in the study?  
Since your child is too young to answer questions, we will instead ask you a few questions on 
the health of your child, and malaria control interventions that you practice at home. We will 
collect about 1 ml of blood from a heel/finger prick (approximately half a teaspoon) from 
your child for malaria tests and checking of haemoglobin levels whenever your child is sick.  
This is part of the standard clinical practice when treating a sick child. However, the same 
blood tests will be done at recruitment, visit 6 (month 12) and visit 12 (month 24). In 
addition, if your child is one of the children selected to take part in the immunology sub 
study, about 5 mls (approximately a tablespoonful) of blood will be collected at months 6, 12, 
18 & 24 to investigate how your child is building up malaria specific immunity.  For these, 
your child will be asked to come to the study clinic even if he/she is not sick. The scheduled 
tests including the immunology tests are not part of standard clinical guidelines, but are done 
specifically for the purpose of this study.    All study visits will take place at home with a visit 
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taking approximately 30 minutes. You will be asked to come back to the clinic with your 
child when he/she is sick. As a guardian you may be selected to take part in some interviews 
and group discussions on your lived experiences with administering daily cotrimoxazole for 
the prevention of HIV related illnesses to a child born to an HIV infected mother.  
 
What are the possible risks for participating in this study?  
The study staff will take every effort to protect your information and that of your child. 
However, the possible risk to your child would be experiencing of some pain when blood is 
being collected.   
 
What are the benefits for participating in this study?  
Apart from study procedures, the study participants will have access to some medical services 
at the study clinic throughout their participation in the study. A dedicated Clinical Officer will 
attend to study participants at any point they present to the clinic sick. The participants taking 
cotrimoxazole will also be monitored for any side effects related to cotrimoxazole and 
managed according to Ministry of Health and hospital guidelines. 
  
Does your child need to participate in the study? 
Participation in the study is entirely voluntary. Even if you agree to participate, you may 
withdraw your child at any point in time. This will not affect the care that the child will 
receive at this hospital.  
 
What will participating in the study cost me?  
You will not pay anything for participating in this study and we will not pay you for taking 
part in the study. If you are asked by study staff to come to the study clinic, we will reimburse 
for the transport costs accordingly.  
 
Who should I contact if I have a problem? 
 This study will be reviewed and approved by the College of Medicine Research and Ethics 
Committee (COMREC) and the Liverpool School of Tropical Medicine Ethics Committee. If 
you have any questions about your rights or the rights of your child for participating in this 
study, please, contact the chairman of the COMREC Prof. Mfutso-Bengo on telephone 
number 01871911. You may also contact the study Clinician Mr Zinenani Truwah on 
0999413775. 
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Participant Agreement  
I have understood the information contained in this consent form and I hereby voluntarily 
agree that my child participate in this study.  
 
Name of child participating 
in the study 
 Date 
   
 
 
  
 
Name of the person giving 
Consent (guardian) 
Signature Date 
   
 
 
  
  
Name of person obtaining 
consent 
Signature Date 
   
 
 
 
For illiterate guardians  
 
Thumb Print of guardian 
 
 
 
 
  
  
Name of Witness  Signature Date 
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Appendix 13:  Informed Consent Form for non-HIV exposed children 
 
Malaria rebound in Cotrimoxazole prophylactic HIV exposed children 
  
Participant Information  
This study is being conducted by the College of Medicine of the University of Malawi in 
collaboration with the University of Liverpool. We invite you and your child to take part 
in this study. Before you decide it is important for you to understand why the research is 
being done and what it will involve.  
 
What is the purpose of this study?  
The aim of this study is to learn more about malaria, other diseases and practices 
associated with the use of cotrimoxazole which is used for prevention of HIV related 
illnesses in children whose mothers are HIV infected. We want to find out whether after 
stopping cotrimoxazole a child born from an HIV infected mother who remains HIV 
negative will be at higher risk than normal children of suffering from malaria. This is 
because it is believed that cotrimoxazole which also treats malaria may be protecting your 
child from getting malaria. We know that a little malaria for young children is good for 
the child to build up its immunity. We do not know whether cotrimoxazole which also 
treats malaria is hindering the development of this immunity. We therefore want to 
compare children who are born to HIV infected mothers and have been on cotrimoxazole 
for prevention of HIV related illnesses against those that are born to HIV negative mothers 
and not been on cotrimoxazole for prevention of HIV related illnesses. A few 
mothers/guardians will also be asked of their experiences of giving their child 
cotrimoxazole which prevents HIV related illnesses over the course of the study.  
 
Why has your child been chosen?  
Your child has been chosen because he/she is born from an HIV negative mother and is 
breastfeeding.   We would like to investigate how your child responds to malaria infection 
compared to other children who are HIV negative but born from HIV infected mothers. 
Your child will be among 1000 children who will be participating in this study. 
 
What will happen to your child if he/she takes part in the study? Since your child is 
too young to answer questions, we will instead ask you a few questions on the health of 
your child, and malaria control interventions that you practice at home. We will collect 
some blood specimen (approximately half a teaspoon) from your child for malaria tests 
and checking for hemoglobin levels whenever your child is sick. This is part of standard 
clinical practice when treating a sick child. However, the same blood tests will be done at 
recruitment, at 12 and 24 months. In addition, if your child is one of the children selected 
to take part in the immunology sub study, about 5 mls (approximately a tablespoonful) of 
blood will be collected at months 6, 12, 18 & 24 to investigate how your child is building 
up malaria specific immunity.  For these, your child will be asked to come to the study 
clinic even if he/she is not sick. The scheduled tests including the immunological tests are 
not part of standard clinical guidelines but are done for the purpose of the study. All study 
visits will take place at home with a visit taking approximately 30 minutes. You will be 
asked to come back to the clinic with your child when he/she is sick.  
What are the possible risks for participating in this study? 
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The study staff will take every effort to protect your information and that of your child. 
However, the possible risk to your child would be experiencing of some pain when blood 
is being collected.  
 
What are the benefits for participating in this study?  
Apart from study procedures, the study participants will have access to some medical 
services at the study clinic throughout their participation in the study. A dedicated Clinical 
Officer will attend to study participants at any point they present to the clinic sick.  
 
Does your child need to participate in the study?  
Participation in the study is entirely voluntary. Even if you agree to participate, you may 
withdraw your child at any point in time. This will not affect the care that the child will 
receive at this hospital.  
 
What will participating in the study cost me?  
You will not pay anything for participating in this study and we will not pay you for 
taking part in the study. If you are asked by study staff to come to the study clinic, we will 
reimburse for the transport costs accordingly.  
 
Who should I contact if I have a problem? 
 This study will be reviewed and approved by the College of Medicine Research and 
Ethics Committee (COMREC) and the Liverpool School of Tropical Medicine Ethics 
Committee. If you have any questions about your rights or the rights of your child for 
participating in this study, please, contact the chairman of the COMREC Prof. Mfutso-
Bengo on telephone number 01871911. You may also contact the study Clinician Mr 
Zinenani Truwah on 0999413775. 
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 Participant Agreement  
I have understood the information contained in this consent form and I hereby voluntarily 
agree that my child participate in this study. 
 
Name of child participating 
in the study 
 Date 
   
 
 
  
 
Name of the person giving 
consent (guardian) 
Signature Date 
   
 
 
  
  
Name of the person 
obtaining consent 
Signature Date 
   
 
 
 
For illiterate guardians  
Thumb Print of guardian 
 
 
 
 
  
Name of Witness  Signature Date 
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Appendix 14: Guiding questions for In-depth Interviews 
 
Lived experiences of HIV infected women administering CPT to their HIV exposed, 
uninfected infants 
 
Introduction 
My name is ___________________. I will be asking you questions on cotrimoxazole 
prophylaxis that is given to your child. Please feel free to answer these questions. The 
answers you provide will help to improve the care that is given to HIV exposed children 
who are receiving cotrimoxazole prophylaxis/Bactrim. Your name will not be recorded on 
this sheet and therefore, no one will know who said what in these interviews.  
 
1. Did you receive information on giving your child contrimoxazole? If yes, what kind of 
information did you receive? Who gave you the information? Where was the 
information given? How was the information given? How sufficient was the 
information? (Probe on sources of counselling messages until they are exhausted) 
2. From the time you first got the information, how often do you get similar kind of 
information? (Probe: where the information is given and by whom) 
3. Do you think that this information is important to you (explain) (Probe: How they 
have used the information, what they have benefited or not benefited by using the 
information)  
4. How best would you like to get messages about adherence to cotrimoxazole 
prophylaxis? (Probe: where the information should be provided, who should 
provide the information and how the information should be provided?) 
5. How are you reminded to give cotrimoxazole to your child? Who reminds you and 
how often do you get reminded? 
6. What problems do you experience when using the approach you use to be reminded 
about giving cotrimoxazole to your child? How can these problems be addressed? 
7. How would you like others help you (spouse, family members, community members, 
religious friends) as regards giving cotrimoxazole to your child? 
8. How much support do you receive from family members as regards to giving your 
child cotrimoxazole prophylaxis? 
9. What things would make you not give cotrimoxazole to your child? How would you 
deal with family members who do not know your HIV status?  
10. How is it important or beneficial to give children cotrimoxazole prophylaxis? 
(Explain) 
11.  What makes you continue giving your child cotrimoxazole prophylaxis even after 
knowing your child is HIV negative at 6 weeks and/or your child is looking healthy? 
(Probe for more reasons why mothers give cotrimoxazole to their children) 
12. What do you do when your child is sick and is receiving other forms of treatment i.e. 
too many other drugs for the sickness (Probe to see if mothers stop giving 
cotrimoxazole when child is on other forms of treatment) 
13. Who makes decisions about health and care in your family? How do you think this 
may impact on giving your child cotrimoxazole on daily basis? 
14. What aspects of your culture/tradition/religion/social norms encourage you continue 
giving cotrimoxazole to your child? (Probe: tradition/religion/social 
norms/personal issues). What aspect of your culture discourages you to continue 
providing cotrimoxazole to your child? (Probe: tradition/religion/social 
norms/personal issues) 
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15. What happens in terms of giving cotrimoxazole prophylaxis to your child when you 
are away from home like attending a funeral or you have travelled to another area 
where you will spend days? 
16. What are your worries with giving your child cotrimoxazole on daily basis for a period 
of one year? How can these worries be addressed? 
17. How can disclosure or non disclosure of your HIV status to your spouse or family 
members affect giving cotrimoxazole to your child (Explain) 
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Appendix 14: Guiding questions for Focus Group Discussions 
 
Lived experiences of HIV infected women administering CPT to their HIV exposed, 
uninfected infants 
 
What kind of information did you receive on giving your child cotrimoxazole? In what 
context was the information given? How was the information given to you? Where did 
you get this information? From the time you first got the information, how often to you 
get similar kind of information? Do you think that this information is important to you? 
(Explain) (Moderator probe on sources of counseling messages on administering 
cotrimoxazole until they are exhausted) 
 
How best would you like to get messages about adherence to cotrimoxazole prophylaxis? 
 
How are you reminded to give cotrimoxazole to your child? Who reminds you and how 
often do you get reminded? What problems do you experience when using the approach 
you use to be reminded about giving cotrimoxazole to your child? 
 
How much support do you receive from family members as regards to giving your child 
cotrimoxazole prophylaxis? 
 
What factors would make you not give cotrimoxazole to your child? How would you deal 
with family members who do not know your HIV status?  
 
How would you like others help you (spouse, family members, community members, 
religion) as regards giving cotrimoxazole to your child?  
 
What makes you continue giving your child cotrimoxazole prophylaxis even after 
knowing your child is HIV negative at 6 weeks and/or your child is looking healthy? 
(Moderator probe for more reasons why mothers give cotrimoxazole to their 
children) 
 
What do you do when your child is sick and is receiving other form of treatment i.e. too 
many other drugs for the sickness (Moderator probe to see if mothers stop giving 
cotrimoxazole when child is on other forms of treatment) 
 
Who makes decisions about health and care in your family? How do you think this may 
have any impact on giving your child cotrimoxazole on daily basis?  
 
What aspects of your culture/tradition/religion/social norms encourage you to continue 
giving cotrimoxazole to your child? (probe: tradition/religion/social norms/ personal 
issues)What aspect of your culture discourages you to continue providing cotrimoxazole 
to your child? (probe: tradition/religion/social norms/personal issues) 
 
What happens when you are away from home like attending a funeral or you have 
travelled to another area where you will spend days? 
 
What are your worries with giving your child cotrimoxazole on daily basis for a period of 
one year? How can these worries be addressed? 
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How do you think disclosure or non-disclosure of your HIV status to your spouse or 
family members affect giving cotrimoxazole to your child? 
 
Do you think you have all the support you need from family members in giving your child 
cotrimoxazole? How adequate is the support that you get from family members in giving 
your child cotrimoxazole? (Explain) 
 
 
 
 
 
